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THE DOPAMINERGIC NETWORK AND GENETIC SUSCEPTIBLITY TO 
SCHIZOPHRENIA 
Michael E. Talkowski, Ph.D. 
University of Pittsburgh, 2008 
 
Background: Schizophrenia is a disabling illness with unknown pathogenesis.  Estimates of 
heritability suggest a substantial genetic contribution; however genetic studies to date have been 
equivocal.  Uncovering liability loci may therefore require analyses of functionally related genes.  
Rooted in this assumption, this dissertation describes a series of studies investigating a genetic 
epidemiological foundation for the commonly cited hypothesis suggesting dopaminergic 
dysfunction in schizophrenia pathogenesis, i.e. the ‘dopamine hypothesis’.   
 
Studies: The initial study investigated DRD3 and identified novel associations across the gene.  
The second study considered a larger network of dopaminergic genes in two independent 
Caucasian samples, detecting replicated associations and epistatic interactions.  The study 
proposed a risk model for schizophrenia centered on the dopamine transporter.  Study #3 
investigated a dopamine precursor, phenylalanine hydroxylase, in four independent samples, 
identifying a single SNP (rs1522305) that was significantly replicated in two samples.  Study #4 
was motivated the hypothesis of a shared genetic etiology for schizophrenia and bipolar disorder.  
This study comprehensively evaluated the dopaminergic network, selecting 431 ‘tag’ SNPs from 
40 genes among large schizophrenia and bipolar cohorts contrasted with adult controls.  Across 
all genes 60% of nominally significant schizophrenia risk factors were also associated with 
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bipolar disorder. The results supported DRD3 variations as risk factors for both disorders, 
confirmed several previously reported associations, and proposed new targets for future research.   
 
Conclusion: These results suggest dopaminergic gene variations could play an etiological role in 
the pathogenesis of schizophrenia and possibly bipolar 1 disorder.  Additional replicate studies 
are warranted 
.     
Public Health Significance: 
Schizophrenia (SZ) is devastating.  When the Global Burden of Disease study calculated 
disability adjusted life years, weighted for the severity of disability, they determined active 
psychosis seen in schizophrenia produces disability equal to quadriplegia.  Schizophrenia has 
been estimated to be among the top ten causes of disability worldwide.  As schizophrenia is 
common (roughly 1% point prevalence worldwide), the economic burden to society is 
substantial.  Pathogenesis is unknown and treatment is palliative.  Therefore understanding the 
genetic etiology could facilitate development of promising therapeutics.   
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1.0  INTRODUCTION 
These data describe an ongoing series of studies aimed at evaluating the genetic epidemiological 
evidence for or against the long held hypothesis that alterations in dopamine neurotransmission 
represent a pathogenic mechanism for schizophrenia.  The hypotheses and analyses presented 
here are not novel.  Biological studies have long suggested dopamine dysfunction in 
schizophrenia etiology, and dopamine receptors are primary targets of antipsychotics.  Genetic 
studies have targeted dopamine gene polymorphisms for the better part of the last two decades.  
However, a review of existing data suggests a substantial gap in knowledge between relatively 
small single variant association studies and large scale genome-wide association studies.  The 
purpose of these studies is therefore to comprehensively reconsider an existing hypothesis that 
remains cursorily evaluated.  
1.1 PUBLIC HEALTH SIGNIFICANCE 
Schizophrenia (SZ) is devastating.  When the Global Burden of Disease study calculated 
disability adjusted life years, weighted for the severity of disability, they determined active 
psychosis seen in schizophrenia produces disability equal to quadriplegia (C. J. L. Murray & 
Lopez, 1996).  One study estimated schizophrenia was among the top ten causes of disability 
worldwide (Lopez et al., 1998).  As schizophrenia is common (1% point prevalence), the 
 17
economic burden to society is substantial.  In 2002, the US healthcare system spent over $62 
billion on schizophrenia patients (Wu et al., 2005) who occupy 30% of all U.S. psychiatric 
hospital beds.  Pathogenesis is unknown and treatment is palliative.  Therefore understanding the 
genetic etiology could facilitate development of promising therapeutics.   
The comprehensive nature of individual gene evaluations conducted herein will also 
impact future studies in other diseases.  Dopaminergic gene variants have been proposed as risk 
factors in diseases such as Alzheimer’s, Parkinson’s, and ADHD, to name a few.  The extensive 
gene mapping, polymorphism discovery, and linkage disequilibrium analyses in these studies 
provide an established set of genetic variants representative of all currently available common 
polymorphisms within the dopaminergic pathway.  Future studies can utilize this resource as a 
source of uniform variations required to test a common variant hypothesis for any spectrum of 
phenotypic traits of interest.   
1.2 SCHIZOPHRENIA 
1.2.1 History 
Schizophrenia is a psychiatric disorder characterized by psychotic phenomena.  Without 
formal definition, observations of ‘diseases of the mind’ stretch as far back as Hippocrates (460 – 
370 B.C.) (Palha & Esteves, 1997).  Clinical pathologies such as mania and melancholia were 
recognized as forms of madness (I. Gottesman, 1991).  The term dementia praecox was first used 
in 1857 by Benedict Morel (I. Gottesman, 1991).  Karl Kahlbaum (1828 – 1899) studied the 
course of dementia praecox and documented clinical psychoses during all stages of the illness, 
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being one of the first to suggest the evolution of psychosis was a measurable symptom.   Based 
on the works of these and others, in 1896 Emil Kraeplin expanded Morel’s model of dementia 
praecox and identified a new nosologic systemization of mental illness.  Although Kraeplin’s 
broad categories of dementia praecox and manic depressive insanity have since been redefined 
(Kraepelin, 1919), the essential features of his concept of dementia praecox are present today in 
the DSM-IV diagnosis of schizophrenia (A.P.A., 1994) (A. Jablensky, 1997) (see (Palha & 
Esteves, 1997) for review). 
1.2.2 Clinical presentation 
Schizophrenia is a highly heterogeneous disorder in which the onset is commonly in late 
adolescence.  The pathogenesis of the disorder is unknown and there is no available biomarker or 
diagnostic test, so diagnoses remain reliant on patient interviews and self-report.  Prior to 1980, 
diagnostic reliability varied widely, particularly across cultures (Cooper & Sartorius, 1977) 
(Kuriansky, Deming, & Gurland, 1974).  The reliability has dramatically improved since 
publication of the third edition of the Diagnostic and Statistical Manual of Mental Disorders, 
Third Edition (DSM-III) (A.P.A., 1980).  Further improvements in the most recent version of the 
DSM (DSM-IV) have established specific diagnostic criteria (A.P.A., 1994).  The first criterion 
state that two or more of the following symptoms must be present for a significant portion of 
time during a one-month period (or less if successfully treated) (Criterion A): delusions, 
hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and can include 
negative symptoms such as flattened affect, alogia (poverty of speech), or avolition (poverty of 
desire or motivation).  Criterion B (social / occupational dysfunction) states that symptoms must 
lead to a disturbance in one or more major areas of functioning (e.g. work, interpersonal 
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relationships, or self care in adults) for a significant portion of time since their onset.  Criterion C 
(duration) requires continuous signs of disturbance that persist for at least six months, including 
one month of ‘active-phase’ symptoms (meeting Criterion A).  Criterion D and E exclude other 
disorders such as schizoaffective and mood disorders with psychotic features, and require the 
disturbance is not a result of direct physiological effects of substance abuse (e.g. drug abuse or 
medication) or a general medical condition.  Criterion F requires that if Autistic Disorder or 
another Pervasive Developmental Disorder were previously diagnosed, schizophrenia can only 
be made as an additional diagnosis if prominent delusions or hallucinations are also present for at 
least a month.  There are subtypes of schizophrenia not discussed in detail here, including 
paranoid, catatonic, disorganized, undifferentiated, and residual type.  Of note for the studies 
presented here, individuals diagnosed with schizoaffective disorder meet Criterion A for 
schizophrenia, but also have a period during which diagnostic criteria of Major Depressive 
Episode, Manic Episode, or Mixed Episode is met concurrently.   
Other symptoms are often seen that lead to chronic impairment, including deficits in 
neurocognitive domains such as executive function, attention, and memory (Carpenter, 1994; 
Peuskens, Demily, & Thibaut, 2005; Sharma & Antonova, 2003).  The course and outcome of 
schizophrenia are as varied as its symptoms.  A series of studies published between 1972 and 
1985 in European and United States Caucasian populations found differing outcomes between 
patients, irrespective of diagnostic criteria used (see (Huber, 1997) for review).  Taken together, 
these studies suggest that full psychopathological remission is seen in about 25% of patients and 
roughly 50% of patients display social remission.  These studies also concluded that course of 
illness could not be reliably predicted at age of onset (Huber, 1997).  Based on the conclusions of 
a series of cross-national World Health Organization (WHO) studies, it has been accepted that 
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patients in developing countries have a better course and outcome (A. Jablensky et al., 1992; 
W.H.O., 1979) (G. Harrison et al., 2001).  However, a recent analysis of 23 longitudinal studies 
of schizophrenia outcomes suggests the data is more complex than originally interpreted and 
those initial findings should be re-examined (A. Cohen, Patel, Thara, & Gureje, 2008).  It has 
also been well accepted that women experience a better outcome than men (R. Z. Cohen, 
Gotowiec, & Seeman, 2000).  The study by Cohen and colleagues found this to be the case in 
some, but not all countries (A. Cohen et al., 2008), further supporting a complex pattern of 
course and outcome of schizophrenia based on a myriad of factors.   
1.2.3 Epidemiology of schizophrenia  
The etiology of schizophrenia is poorly understood, but clearly complex and likely to involve 
major genetic and environmental contributions.  Schizophrenia occurs in all populations studied 
to date.  The lifetime prevalence is often referenced as 1%, and incidence rates have varied from 
0.16 – 0.42 across populations (A. Jablensky, 2000), however there have been significant 
differences in estimates between studies. Although the incidence is often quoted as stable 
worldwide, one systematic review suggested significant variation in incidence rates around the 
world (McGrath, 2006).  Another review suggested the median lifetime prevalence was only 
about 0.4% among studies (Saha, Chant, Welham, & McGrath, 2005).  A recent population 
based survey of more than 8,000 individuals from Finland suggested significant differences 
between psychotic disorders, age groups, and gender within the population studied (Perala et al., 
2007), lending further credence to the need for diagnostic reliability highlighted in section 1.2.2 
above.  Specifically, the authors found a lifetime prevalence of schizophrenia that was slightly 
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lower than 1% (0.83%); however the lifetime prevalence of all psychotic disorders was roughly 
3%.  A summary of these findings are detailed in Table 1.   
 
Table 1 Lifetime Prevalence Estimates of DSM-IV Nonaffective and Affective Psychoses 
Diagnosis N LTP All LTP Men LTP Woman 
Nonaffective psychotic 
disorders 
153 1.94 (1.63-2.29) 1.64 (1.24-2.17) 2.19 (1.78-2.70) 
Schizophrenia 67 0.87 (0.68-1.11) 0.82 (0.56-1.19) 0.91 (0.65-1.27) 
Schizoaffective disorder 24 0.32 (0.21-0.46) 0.14 (0.06-0.34)* 0.47 (0.30-0.72) 
Delusional disorder 15 0.18 (0.11-0.30) 0.16 (0.07-0.34) 0.21 (0.11-0.40) 
Psychotic disorder NOS 38 0.45 (0.33-0.62) 0.33 (0.19-0.56) 0.56 (0.39-0.82) 
All psychotic disorders 249 3.06 (2.66-3.51) 3.11 (2.54-3.57) 3.01 (2.54-3.57) 
This is a summary table of lifetime prevalence estimates based on population based survey of 8,028 
persons 30 years or older screened for psychotic and bipolar I disorders from Perala et al., 2007. LTP = 
lifetime prevalence.  Data are given as percentages and 95% confidence interval provided. Only 
nonaffective psychotic disorders with > 5 affected subjects detected are provided by diagnosis.  ‘All 
psychotic disorders’ includes individuals with nonaffective psychotic disorders as well as those with 
affective psychoses, substance-induced psychotic disorder, and psychotic disorder to to a general 
medical condition.  *Statistically significant difference (p < 0.05) between sexes detected. 
  
The age at onset of the disorder is early adulthood, with estimates ranging from about 18 
– 24 years.  There are detectable gender differences in various aspects of schizophrenia.  The 
Perala et al study opposed the commonly held view that schizophrenia occurs equally frequently 
in males and females, instead documenting a 1.4:1 male:female ratio (Perala et al., 2007).  Males 
have been shown in some studies to have a lower age at onset and more frequent occurrence of 
brain abnormalities whereas females generally have better premorbid functioning and less 
disability (Angermeyer & Kuhn, 1988; A. Jablensky et al., 1992; W.H.O., 1979).  The decreased 
age at onset in seen in males has been replicable, and in some studies dramatic, but results have 
varied across studies (Hambrecht, Maurer, & Hafner, 1992; W.H.O., 1979) (see (A. Jablensky, 
2000) for review).  One plausible case of discrepancies between populations is the finding of a 
marked difference in sex ratio for late-onset schizophrenia (onset after age 40), which has been 
estimated at 1:1.9 male to female ratio after age 40 and up to 1:6 ratio after age 60 (Huber, 
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Gross, & Schuttler, 1979; A. Jablensky, 2000).  It is therefore possible that difference in age at 
onset seen between males and females are a sampling artifact.  For example, analysis of the more 
than 500 schizophrenia cases analyzed in this dissertation from Pittsburgh, PA, U.S. did not 
detect significant differences in age at onset of the disorder (unpublished data).  However, 
subsets of cases were ascertained on the basis of family configurations, requiring both parents to 
participate as a case-parent trio, a sampling bias against ascertainment of late onset cases.  
Ascertainment criteria and study design can therefore have a significant impact on such analyses. 
The environmental risk factors that have been associated with schizophrenia are too 
numerous and speculative to discuss at length here.  Some of the more highly cited and 
replicated results across populations have included season of birth, maternal and / or paternal 
age, substance abuse, prenatal complications, comorbid medical conditions, viral infection, 
immune response, urban birth, urban versus rural residence, and immigration (see (A. Jablensky, 
2000) for review).  That there is an environmental influence in the etiology of schizophrenia 
seems certain based on the currently available data; however the ability to quantify the 
contribution of specific environmental factors on any given individual is limited.  Therefore, to 
reduce the analytic space, the studies conducted herein consider environmental effects as an 
unknown confound and focus only on gender and age at onset of illness as potential covariates in 
the development of schizophrenia.  
1.2.4 Treatment of schizophrenia 
The first meaningful pharmacological success in the treatment of schizophrenia came with the 
introduction of chlorpromazine in the late 1950’s.  The therapy was extremely successful in 
reducing positive symptoms of schizophrenia, but not negative symptoms and cognitive deficits 
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often seen (Crow, 1980a, 1980b; Kane, 1990; Kane, Honigfeld, Singer, & Meltzer, 1988).  
Furthermore, the medication did not reduce symptoms in 5% - 25% of patients (Christison, 
Kirch, & Wyatt, 1991; Meltzer, 1992a, 1992b).  About a decade later came the introduction of 
second generation, or atypical antipsychotics such as clozapine, olanzapine, risperidone, and 
others.  While both generations of antipsychotics exert their influence on the dopaminergic 
system, specifically dopamine D2 receptors, the atypical antipsychotics also affect the 
serotinergic system.  These second generation agents were effective in reducing extrapyramidal 
side effects compared to typical antipsychotics, and were effective in the treatment of negative 
symptoms and cognitive deficits.  The side effects of atypical antipsychotics include weight gain 
and metabolic effects.  Atypical antipsychotics are significantly more expensive than typical 
antipsychotics, and recent clinical trials suggest atypical antipsychotics are not more effective 
than first generation agents and are not associated with better cognitive or social outcomes 
(Swartz et al., 2007).  Nonetheless, the reduced extrapyrimidal side effects and improved 
reduction in negative symptoms still make atypical antipsychotics successful therapeutic agents 
in many cases.  The current availability of first and second generation antipsychotics, as well as 
the newer ‘third generation’ antipsychotics, ‘dopamine-serotonin stabilizers’, give clinicians a 
range of options for patient specific therapy. 
1.2.5 Schizophrenia pathogenesis: dopaminergic neurotransmission 
Despite several decades of research and promising leads suggesting structural and functional 
neurological alterations, the pathogenesis of schizophrenia remains unknown (D. A. Lewis & 
Lieberman, 2000).  The mechanism of antipsychotic agents, exerting their influence by binding 
targets in the central nervous system, suggests neurotransmitter dysfunction is a critical area for 
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study.  Typical antipsychotics significantly reduce positive symptoms of schizophrenia by 
blocking dopamine receptors, whereas atypical antipsychotic include occupancy of serotonin 
receptors with consequent reduction in negative symptoms and cognitive deficits of the disorder.   
Neurotransmitter theories of schizophrenia have suggested multiple pathways, including 
glutamate and GABA alterations (Collier & Li, 2003).  Yet the majority of evidence suggests 
dopamine is the final common pathway underlying psychotic symptoms, as well as negative and 
cognitive symptoms.  
 Dopaminergic neurons in the central nervous system project an extensive network of 
connections throughout the brain.   Substantia nigra dopaminergic neurons project primarily to 
the striatum, and neurons in the ventral tegmental area project primarily to cortical (mesocortical 
pathway) and limbic (mesolimbic pathway) regions of the brain (Sillitoe & Vogel, 2008).  The 
neostriatal dopaminergic pathway is thought to regulate motor control, while the mesocortical 
and mesolimbic pathways mediate many of the behavioral functions influenced by the 
dopaminergic system.  These projections enable dopaminergic neurons to exert their diverse 
influence on a spectrum of behaviors from movement to cognitive function. 
Hyperactivity of dopaminergic transmission was the first proposed ‘dopamine 
hypothesis’ of schizophrenia.  The hypothesis broadly suggests that ‘positive symptoms’ result 
from hyperstimulation of D2 receptors from hyperactive subcortical mesolimbic projections, and 
hypoactive mesocortical projections to the prefrontal cortex induce negative symptoms (Lang, 
Puls, Muller, Strutz-Seebohm, & Gallinat, 2007; Toda & Abi-Dargham, 2007).  The hypothesis 
was initially supported by the correlations between the clinical potency of antipsychotics 
specifically on the D2 receptors (Carlsson & Lindqvist, 1963; Creese, Burt, & Snyder, 1976; 
Crow, 1980a; Seeman, Lee, Chau-Wong, & Wong, 1976).  It remains today that all effective 
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antipsychotics have some affinity for the D2 receptor (Kapur & Mamo, 2003).  Traditional 
antipsychotics bind tightly to the D2 receptor with slow dissociation rates whereas atypical 
antipsycotics display faster dissociation rates, presumably accounting for the reduced 
extrapyramidal side effects (Seeman, 2002; Seeman & Tallerico, 1998, 1999).  To test the 
hypothesis, a large number of variables have been investigated among cases and controls.  They 
include post mortem dopamine receptor density, dopamine metabolite concentrations, in vivo 
measures of dopamine receptor density using PET scans, and the psychotogenic effects of agents 
that increase synaptic dopamine release (Abi-Dargham et al., 1998; Angrist & van Kammen, 
1984; Breier et al., 1997; Davidson et al., 1987; Farde et al., 1987; Hess, Bracha, Kleinman, & 
Creese, 1987; Lieberman et al., 1984; Mackay et al., 1982; Seeman et al., 1987; D. F. Wong et 
al., 1986).  Despite controversies, dopamine antagonism remains a key characteristic evaluated 
when novel agents are designed for schizophrenia (Davis, Kahn, Ko, & Davidson, 1991; D. A. 
Lewis & Lieberman, 2000).  Recent evidence suggests that subtle dopamine dysregulation could 
occur in schizophrenia, rather than overall dopamine hyperactivity (Davis et al., 1991; Greene, 
2006; Laruelle, Abi-Dargham, Gil, Kegeles, & Innis, 1999; Seeman et al., 2006).  These 
subtleties likely reflect the impact of a number of susceptibility factors.   
There is growing evidence for intricate homeostatic mechanisms that regulate dopamine 
homeostasis.  The intensity and duration of dopamine signaling in the brain is determined by the 
amount of vesicular release, dopamine receptor sensitivity and the efficiency of dopamine 
clearance from the extracellular compartment (Gainetdinov, Sotnikova, & Caron, 2002; Torres, 
Gainetdinov, & Caron, 2003).  Dopamine released into the synaptic space can undergo 
enzymatic degradation and dilution by diffusion. Two enzymes metabolize dopamine 
intracellularly, oxidative deamination by monoamine oxidase (MAO) and O-methylation by 
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COMT (Napolitano, Cesura, & Da Prada, 1995).  However, the primary mechanism controlling 
extracellular dopamine levels has proven to be reuptake by presynaptic neurons via the plasma 
membrane dopamine transported (DAT) (Amara & Kuhar, 1993; Cragg & Rice, 2004; Giros & 
Caron, 1993).  Thus, re-uptake through DAT is the most effective way to limit the lifetime of 
dopamine signaling in the brain. 
 
Figure 1 Key genes, localization, and function in the dopaminergic pathway 
Figure from (Youdim, Edmondson, & Tipton, 2006).  This figure shows the localization and action of 
several key dopaminergic genes investigated in this series of studies.   
 
There are potential interactions that influence dopaminergic neurotransmission.  
Degradation of dopamine by COMT can influence the activity of DAT.  The activity of DAT can 
also be regulated by dopamine autoreceptors.  Both the DRD2 and DRD3 subtypes have been 
shown to be involved in the regulation of DAT function (Zahniser & Doolen, 2001).  For 
example, the DRD3 receptor-preferred agonist PD 128907 produced an increase in DAT 
function in striatal slices as measured by rotating disk electrode voltametry (Zapata & 
Shippenberg, 2002) suggesting a cross-talk between the DRD3 and DAT.  The molecular details 
of this cross-talk are not known, however these functional studies suggest important interactions 
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within the dopaminergic pathway could modulate dopamine transmission.  The genes encoding 
dopaminergic proteins are further discussed in Chapter 3.0 below.  One primary motivation for 
the genetic studies conducted herein is to determine if such functional interactions influence 
schizophrenia pathogenesis.   
1.3 SCHIZOPHRENIA: A COMPLEX GENETIC DISORDER 
1.3.1 Genetic epidemiology 
Since its conception it has been observed that schizophrenia tends to cluster in families.  The 
morbid risk in the general population is roughly 1%, however risk to children of schizophrenic 
probands is 13%.  The morbid risk for monozygotic twins and offspring of dual patient mating 
are 48% and 46%, respectively, indicating a substantial genetic contribution (Figure 1) (I. 
Gottesman, 1991).  Adoption studies also suggest a genetic basis for the disorder, finding that the 
familial aggregation cannot be explained solely by environmental influence (Heston, 1966; Kety 
& Ingraham, 1992).  The sibling recurrence risk ratio, λs, is estimated at 8-10 (Risch, 1990).  
Heritability estimates have varied widely, ranging from 41-80% (Kendler & Robinette, ; McGue, 
Gottesman, & Rao, 1983; Rao, Morton, Gottesman, & Lew, 1981). Although controversial, 
particularly due to questions regarding clinical diagnoses (Farmer, McGuffin, & Gottesman, 
1987; McGuffin, Farmer, Gottesman, Murray, & Reveley, 1984), recent review of 224 twin 
probands from the Maudsley Twin Register in London conducted after publication of the DSM-
IV suggests the heritability of the disorder is on the high end of this distribution (Cardno et al., 
2007).  The authors derived estimates of heritability between 82% – 85%, with no significant 
 28
differences between diagnostic tools or diagnoses themselves in the full range of functional 
psychoses (schizophrenia, schizoaffective disorder, and mania).  Similar estimates were derived 
from an earlier population based twin study in Finland (1180 male pairs and 1315 female pairs), 
which found that 83% of the variance in liability was due to additive genetic factors (Cannon, 
Kaprio, Lonnqvist, Huttunen, & Koskenvuo, 1998).   Mode of inheritance is also unknown.  
Both autosomal dominant and recessive modes of inheritance have been suggested (Hurst, 1972; 
Slater, 1958).  Complex segregation analyses of published family and twin data on the diagnostic 
trait suggest polygenic inheritance, likely including multiple genes of small effect (Carter & 
Chung, 1980; McGue et al., 1983; Rao et al., 1981).  Regarding qualitative and quantitative traits 
associated with the disorder, a study currently in press found significant heritability and 
autosomal dominant inheritance for several endophenotypes (Aukes et al., 2008).  It should be 
noted that the heritability of endophenotypic measures have not been shown to be higher than the 
diagnosis of schizophrenia itself (heritability range from 24% - 55% in various neurocognitive 
endophenotypes) (Greenwood et al., 2007).  Based on these and similar studies over the last 
century, it is now widely accepted that the distribution of the disorder in families and populations 
is consistent with genetic models including multiple interacting loci of modest effect (Risch, 
1990; Schliekelman & Slatkin, 2002).   
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Figure 2 Morbid risks for schizophrenia 
Lifetime risk of developing schizophrenia based on relationship to an affected individual.  Values are 
given in percentages.  Blue arrow shows discrepancy between monozygotic twins and dyzogotic twins.  
Figure adapted from Gottesman, 1991.   
  
1.3.2 Linkage to schizophrenia 
Genetic linkage is a test of the co-segregation within families of a phenotypic trait and a genetic 
locus.  Linkage analyses have been extremely successful in mapping disease genes for many 
human diseases, including Huntington’s disease, breast cancer, and cystic fibrosis, to name a 
 30
very few.  The general strategy in gene mapping studies has been to first detect significant 
linkage, usually over a broad genomic region, then conduct focused fine mapping analyses to 
identify genes contributing to the linkage signal.  Despite many documented successes of this 
‘positional cloning’ method, the strategy has been relatively ineffective in psychiatric genetics.  
The potential reasons for this lack of success have been well documented and are likely due to 
limitations in power of most studies, presence of multiple disease genes of small effect, low 
penetrance, and a high degree of genetic heterogeneity between families.  A large literature of 
linkage studies exists over the past two decades and putative linkage has been reported on nearly 
all autosomes and the X chromosome across populations, but there has been little consistency 
between studies.  Initial studies were designed using a small number of extended pedigrees, a 
design ideally suited for identifying genes of large effect within families.  One such strategy 
identified a “major susceptibility locus” on chromosome 1q21 – 22, with a reported LOD score 
of 6.50 (Brzustowicz, Hodgkinson, Chow, Honer, & Bassett, 2000).  Yet a subsequent large 
scale, multi-site study with substantial power failed to confirm linkage in this region (Levinson 
et al., 2002).  The more recent trend has been to incorporate large samples of smaller families in 
an effort to increase power to detect loci of small effect.  A meta-analysis of the 20 largest 
linkage scans identified several regions of suggestive, but not significant, linkage to 
schizophrenia (C. M. Lewis et al., 2003).  Subsequent analyses indicate these large studies could 
be more consistent than expected by chance (Zintzaras & Ioannidis, 2005), but it should be noted 
that the three largest sibling pair studies of schizophrenia in those analyses (> 300 sibling pairs 
per study) failed to detect overlapping linkage at a single locus in the genome (Crow, 2007).   
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1.3.3 Genetic association studies of schizohprenia       
Unlike linkage, genetic association relies on linkage disequilibrium between a genetic marker 
and a disease locus over a relatively short genetic distance. When the frequency of a genetic 
marker is observed more / less frequently in a case sample than an unaffected comparison group 
at a level greater than one would expect by chance, the conclusion is genetic association with 
that variant or a correlated variation.  The phenomenon is dependent on the presumption that the 
disease causing mutation occurred relatively recently, meaning the accumulation of 
recombination events within the population was insufficient to restore independence between the 
marker evaluated and the disease causing variant.  There are several advantages of association 
studies compared to linkage; most notably the relative short genetic distance expected between 
actual liability locus and genetic marker, as well as the ability to accumulate large population 
based samples rather than the expense of ascertaining intact families.    
The number of genetic association studies conducted on schizophrenia and related 
phenotypic traits over the last two decades are staggering.  A PubMed search of “schizophrenia” 
“gene” and “association” retrieves 1,973 studies.  According to a systematic meta-analysis and 
field synopsis of genetic association studies in schizophrenia (SzGene database), as of April 
2007, 1,179 genetic association studies have been published worldwide reporting on 3,608 
genetic variants from 516 different genes (Allen et al., 2008).  The results of these studies have 
been largely inconsistent.  Several promising targets, such as DTNBP1 and NRG1 have emerged, 
but in the estimation of this dissertation no robust genetic risk factors have been established from 
any individual genes.  Despite these inconsistencies, reviews have suggested significant success 
in genetic epidemiological studies of schizophrenia, several of which are listed here (Harrison & 
Weinberger, 2005; (P. J. Harrison & Owen, 2003); (Craddock, O'Donovan, & Owen, 2005) 
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(Craddock, O'Donovan, & Owen, 2006) (Shirts & Nimgaonkar, 2004) (Owen, Williams, & 
O'Donovan, 2004), (Owen, Craddock, & O'Donovan, 2005); (Owen, Craddock, & Jablensky, 
2007).  The successes claimed in these reviews have been met with dissenting opinions, as Dr. 
Crow states “Thus this body of work must be regarded as an indicator of the extent to which the 
‘eye of faith’ is able to discern meaning in complex data when none is present” (Crow, 2008b).   
A detailed review of the literature regarding dopaminergic gene polymorphisms and 
schizophrenia pathogenesis are described in chapter two.  The details of the remaining candidate 
genes reviewed in the articles listed above are too numerous and cumbersome to describe here, 
however it should be noted that many of these past genetic association studies followed a similar 
pattern.  An initial study investigated very few variations (usually coding or putatively 
functional) for a single gene in a small sample.  Replicate studies would then analyze only 
associated variants, leaving a sizeable gap in the literature regarding evaluation of representative 
genetic variation.  A good example of this pattern can be seen in the investigative course of 
RGS4, where putative linkage and expression evidence lead to a significant association study 
with differing risk alleles and haplotypes between populations (Brzustowicz et al., 2000; 
Chowdari et al., 2002; Mirnics, Middleton, Stanwood, Lewis, & Levitt, 2001).  No gene of large 
effect has subsequently identified to validate the linkage results, and the associations were 
proven to be false positive findings based on power and technological limitations in the initial 
reports, yet more than 25 samples have been studied to date since those findings.  Nonetheless, 
analysis of over 13,000 individuals could neither support nor reject the null hypothesis of no 
association (Chowdari et al., 2007; Chowdari et al., 2002; Talkowski, Chowdari, Lewis, & 
Nimgaonkar, 2006; Talkowski, Seltman et al., 2006) (Talkowski et al., unpublished data).   
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Ambiguous results such as those at RGS4 permeate the literature of schizophrenia 
association studies.  The hypothesis underlying the series of studies presented in this dissertation 
is that any assumptions regarding these genes as schizophrenia susceptibility factors are 
premature and potentially erroneous.  The empirical evidence obtained to date for most genetic 
association studies is insufficient to enable conclusions for, or against, credible risk factors.  As 
simulations have shown, in the presence of an unmeasured liability locus, patterns of association 
can be complex amongst measured SNPs (Roeder, Bacanu, Sonpar, Zhang, & Devlin, 2005).  
This complexity obviously grows as the ratio of unmeasured SNPs to measured SNPs gets large, 
as is the case with most of these genes.  Recent large scale efforts such as a study of 14 candidate 
genes by Sanders and colleagues (Sanders et al., 2008) and ongoing genomewide studies from 
the genetic analysis and information network (GAIN) initiative have begun to fill the void in the 
current literature and provide more reliable, if unspectacular, estimations of genetic risk 
conferred by susceptibility gene candidates.   
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2.1 ABSTRACT 
The dopamine hypothesis of schizophrenia has motivated a large number of genetic 
association studies, but few if any dopaminergic polymorphisms are accepted as credible risk 
factors at present.  To evaluate whether dopamine related genes have been investigated 
adequately, we surveyed public genetic databases and published schizophrenia association 
studies with regard to fourteen conventional dopaminergic genes and seven selected dopamine 
interacting proteins.  We estimate that 325 polymorphisms would be required to evaluate the 
impact of common variation on schizophrenia risk among Caucasian samples.  To date, 98 
polymorphisms have been analyzed in published association studies.  We estimate that only 19 
of these variations have been evaluated in samples with at least 50% power to detect an 
association of the effect size commonly found in genetically complex disorders. While it is 
possible that dopaminergic genes do not harbor genetic risk factors for schizophrenia, our review 
suggests that satisfactory conclusions for most genes cannot be drawn at present.  Whole genome 
association studies have begun to fill this void, but additional analyses are likely to be needed.  
Recommendations for future association studies include analysis of adequately powered samples, 
judiciously selected polymorphisms, multiple ethnic groups and concurrent evaluation of 
function at associated SNPs.   
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2.2 INTRODUCTION 
Over the past two decades schizophrenia (SZ) mapping studies have grappled with 
several difficulties inherent to all studies of common, genetically complex disorders.  Heritability 
estimates for the disorder vary from 60-70% (McGue et al., 1983; Rao et al., 1981), but complex 
segregation analyses have consistently rejected monogenic models of inheritance in favor of 
polygenic / multi-factorial threshold models (Carter & Chung, 1980; McGue et al., 1983). A 
genetic model including multiple interacting loci of small effect may provide the best fit for the 
available data (Risch, 1990; Schliekelman & Slatkin, 2002; Sha, Zhu, Zuo, Cooper, & Zhang, 
2006), making it difficult to identify individual genetic risk factors.  Some analyses suggest that 
common genetic variants confer risk (also called the ‘common variant common disease’ 
hypothesis, CDCV) but others have argued in favor of rare variants (I. I. Gottesman, 1994; Jorde, 
2000; McClellan, Susser, & King, 2007).  Aided by technological and statistical advances, 
genetic association studies have grown in size and sophistication (Collins, Guyer, & Chakravarti, 
1997; Hirschhorn, 2002).  Thanks to these advances, some promising associations have been 
detected.  For example, studies utilizing extended panels of single nucleotide polymorphisms 
(SNPs) have identified associations with polymorphisms of dysbindin (DTNBP1), neuregulin 1 
(NRG1), disrupted in schizophrenia (DISC1), regulator of G protein signaling (RGS4), G72 and 
D-amino-acid oxidase (Craddock et al., 2005; P. J. Harrison & Weinberger, 2005; Owen et al., 
2005; K. M. Prasad & Nimgaonkar, 2007).  Consistent with the polygenic model, the risk 
conferred by the associated alleles is modest (odds ratios, OR ~1.2) (Shirts & Nimgaonkar, 
2004)  
A sizable fraction of other association studies have focused on dopaminergic genes, but 
few credible genetic risk factors have emerged. Two broad conclusions are thus possible: either 
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there are no significant associations between schizophrenia and dopamine polymorphisms or 
sufficient evidence is not currently available. In this review, we evaluate the possible impact of 
dopaminergic gene polymorphisms on schizophrenia risk.  We summarize the motivation for, 
and details of, prior genetic association studies involving dopamine genes.  We also survey 
public database information to determine the proportion of representative common variants that 
have actually been evaluated at these genes, and the number of SNPs analyzed with adequate 
power to detect an association of the modest effect sizes expected.  We conclude with suggested 
designs for future studies and discuss the relevance of such studies in the context of whole 
genome association studies. 
2.2.1 The dopamine hypothesis 
The dopamine hypothesis suggests hyperactivity of dopamine brain function in 
schizophrenia pathogenesis.  It originated from correlations between the clinical potency of anti-
psychotic drugs and their affinity for dopamine D2 receptors (DRD2) (Carlsson & Lindqvist, 
1963; Creese et al., 1976; Seeman et al., 1976).  Two lines of enquiry have yielded relatively 
consistent results regarding the dopamine hypothesis of schizophrenia.  First, patients with 
schizophrenia display increased sensitivity to the psychotogenic effects of agents that increase 
synaptic dopamine release (Angrist & van Kammen, 1984); Lieberman, 1984 #2673; Davidson, 
1987 #2672; Laruelle, 1999 #2664}.  Second, acute amphetamine challenge to patients leads to 
increased dopamine transmission in vivo, as measured by radioligand binding to dopamine D2 
receptors during positron emission tomography (PET) scans (Abi-Dargham et al., 1998; Breier et 
al., 1997; Laruelle et al., 1996).  However, the dopamine hypothesis has not been supported 
consistently using measures such as post mortem dopamine receptor density or dopamine 
  38
metabolite concentrations, in vivo measures of dopamine receptor density using PET scans or 
dopamine metabolite concentrations in the cerebrospinal fluid (Bird et al., 1977; Cross, Crow, & 
Owen, 1981; Farde et al., 1987; Hess et al., 1987; Mackay et al., 1982; Seeman et al., 1987; 
Widerlov, 1988; D. F. Wong et al., 1986).  The discrepancies could be due to medication effects 
and sampling variation (Davis et al., 1991; D. A. Lewis & Lieberman, 2000).   
Refining the dopamine hypothesis: Subtle dopamine dysregulation could occur in schizophrenia, 
rather than overall dopamine hyperactivity; e.g., regional variation, selected receptor types, 
temporal sensitization or variations during different phases of illness (Davis et al., 1991; Greene, 
2006; Laruelle et al., 1999; Seeman et al., 2006).  Hypofunction in prefrontal neuronal circuits 
has been documented repeatedly in post-mortem brain studies of schizophrenia; this may also 
lead to disinhibition of the prefrontal drive to the limbic striatum with a resultant 
hyperdopaminergic state in the limbic striatum (D. A. Lewis & Lieberman, 2000; Weinberger, 
1987).  These subtle changes likely reflect a chain of events, so a number of susceptibility factors 
may be present.  This is consistent with the polygenic model of schizophrenia. 
 
2.2.2 Genetic association studies using dopamine polymorphisms   
The extensive interest in the dopamine hypothesis has also motivated numerous 
association studies of dopamine genes under the rationale that credible genetic associations 
would motivate further studies of pathogenesis.  However, most early association studies were 
hampered by significant deficiencies in technology and relatively modest sample sizes available.  
Despite these limitations, the gamut of genes involved in dopamine neurotransmission was 
investigated.  We conducted PubMed searches using the following combinations of terms: (1) 
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“(individual gene name)” and “schizophrenia”; (2) “(gene symbol)” and “schizophrenia”; (3) 
“dopamine” and “schizophrenia”.  Genetic association studies were then extracted from these 
sets.  As discussed below, most studies followed a similar pattern.  An initial study reported on 
one or a few putatively functional polymorphisms and subsequent studies analyzed only those 
variants.  Some study designs, such as mutation detection followed by association tests in 
relatively small samples, are better suited to identify susceptibility loci harboring a substantial 
impact on risk.  Thus, no consistent associations have been detected for a number of key 
dopaminergic genes, potentially leading to the conclusion that susceptibility variants are not 
present in the dopaminergic network.   
The dopaminergic genes investigated in multiple independent samples include tyrosine 
hydroxylase (TH) (Chao & Richardson, 2002; Ishiguro, Arinami et al., 1998; D. Li & He, 2006), 
dopamine decarboxylase (DDC) (Borglum et al., 2001; Zhang et al., 2004), dopamine beta 
hydroxylase (DBH) (Cubells & Zabetian, 2004; Jonsson, Abou Jamra et al., 2003; Tang et al., 
2006; Yamamoto et al., 2003), COMT (see below), MAOA (Jonsson, Norton et al., 2003; Nolan, 
Volavka, Lachman, & Saito, 2000; Norton et al., 2002; Sabol, Hu, & Hamer, 1998; Syagailo et 
al., 2001; Tunbridge, Harrison, & Weinberger, 2006), and one of the two isoforms of the 
vesicular monoamine transporter (SLC18A1, alias VMAT1) (Bly, 2005; S. F. Chen et al., 2007; 
Richards et al., 2006).  The dopamine receptors DRD1, DRD2, DRD3, DRD4, and DRD5 have 
also been investigated (Cichon et al., 1996; Fanous et al., 2004; Glatt & Jonsson, 2006; Jonsson, 
Kaiser, Brockmoller, Nimgaonkar, & Crocq, 2004; Muir et al., 2001; A. H. Wong, Buckle, & 
Van Tol, 2000).  The vesicular monoamine transporter, member 2 (VMAT2, SLC18A2) has only 
been investigated in one study to date (Kunugi, Ishida, Akahane, & Nanko, 2001).   
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Other investigators have reported on dopamine interacting proteins, with similarly 
inconsistent results.  They include Orphan Nuclear Receptor Subunit 4 (NURR, NR4A21); D1 
Receptor Interacting Protein (CALCYON, DRD1IP); Protein Phosphatase 1, Regulatory 
(inhibitory) subunit 1B (dopamineRPP-32, PPP1R1B); Syntaxin 1A (STX1A); Protein Interacting 
with PRKCA 1 (PICK1); Synaptosomal-Associated Protein, 25kDa (SNAP25); and Beta 
Adrenergic Receptor Kinase 2 (GRK3, ADRBK2) (Y. H. Chen, Tsai, Shaw, & Chen, 2001; Fujii 
et al., 2006; Hong, Liao, Shih, & Tsai, 2004; Ishiguro et al., 2007; Iwayama-Shigeno et al., 2003; 
C. H. Li, Liao, Hung, & Chen, 2006; Luo et al., 2004; Tachikawa, Harada, Kawanishi, Okubo, & 
Suzuki, 2001; A. H. Wong et al., 2004; S. Y. Yu et al., 2004).  
Since space restrictions preclude detailed discussion of each gene, we have reviewed four 
of the most extensively analyzed dopamine genes.  While early association studies have been 
inconsistent for all of them, studies published in the past decade have provided intriguing new 
facets.  Each gene thus provides precepts for future association studies. 
2.2.3 Dopamine D2 receptor (DRD2) 
 The dopamine D2 receptor was a logical early target for association studies because of the 
effects of therapeutic agents reviewed above.  Two genetic variants have been the target of most 
studies.  One is a cysteine to serine substitution at codon 311 (Cys311Ser); the other an insertion 
/ deletion 141 bases in the 5’ region of the gene (-141C ins/del).  Two independent meta-analyses 
identified a significant association between the rare Cys311 allele and schizophrenia (Glatt, 
Faraone, & Tsuang, 2003b; Jonsson, Sillen et al., 2003), a result that has since been confirmed 
by a more comprehensive meta-analysis including data from 3,707 cases and 5,363 controls 
(Glatt & Jonsson, 2006).  In contrast, a meta-analysis did not support an association with the 
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insertion / deletion polymorphism.  Other polymorphisms have been investigated more recently 
with significant results from four different studies (Dubertret et al., 2004; Hanninen et al., 2006; 
Kukreti et al., 2006; Parsons et al., 2007) but significant associations were not detected when 5 
SNPs were analyzed among a family cohort of Askhenazi Jewish families (M. D. Fallin et al., 
2005).  It would be instructive if the same set of polymorphisms could be analyzed in all these 
samples, followed by meta-analysis. 
2.2.4 Dopamine D3 receptor (DRD3)  
Over 50 studies have sought associations at DRD3, but most have focused exclusively on rs6280 
(Ser9Gly), a non-synonymous SNP in the first exon with possible functional effects (Jeanneteau 
et al., 2006).  Repeated meta-analyses have suggested a modest association, but all meta-analyses 
have not been consistent (Ioannidis, Ntzani, Trikalinos, & Contopoulos-Ioannidis, 2001; Jonsson 
et al., 2004; Shaikh et al., 1996). Recent studies have evaluated other variations with somewhat 
more consistent results.  Four studies focused on associations with SNPs upstream to exon 1 
(Anney et al., 2002; Ishiguro, Ohtsuki et al., 1998; Sivagnanasundaram et al., 2000; Staddon et 
al., 2005).  Three of these studies detected significant associations, suggesting inconsistencies at 
rs6280 could represent associations with other, correlated SNPs.  However, one large case-
control study and analysis of a family based sample did not reveal any significant associations 
(M. D. Fallin et al., 2005).  Two recent studies evaluated a larger proportion of representative 
variation; both detected significant haplotype based associations.  We found significant 
associations with SNPs and haplotypes spanning the gene in two independent samples 
(Talkowski, Mansour et al., 2006).  Another group reported significant haplotype based 
associations in the 3’ region of DRD3 in a Galician population (Dominguez et al., 2007).  In 
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sum, the numerous association studies conducted at rs6280 appear to be equivocal with respect 
to schizophrenia susceptibility; however more recent results considering a greater proportion of 
common variation within the gene have been more encouraging.  These recent findings may 
represent other liability loci at this gene and might highlight the value of comparative analyses of 
varied ethnic groups.  Such studies lend themselves to evolutionary analyses that may identify 
ancient mutations (Seltman, Roeder, & Devlin, 2003; Templeton, Boerwinkle, & Sing, 1987; 
Templeton, Weiss, Nickerson, Boerwinkle, & Sing, 2000). 
2.2.5 Catechol-o-methyltransferase (COMT)  
COMT is localized to chromosome 22q11, a region implicated in several linkage studies (C. M. 
Lewis et al., 2003).  Deletions in this region also lead to the velocardiofacial syndrome, with an 
increased risk of psychoses (Karayiorgou et al., 1995). Most association studies have 
investigated an exonic Met158Val polymorphism, which appears to influence COMT activity in 
vitro. Two different meta-analyses suggest that an association between this variant and 
schizophrenia, if present, is complex and may be influenced by population substructure (Glatt, 
Faraone, & Tsuang, 2003a; Lohmueller, 2003).  Interest in the Met158Val polymorphism has 
continued because it may be correlated with working memory, a trait known to be impaired in 
schizophrenia (Barnett, Jones, Robbins, & Muller, 2007; Egan et al., 2001; Tunbridge et al., 
2006).   
Recent association studies have investigated a larger set of SNPs.  Li examined eight markers 
in a Chinese sample and detected a significant association with an extended haplotype including 
Met158Val (T. Li et al., 2000).  Another large study of Ashkenazi Jewish patients revealed a 
highly significant association with two COMT SNPs, as well as a haplotype comprising 3 SNPs 
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spanning the 5’ to 3’ region of the gene (rs737865–rs4680–rs165599) (Shifman et al., 2002).  
However, a study among unrelated cases and controls did not replicate this finding (H. J. 
Williams et al., 2005), nor did a study of 274 Ashkenazi families investigating 7 COMT SNPs 
(M. D. Fallin et al., 2005).  Intriguingly, The Met158Val polymorphism was part of this 
haplotype and the association was more prominent among women.  Gender specific associations 
have been detected with a variant within this haplotype (rs737865) in Alzheimer’s disease as 
well (Sweet et al., 2005).  Notably, rs737865 is in proximity to an estrogen response element 
(Sweet et al., 2005).  These associations highlight the need to evaluate valid sub-groups of 
schizophrenia and the need to consider functional impacts of associated alleles. 
2.2.6 Dopamine transporter (DAT, DAT1, SLC6A3)    
Most association studies have focused on a functional tandem repeat (VNTR), 3’ to the stop 
codon in exon 15, but meta-analyses suggest no significant association (Fanous et al., 2004; 
Gamma, Faraone, Glatt, Yeh, & Tsuang, 2005; Mitchell et al., 2000; Vandenbergh et al., 1992).  
An association has been reported with an exonic SNP among Koreans (1389 C>T; rs2270912) 
(Jeong, Joo, Ahn, & Kim, 2004).  A case-control study among Iranians identified a significant 
association with a putative promoter variant (-67A/T; rs2975226; p = 0.0003; OR = 2.25) 
(Khodayari et al., 2004).  The association is particularly intriguing because cis-acting variation in 
the 5’ region of this locus may contribute to differential SLC6A3 expression in vitro and in vivo 
(Drgon et al., 2006; Kelada et al., 2005).  The Korean and Iranian studies need to be evaluated in 
additional samples.  Additional studies using common polymorphisms spanning the gene are also 
required.     
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2.3 PUBLISHED DOPAMINE ASSOCIATION STUDIES 
We examined 14 dopamine genes and 7 dopamine interacting proteins that have been used for 
prior association studies.  Our goal was to identify a representative set of common SNPs that 
should be evaluated to enable a reasonable test of the CDCV hypothesis for each gene.  The 
samples utilized were 60 unrelated Caucasians from the International HapMap project (CEPH 
population) (HapMap, 2003) or 90 unrelated individuals representative of the US population 
from the NIH Polymorphism Discovery Resource 90 individual subset (PDR90) 
(http://egp.gs.washington.edu/).  Data was obtained using the Genome Variation Server resource 
(http://gvs.gs.washington.edu/GVS/) (Carlson et al., 2004).  All SNPs with minor allele 
frequencies over 5% were identified, since currently available samples may lack power to detect 
associations with less frequent polymorphisms.  Since genotypes at many of these SNPs may be 
correlated due to linkage disequilibrium (LD), we selected representative ‘tag’ SNPs using a 
conventional cutoff (r2 < 0.8 between loci).  Based on these analyses, we found that 325 tag 
SNPs would be needed to tag all available common variations from these populations (Table 2).   
These estimates were next compared with the published association studies.  At each 
gene, we listed the number of variations evaluated in previous association studies (SNPs and 
other polymorphisms), as well as the largest individual association study for each gene (defined 
in terms of the number of cases, see Table 2).  If possible, LD between the polymorphisms was 
analyzed.  We also estimated the number of studies that had 50% power to detect associations of 
modest effect size for each of the polymorphisms tested (alpha = 0.05). We assumed an additive 
risk model with a genotype relative risk of 1.5 for homozygous individuals, 1.25 for 
heterozygous individuals, and a disease prevalence of 1%.  We also assumed that the marker 
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being considered was the actual liability variant and that genotyping errors were negligible.  
Thus, our power estimates are relatively lax.  
Ninety eight different polymorphisms have been investigated in all the association studies 
to date.  We find that only DRD5 has been comprehensively covered when considering the 
proportion of representative variations genotyped and power (Table 2).  If each of the published 
polymorphisms represents a tag SNP, 30.1% of the required tag SNPs may have been evaluated.  
In reality, the proportion of representative SNPs analyzed in the publications is almost certainly 
lower, since we were unable to estimate LD between many of these polymorphisms and several 
rare polymorphisms have been analyzed (data not shown).  We estimate that 19 of the 
polymorphisms studied had greater than 50% power to detect a genotype relative risk expected at 
an alpha threshold of 0.05.  Thus, most of the published studies, including those reporting on the 
genes with extensive numbers of polymorphisms are likely to lack sufficient power, even using 
our relaxed criteria. Under more realistic conditions (D’ = 0.9 between the genotyped marker and 
liability locus, 0.5% error rate, 1:1 case/control ratio, and a risk allele frequency of 0.2), we 
estimate that 595 cases and 595 controls would be required for 50% power under an additive 
model and 275 cases / 275 controls would be required under a dominant model of inheritance 
(1217 cases and 561 cases, respectively, would be required for 80% power under each model) 
(Purcell, Cherny, & Sham, 2003; Sham, Cherny, Purcell, & Hewitt, 2000).  These estimates are 
with regard to single marker analysis.  Additional corrections would be required for multiple 
independent tests.  Since analyses of epistatic interactions would require further corrections for 
multiple comparisons, the sample size requirements for identifying such effects will be even 
larger. 
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2.4 SUGGESTIONS FOR FUTURE ANALYSES 
2.4.1 Are more genetic association studies needed?   
Given the difficulties outlined above, it is worthwhile to weigh the utility of further gene 
mapping studies for schizophrenia.  We believe such studies are needed, primarily because it has 
been difficult to pinpoint environmental risk factors reliably (A. Jablensky, 1997; A. V. 
Jablensky & Kalaydjieva, 2003).  Gene mapping studies have been recommended for such 
disorders, particularly if they have substantial heritability (Merikangas & Risch, 2003). The 
substantial body of evidence pointing to dopamine dysfunction in schizophrenia is a natural 
starting point to re-evaluate available evidence. 
Some may argue against the need for further dopamine genetic studies because dopamine 
function is already an area of intensive research, including drug development efforts.   However, 
genetic association studies may provide additional value for such research.  First, emerging 
evidence suggests that networks of functionally related genes may be involved in pathogenesis of 
many multi-factorial disorders (Vogelstein, Lane, & Levine, 2000).  Carefully designed genetic 
studies might enable the identification of such networks, including key nodes to which novel 
therapeutics can be targeted (Goh et al., 2007).  Second, such analyses might help identify novel 
genes related functionally to ‘conventional’ dopamine genes.   
2.4.2 Which genes should be targeted?   
Apart from the genes involved in dopamine metabolism or those encoding dopamine receptors, a 
definition of ‘dopamine’ genes is difficult, because of the known cross-talk between 
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neurotransmitter systems.  Any list of ‘dopamine genes’ is also unlikely to remain static in the 
face of advances in neuroscience research.  We recommend starting with genes for which prior 
association evidence is available.  If further studies provide credible, consistent associations, 
additional functional interactants of the associated genes can be targeted.  
2.4.3 Which polymorphisms should be investigated? 
 Different types of polymorphisms are known in the human genome, ranging from SNPs to large 
copy number variations (CNVs) (Fanciulli et al., 2007).  SNPs are obvious starting points 
because they have been characterized extensively and because they can be assayed cheaply and 
accurately.  A secondary question is the choice of SNPs.  While it is relatively easy to select 
representative tag SNPs, the allele frequency of the selected SNPs is a more difficult choice.  The 
feasibility of detecting associations for common diseases using ‘common’ SNPs has been 
questioned on the grounds that they may not mirror the primary associations accurately and / or 
because risk may be due to relatively rare alleles (McClellan et al., 2007; Moskvina & 
O'Donovan, 2007; Terwilliger & Goring, 2000; Terwilliger & Hiekkalinna, 2006).   
While the possibility of rare variants predisposing to schizophrenia can not be 
discounted, currently available samples may not enable detection of statistical associations if 
such variants are examined directly.  One practical solution may be to select common tag SNPs, 
and follow up suggestive associations with more dense sets of SNPs, including rare variants.  
Such intensive analyses may enable us to detect causal variants. 
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Table 2 Published dopaminergic gene association studies and estimates of coverage 
Gene Location Gene Name (alias name) Size (kb)4
Publicly Available 
SNP Data1 Published Studies2 Largest Study* Meta-Analyses3 
Common 
SNPs  
(MAF> 5%)
Tag 
SNPs5
# Markers 
Studied6 
Power > 
50%7 
Cases / Controls 
** SNPs Result 
Dopamine Pathway Genes     
TH 11p15.5 Tyrosine hydroxylase 17.9 14 10 2 1 334/391 1 - 
DBH 9q34 Dopamine beta hydroxylase 33 68 39 2 0 178/178   
DDC 7p11 Dopamine decarboxylase 112.6 204 36 2 0 173/204   
DRD1 5q35.1 Dopamine D1 receptor 13.1 12 7 2 1 407/399   
DRD2 11q23* Dopamine D2 receptor 75.6 78 19 7 0 -274 2 +/- 
DRD3 3q13.3 Dopamine D3 receptor 60.2 69 18 17 4 331/280, (291) 1 + 
DRD4 11p15.5 Dopamine D4 receptor 13.4 4 2 5 5 630/520 2 - 
DRD5 4p16.1 Dopamine D5 receptor 12.1 1 1 2 0 158/437   
SLC18A1 8p21.3* 
Vesicular monoamine 
transporter, member 1 
(VMAT1) 48.4 60 20 4 0 354/365   
SLC18A2 10q25 
Vesicular monoamine 
transporter, member 2 
(VMAT2) 45.9 43 15 6 0 50   
SLC6A3 5p15.3 
neurotransmitter transporter, 
dopamine (DAT, DAT1) 62.6 120 49 7 0 252/271 1 - 
COMT 22q11.2* 
Catechol-O-
methyltransferase 37.2 50 30 11 3 1643/3980 1 +/- 
MAOA Xp11.3 Monoamine oxidase A 100.7 38 8 3  346/334   
MAOB Xp11.3 Monoamine oxidase B 125.8 16 12 0 0       
Dopamine Interacting Genes       
NR4A2 2q24.1* 
orphan nuclear receptor 
subunit 4 (NURR1) 18.3 6 3 2 0 180/180     
DRD1IP 10q26.3 
D1 receptor interacting 
protein (CALCYON)  21.5 5 4 1 0 276/253   
PPP1R1B 17q21.2 
protein phosphatase 1, 
regulatory (inhibitory) 
subunit 1B (DARPP-32) 19.7 3 1 3 0 249/273   
STX1A 7q11.23 Syntaxin 1A 30.4 7 3 4  192/192, (238)   
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Table 2.  Continued   
 
 
PICK1 22q13.1 
Protein interacting with 
PRKCA 1 28.4 17 6 3 
 
1765/1851   
SNAP25 20p12-p11.2 
Synaptosomal-associated 
protein, 25kDa 98.5 97 32 1 
0 
87/100   
ADRBK2 22q12.1 
beta adrenergic receptor 
kinase 2 (GRK3) 159.9 10 10 14 
0 
(16) and (97)     
1Publicly available genotype data: HapMap build 36 (www.Hapmap.org) (Thorisson, Smith, Krishnan, & Stein, 2005), and the NIHPDR 90 
screening subset (http://gvs.gs.washington.edu/GVS/index.jsp).  2Data from PubMed searches, see details in the text. 3Number of SNPs at which 
meta-analysis has been conducted is provided.  (+) = significant association detected, (-) = no significant association, (+/-) = conflicting results 
among meta-analyses.  Blank spaces indicate that meta-analyses have not been published. 4Includes sequences 5 kb upstream (5’) and 5 kb 
downstream (3’) of the gene.  5 Tag SNPs selected as described in the text.  Repeat polymorphisms not included. 6 Indicates number of studied 
polymorphisms that were not redundant (r2 < 0.8, where feasible).  7Number of SNPs for which individual study evaluating the SNP had 50% or 
greater power to detect an association; see details in the text. 8Study included samples from the US (151 trios, 331 cases, 274 controls) and India 
(141 trios)  9Study analyzed 16 Japanese families and 97 Chinese families.  *Studies with largest number of cases are included. ** Where family 
based samples were used, the number of families is listed in brackets.                                                                                                                                                   
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2.4.4 Sample Configurations   
The possibility of spurious associations due to ethnic admixture has motivated much 
debate and the espousal of family based association studies (Spielman & Ewens, 1993; 
Wacholder, Rothman, & Caporaso, 2000).  While family based samples detect 
association only in the presence of linkage and are thus particularly valuable, it is now 
feasible to correct for population sub-structure (Bacanu, Devlin, & Roeder, 2000; 
Pritchard & Rosenberg, 1999; Spielman & Ewens, 1993).  Though the choice of controls 
may be dictated by convenience, biased selection of controls has obvious implication for 
detecting associations.  Hence it is important to plan for follow up initial associations in 
other independent samples.   
2.4.4.1  Sample size  
The power analyses reviewed above suggest the need for relatively large samples.  Given 
the possibility of false positive associations, replicate analyses are also recommended 
(Editorial, 1999).  While sample size limitations remain significant hurdles for 
association studies, the availability of public repositories (http://www.nimh.nih.gov/), and 
the feasibility of staged analyses (Skol, Scott, Abecasis, & Boehnke, 2006) may make 
this issue more tractable. 
2.4.4.2 Which ethnic group/s?   
The overwhelming majority of genetic association studies are being conducted among 
individuals of Caucasian ancestry.  Our review suggests ethnic variation in the magnitude 
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of some of the associations.  Such variation is known in other disorders, for example the 
association between ApoE alleles and Alzheimer disease (Farrer et al., 1997).  Evaluation 
of multiple ethnic groups may also enable us to identify primary associations based on 
ancestral recombinations (Templeton et al., 2000).   
2.4.4.3  Functional Analysis 
The majority of genetic associations for schizophrenia have been reported with non-
coding polymorphisms, making it difficult to attribute function to the associated alleles.  
Nevertheless, such analyses are critical for understanding pathogenesis and may also be 
helpful in determining primary associations.  An interactive design, with genetic 
associations informing functional analyses, and vice versa, is desirable. 
2.4.4.4  Should genomewide associations (GWAS) supplant candidate gene studies?   
Recently, GWAS have come to the fore, thanks to the availability of a comprehensive 
trove of common polymorphisms, rapid and accurate genotyping platforms and 
sophisticated analytic techniques.  By analyzing a representative set of SNPs among 
cases and controls, GWAS studies seek to evaluate the relative impact of common 
polymorphisms.  Judicious analyses may also provide insights into epistatic interactions.  
Remarkable consistencies have recently been attained for a diverse set of common 
diseases, including age related macular degeneration, prostate cancer, Crohn’s disease 
and type I diabetes mellitus (Ennis et al., 2007; Gudmundsson et al., 2007; Libioulle et 
al., 2007; Saxena et al., 2007).  GWAS studies have already been reported for 
schizophrenia (Lencz et al., 2007) and other independent studies are in progress.  These 
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studies are likely to yield important new insights, so it is reasonable to question the need 
for focused candidate gene studies.   
It is important to note that GWAS represent the beginning of a new effort, rather 
than an end point in the gene mapping effort.  For example, GWAS studies will  
undoubtedly require replicate studies, followed by more detailed analysis of prioritized 
genes using more dense sets of polymorphisms.  Thus, ‘candidate gene analyses’ will still 
be needed. Indeed, common polymorphisms are not tagged uniformly across the genome 
in some arrays used for GWAS.  Thus, key associations may remain undetected, even 
with GWAS.  In other diseases, candidate gene analyses have also identified associations 
with SNPs that were not sufficiently large for detection using GWAS; e.g., associations 
between late-onset Alzheimer disease and SORL1 SNPs (Rogaeva et al., 2007).   
2.5 CONCLUSIONS 
Our review of published association studies involving dopaminergic genes highlights the 
lack of adequate analyses of variation at these genes.  Our findings suggest more 
comprehensive analyses are required in sufficiently powered samples, particularly in 
view of some promising recent results.  Replicate analyses, as well as analyses of 
multiple ethnic groups, in conjunction with functional evaluation of associated SNPs 
would be preferable. 
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3.1 ABSTRACT 
Meta-analyses have suggested an association between schizophrenia and a coding 
polymorphism (rs6280/Ser9Gly) at the dopamine D3 receptor gene (DRD3), but results 
have been inconsistent.  Since most studies have evaluated only rs6280, the 
inconsistencies may reflect associations with other variants.  We analyzed 13 
polymorphisms spanning 109kb in two independent samples (US: 331 cases, 151 trios, 
274 controls; India: 141 trios). In the U.S. samples, significant associations were detected 
with eight SNPs, including rs6280 (p = 0.001, OR:1.5, 95% CI:1.2-1.9).  Consistent 
associations in the case-control and family-based analyses were detected with a common 
haplotype spanning intron 1 to the 3’ region of the gene (rs324029-rs7625282-rs324030-
rs2134655-rs10934254; case-control, p=0.002, TDT, p=0.0009; global p-values = 0.002 
and 0.007, respectively).  In the Indian sample, one SNP was associated (rs10934254, 
p=0.03).  Moreover, over-transmission of the same common haplotype as the U.S. sample 
was observed in this cohort (TDT, p=0.005; global test, p=0.009).  Ser9Gly (rs6280) was 
associated with schizophrenia against this haplotype background, but not other 
haplotypes. 
These data suggest inconsistent findings at rs6280 may result from associations with 
other DRD3 variants.  A liability locus may be in LD with, or carried against, an 
associated haplotype spanning the gene.  Comprehensive SNP evaluation in larger 
samples is needed.  
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3.2 INTRODUCTION 
Dysfunction in the dopamine D3 receptor (DRD3) has long been implicated in the 
pathogenesis of schizophrenia (see (Gingrich & Caron, 1993); (Sokoloff & Schwartz, 
1995) for review).  DRD3 mRNA is predominantly expressed in the limbic system, a 
region thought to be dysfunctional in schizophrenia (Suzuki, Hurd, Sokoloff, Schwartz, 
& Sedvall, 1998).  Indeed, increased DRD3 receptor density has been noted in the 
mesolimbic region of post-mortem brain samples from patients with schizophrenia (A. 
M. Murray, Ryoo, Gurevich, & Joyce, 1994).  Post-mortem studies have also revealed 
decreased levels of DRD3 mRNA in cortical regions (Schmauss, Haroutunian, Davis, & 
Davidson, 1993).  These changes may be pathogenic, since D3 receptors are thought to 
mediate antipsychotic drug action (Sokoloff et al., 1992) (Schwartz, Diaz, Pilon, & 
Sokoloff, 2000).   
 DRD3 maps to chromosome 3q13.3.  Within the gene there is a common, non-
synonymous coding polymorphism in exon 1.  The single base change codes for either 
serine or glycine at the ninth amino acid in the N-terminal extracellular domain (Ser9Gly; 
rs6280) (A. H. Wong et al., 2000).  Genotypes of this variant have been reported to show 
differential affinity for dopamine (Lundstrom & Turpin, 1996), rendering it an intriguing 
functional candidate polymorphism.  Since the initial study reporting an association with 
schizophrenia (Crocq et al., 1992), this polymorphism has been among the most 
extensively investigated variants in psychiatric genetics.   
Consistent associations with schizophrenia have been sought at this locus in over forty 
samples to date, the majority involving case-control designs (see (Jonsson, Flyckt et al., 
2003).  Associations have been reported and replicated with increased homozygosity, as 
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well as the serine allele (rs6280 allele A; often reported as allele 1).  However, a number 
of studies have not replicated these results.  These data have motivated multiple meta-
analyses (Nimgaonkar et al., 1996) (Shaikh et al., 1996) (J. Williams et al., 1998) 
(Dubertret et al., 1998) (Jonsson, Flyckt et al., 2003) (Jonsson et al., 2004).  Meta-
analyses were conducted successively, and in sum they appeared to suggest a significant, 
but modest association with the serine variant (n = 8,761; estimated OR = 1.10, 95% CI = 
1.01 – 1.20) (Jonsson, Flyckt et al., 2003).  However, the most recent and largest effort to 
evaluate this polymorphism did not detect significant associations with schizophrenia (n 
= 11,066; Jonsson et al. 2004).    
Thus, despite an impressive compilation of data across multiple populations, the 
impact of this variant in schizophrenia pathogenesis has remained inconclusive.  There 
are several explanations for inconsistent results apart from stochastic variation.  One 
possibility is that the Ser9Gly variant itself is not associated with schizophrenia, but is in 
modest linkage disequilibrium (LD) with an unidentified liability locus.  Such a scenario 
could produce inconsistent associations similar to those previously reported.  Several 
investigators have attempted to address this hypothesis, focusing primarily on exon 1 and 
the immediate 5’ region of the gene.  Three studies have reported associations with 
polymorphisms spanning approximately 7 kb 5’ to exon 1 (Ishiguro, Ohtsuki et al., 1998) 
(Sivagnanasundaram et al., 2000) (Staddon et al., 2005).  In contrast, Anney and 
colleagues failed to detect associations in this region following mutation screens and 
analysis of 736 Caucasian cases and controls (Anney et al., 2002).  Asherson et al. 
screened all exons and regulatory regions at DRD3 in a small number of cases and 
controls (36 cases, 36 controls) and found two variations, one at exon 3 and a 5 bp 
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deletion in the 3’ intron flanking exon 5.  Neither of these mutations alter the protein 
structure, nor were they associated with schizophrenia in this study (Asherson et al., 
1996).   
Given the considerable number of positive, albeit inconsistent associations reported, 
results of these past studies may be reflecting an association between schizophrenia and 
another variant at DRD3.  As available databases such as the International Hapmap 
Project reveal SNPs within and flanking the gene are not in strong linkage disequilibrium 
with rs6280, it appears that other variants at this locus have not been accounted for in the 
current literature.  We report here analyses of 13 polymorphisms spanning the DRD3 
gene and flanking regions (109 kb) in two independent samples using both case-control 
and family-based designs.  We also evaluate coverage of this and past studies through 
linkage disequilibrium analyses using all publicly available genotype data across this 
region.    
3.3 METHODS 
3.3.1 Clinical 
Recruitment of probands was performed in Pittsburgh and surrounding regions for the 
U.S. sample (n = 331 cases), as well as New Delhi and surrounding regions for the Indian 
sample (n = 141 cases).  In a concerted effort to limit heterogeneity between populations, 
both samples were ascertained using identical criteria.  All participants completed a semi-
structured interview (Diagnostic Interview for Genetic Studies (Nurnberger et al., 1994).  
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In addition, supplemental information was obtained from medical records and relative 
reports as required for consensus diagnosis by board certified psychiatrists / 
psychologists.  All cases were diagnosed with schizophrenia  or schizoaffective disorder 
(DSM-IV criteria).  Cross-site inter-rater reliability for diagnostic measures was 
monitored throughout the study (Deshpande et al., 1998). All cases from the U.S. sample 
were Caucasian, and when available both parents of the probands were recruited (U.S., n 
= 151 families; India, n = 141 families).  Anonymized cord blood samples from 
Caucasian live births at a local Pittsburgh hospital served as unscreened, community 
based controls in the U.S. sample (n = 274).  These samples are completely independent 
of those previously reported by our groups (Nimgaonkar, Zhang, Caldwell, Ganguli, & 
Chakravarti, 1993), (Nimgaonkar et al., 1996), (S. Prasad et al., 1999). 
The study was approved by Institutional Review Boards (IRBs) at the University of 
Pittsburgh and Dr. Ram Manohar Lohia Hospital, New Delhi.  Written informed consent 
was obtained from all participants, but was not required for the anonymous neonate DNA 
according to the University of Pittsburgh IRB regulations.   
3.3.2 Laboratory 
Venous blood was obtained from all participants and genomic DNA extracted using the 
phenol chloroform method.  Using pooled DNA samples from Caucasian SZ/SZA cases 
(n = 100), we sequenced 500 - 700 bp amplicons extending over all DRD3 exons and 
exon-intron boundaries.  We also sequenced amplicons spanning reported database SNPs 
that were available at the time (http://www.ncbi.nlm.nih.gov, NT_005795.5, Hs3_5952, 
chromosome 3 working draft sequence; 2001).  In total, 40 amplicons were surveyed 
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spanning 109 kb genomic region within and flanking DRD3.  Sequencing was performed 
using Big Dye Terminator kit v3.1 (Applied Biosystems, Inc.) and isopropanol 
precipitation followed by centrifugation.  Using this method, we were able to identify 
SNPs with minor allele frequencies over 5-10% (Chowdari et al., in review).  A total of 
20 common SNPs were identified from the 40 amplicons (only rs6280 and a rare SNP in 
LD with rs6280, rs3732783, were detected from the exon screening).  Following SNP 
identification, amplicons spanning polymorphisms were re-sequenced in a panel of 24 
unrelated Caucasian individuals.  Linkage disequilibirum (LD) analysis was then 
evaluated in these individuals. 
3.3.3 SNP Selection 
We found that 9 “tag” SNPs were required to reasonably represent all 20 SNPs identified, 
i.e. the pair-wise correlation of genotypes as assessed by r2 was greater than 0.8 between 
loci and minimal information was gained by analyzing all SNPs independently.  Two 
other SNPs (rs1503670, rs1800828) had been investigated in previous studies and were 
added for replication purposes (Anney et al., 2002) (Ishiguro, Ohtsuki et al., 1998) 
(Sivagnanasundaram et al., 2000) (Staddon et al., 2005).  Two redundant SNPs within 
intron 1 were also included.  13 total SNPs were therefore genotyped in the U.S. sample 
(see Figure 3; Table 3).   
In the Indian sample, we evaluated 141 case-parent trios.  Analyses were initiated 
with all 13 SNPs from the U.S. panel, but two were discarded due to failed genotyping 
assays (rs7625282 and rs7616367).  Of these SNPs, one was a redundant SNP and the 
information loss was minimal (rs7625282).  The second (rs7616367) was only in modest 
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LD (r2 > 0.5) with a successfully assayed SNP (rs2399504) and some information loss 
resulted.    
3.3.4 Genotyping 
A PCR based assay using a single base extension method was used to gentoype all 
samples (SNaPshot; ABI Biosystems Inc.).  Interplate and intraplate duplicate samples, as 
well as water negative controls, were used as quality control measures in all assays.  In 
addition, one SNP (rs2134655) was typed in duplicate on 384 samples to estimate error 
rates.  Two individuals read genotypes independently, blind to clinical status.  In case of 
ambiguous calls, samples were re-assayed or sequenced. 
 
 
Figure 3 DRD3 genomic organization and variants studied in US sample 
Dopamine D3 receptor (DRD3) genomic organization and SNPs investigated in the U.S. sample.  
Known exons are numbered, as well as an additional exon (numbered 0) suggested by Anney et 
al. (Anney et al., 2002).  Chromosome location of each SNP based on dbSNP build 128 provided 
in brackets.  *Denotes associated SNP in U.S. analyses. 
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3.3.5 Statistical Analysis 
We tested for Mendelian inconsistencies (O'Connell & Weeks, 1998) in the family 
samples and Hardy-Weinberg equilibrium in the case-control samples (GENEPOP 
software, version 1.31).  Differences in genotype distributions between cases and controls 
for individual SNPs were assessed using the Armitage Trends test (SAS software).  
Haplotype frequencies were estimated with PHASE software (version 2.0.2) (J. C. 
Stephens et al., 2001) (M. Stephens & Donnelly, 2003).  We tested for haplotype 
associations using SNPEM software (D. Fallin et al., 2001).  Where significant, global 
haplotype results were retested with COCAPHASE from the UNPHASED software suite 
(version 2.403; http://www.rfcgr.mrc.ac.uk/~fdudbrid/software/unphased/).  
COCAPHASE uses a method of standard unconditional logistic regression.  Correction 
for multiple tests was performed using 5,000 permutations.  For these analyses, “case” 
and “control” status are reassigned, and in each replicate all the selected markers are 
analyzed and the most significant p-value stored.  As a result, the permutation procedure 
gives a significance level corrected for the multiple haplotypes and markers tested.  
Permutation test results from COCAPHASE are reported for global analyses. 
Family-based associations were evaluated for individual SNPs / haplotypes using the 
transmission disequilibrium test (TDT; (Kruglyak, Daly, Reeve-Daly, & Lander, 1996)).  
Global tests assessing transmission distortion were performed using TRANSMIT 
software (Clayton, 1999), and significant results were retested with the permutation test 
available through FBAT software (100,000 permutations) 
(http://www.biostat.harvard.edu/~fbat/fbat.htm).  Good agreement in p-values was found 
between tests, and FBAT results are reported here. 
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Linkage disequilibrium (LD) was evaluated using a clustering algorithm available 
in Hclust software (Rinaldo et al., 2005).  Briefly, Hclust computes a similarlity matrix 
from the square of Pearson’s correlation (r2) between allele counts at pairs of loci, then 
uses hierarchical clustering to group correlated SNPs.  For some analyses, we were 
interested in identifying a subset of SNPs that are reasonably correlated with all other 
SNPs in the dataset, i.e. “tag” SNPs.  Hclust identifies a set of tag SNPs based on the user 
specified minimum correlation between SNPs within a cluster.  We used a conservative 
cutoff in which allele counts between all SNPs in a cluster had a correlation of r2 > 0.8. 
3.3.5.1 Genomic Control 
To control for possible population sub-structure in our case-control sample, we employed 
a variation of the original genomic control method described by Devlin and Roeder 
(Devlin & Roeder, 1999) (Bacanu et al., 2000) (Devlin, Roeder, & Bacanu, 2001).  We 
assessed a pool of 420 SNPs from 63 independent genomic regions that had been 
previously chosen for schizophrenia association studies and genotyped in these samples.  
Since these SNPs were selected on the basis of being either functional or positional 
schizophrenia candidates, these analyses were biased towards an a priori hypothesis of 
association and may represent a more conservative correction than proposed originally by 
Devlin and Roeder.  From this pool, we randomly selected one SNP per region (63 SNPs, 
total) and determined the median chi square test statistic for case-control comparisons 
across these SNPs.  This process was repeated 10,000 times to yield a distribution of 
median chi square test statistics (df = 1).  We then divided the mean of this result by the 
expected median of the chi square distribution with one degree of freedom (0.456) to 
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generate a single correction factor for all of our SNP based case-control analyses 
previously described (Bacanu et al. 2000). 
3.4 RESULTS 
3.4.1 Quality Control 
Sequencing was performed for all SNPs using DNA from 24 unrelated parents from 
among the Caucasian U.S. case-parent trios.  Sequencing traces were compared with 
genotype calls from the SNaPshot assays and no inconsistencies were found.  We 
genotyped one SNP, rs2134655, in duplicate for 384 samples and found no discrepancies.  
Four Caucasian cord samples were also used as positive controls in all genotyping from 
the U.S. and Indian samples (4 per 96-well plate, 56 total duplicate genotypes), and no 
discrepancies were detected.  Genotype failure rates were low for all samples, and rates 
were similar between populations studied (U.S., mean failure rate per SNP = 0.0172, 
standard deviation = .0157, range 0.0 - 0.067; India, mean = 0.0424, standard deviation = 
0.0156, range 0.018 - .070).   We performed checks for Mendelian inheritance 
inconsistencies and found no Mendelian errors in the U.S. sample (13 SNPs, 151 trios) or 
the Indian sample (11 SNPs, 141 trios).  We tested for deviations from HWE among all 
sample groups (controls, parents, cases) for all SNPs.  The U.S. cases deviated from 
HWE at rs6280 (p = 0.025). We found no deviations from HWE in the Caucasian cords 
or parents.  In the Indian sample, we found deviation from HWE in the parents for one 
SNP (p = 0.035), rs905568.       
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3.4.2 Comparison of linkage disequilibrium (LD) between samples 
We performed LD analyses for the eleven SNPs genotyped in both samples using the 
community-based controls and parents of probands in the U.S. sample (n = 576), and the 
parents in the Indian sample (n = 282).  Our results suggested similar patterns of LD, 
SNP clusters, and tag SNPs between the two samples (Figure 4). 
 
Figure 4 Linkage disequilibrium between SNPs analyzed in both US and Indian samples 
Cluster dendrogram for SNPs genotyped in both samples shows similar patterns of LD.  “Tag” 
SNPs are denoted by an asterisk (*), and the tag SNP set is identical between samples.  Analysis 
restricted to the 11 SNPs genotyped in both samples.  SNP numbers correspond to Table 3. 
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3.4.3 Association testing in U.S. sample 
3.4.3.1 SNP analyses 
In the U.S. sample, significant differences in genotype distributions between cases and 
controls were detected for three SNPs (rs905568, p < 0.001; rs6280, Ser allele, p = 0.001; 
rs2134655, p = 0.022; see Table 1).  A trend for association was detected at rs10934254 
(p = 0.073).  We did not find a significant increase in homozygosity among cases at 
rs6280 (ser/ser, ser/gly, gly/gly genotype counts: cases 173 / 136 / 12, controls 119 / 127 / 
26, respectively).  Of these SNPs, only rs6280 has been investigated in previous studies.   
Our genomic control analyses of the median χ2 distributions from SNPs within 63 
independent genomic regions sampled 10,000 times yielded a mean of 0.57.  When 
dividing this by 0.456, the expected median of a χ2 distribution with 1 d.f. (see Bacanu et 
al. 2000), we derived a correction factor of 1.25.  All SNP based analyses were re-
analyzed using this correction, and the results are displayed in Table 3. 
Family-based analyses detected significant transmission distortion at six SNPs (p 
< 0.05; see Table 1), including four SNPs confined to the region from intron 1 to 5.9 kb 
downstream of DRD3 (rs324029, rs7625282, rs324030, rs10934254; see Table 1).   
Alleles at rs6280 were not significantly over-transmitted in these analyses (p = 0.13). 
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Table 3 DRD3 SNP-based results across samples 
  U.S. Samples India Trios 
# SNP 
Gene 
Region Nuc Strand 
Allele  
Code
aFreq. 
(Case/ 
Control)
bCase-
Control 
p-value
cGC   
p-value
dTDT   
(T/NT) 
TDT    
p-value 
TDT    
(T/NT)
TDT    
p-value
1 rs905568 5’ C + 2 .48/.37 <0.0001 0.0008 78/72 0.62 51/47 0.69 
2 rs2399504 5’ C + 1 .82/.81 0.923 0.933 49/36 0.16 28/27 0.89 
-- rs7616367 5’ A + 2 .74/.74 0.944 0.95 66/43 0.02 --   -- 
3 rs1394016 5’ T* - 2 .37/.33 0.145 0.194 77/62 0.2 64/46 0.07 
4 rs1503670 5’ G + 1 .63/.64 0.72 0.75 83/65 0.14 74/64 0.39 
5 rs1800828 5’ G - 1 .80/.77 0.175 0.23 62/39 0.02 59/45 0.17 
6 rs324026 5’ T* + 2 .69/.68 0.62 0.66 78/59 0.1 70/56 0.21 
7 rs6280 Exon A* - 1 .75/.67 0.001 0.004 71/54 0.13 70/60 0.36 
8 rs324029 Intron C* - 2 .73/.72 0.855 0.87 72/50 0.04 60/42 0.07 
-- rs7625282 Intron T - 2 .77/.76 0.776 0.806 71/45 0.01 -- -- 
9 rs324030 Intron C* + 2 .72/.73 0.813 0.83 72/49 0.04 59/44 0.14 
10 rs2134655 Intron G - 2 .73/.67 0.022 0.075 65/53 0.27 48/42 0.53 
11 rs10934254 3’ C - 1 .44/.39 0.073 0.12 80/57 0.05 71/48 0.03 
 
Single nucleotide polymorphism (SNP) # is given in sequential order according to DRD3 
transcription (5’ to 3’) from the most upstream (telomeric) to downstream (centromeric) SNP.  
SNP# is only given for SNPs assayed in both samples.  Nuc = nucleotide. Strand = genomic 
strand genotyped in this study.  *Nucleotide provided is designated as “other” allele, not 
“reference” allele by HapMap (HapMap, 2003).   aFrequency of the allele provided in cases and 
controls.   bTrends test p-values from genotype distributions.  cGC p-value = p-value after 
genomic control correction applied.  dT = transmitted allele, NT = not transmitted allele 
(transmission disequilibrium test [TDT]). 
3.4.3.2 Haplotype analyses 
Haplotype analyses in the case-control sample suggested significant associations with 
all haplotypes incorporating the significantly associated SNPs.  Global tests (SNPEM 
omnibus likelihiood ratio) supported associations with these haplotypes (data not shown).  
All results remained significant after permutation testing (COCAPHASE global tests, 
1,000 permutations; data not shown).  However, to mitigate against false positives in 
haplotype analyses, we interpreted individual haplotype results as significant only if they 
were also associated in family-based analyses.  Using this criterion, we observed 
significant over-transmission of all 2, 3, and 4 SNP haplotypes comprised of SNPs from 
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intron 1 to the 3’ region of the gene (see Table 4).  Analyses of global transmission 
distortion across these SNPs supported significant associations (see Table 5).  For 
comparison purposes, these data were re-analyzed for the 11 SNPs available in the Indian 
sample and results are shown in Table 2. 
3.4.4 Replication testing in the Indian family sample 
SNP-based analyses of 11 SNPs detected a significant association with rs10934254 in 
the DRD3 downstream region (Table 1).  Significantly increased transmission was 
observed with the same allele as the U.S. sample (rs10934254, transmitted alleles / 
untransmitted alleles: U.S., 80/57; Inidia, 71/48).  Non-significant over-transmission of 
the same alleles significantly associated with schizophrenia in the U.S. sample was 
observed for two additional SNPs within intron 1.  As in the initially tested U.S. sample, 
we found significant over-transmission of a common haplotype spanning intron 1 to the 
3’ region of DRD3 (markers rs324029-rs324030-rs2134655-rs10934254).  The associated 
alleles comprising this common haplotype in the Indian sample were identical to those in 
the U.S. sample (see Table 4).  Global tests of transmission distortion at these SNPs also 
supported associations in this cohort (see Table 5).   
We conducted exploratory analyses in an attempt to explain inconclusive results from 
previous studies.  We investigated whether associations at rs6280 could be attributed to 
differing haplotype backgrounds.  To accomplish this, we separately combined rs6280 
with haplotypes spanning the 5’ region of the gene and haplotypes 3’ to exon 1.  We first 
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explored associations in our U.S. case-control sample, then our U.S. family sample.  If 
results were consistent, we tested for replication in the Indian cohort.   
Similar to inconsistent replications in previous studies, we detected case-control 
differences at rs6280 in the U.S. sample, but neither family sample (Table 1).  Significant 
associations were also not detected with either allele when combined with other SNPs 5’ 
to the gene, as was done in previous studies (Anney et al., 2002) (Ishiguro, Ohtsuki et al., 
1998) (Sivagnanasundaram et al., 2000) (Staddon et al., 2005).  However, when rs6280 
was combined with the associated common haplotype in both samples from our initial 
analyses (SNPs 3’ to exon 1), significant associations were consistently observed with the 
Ser allele (Table 2).  These results were replicated in the Indian sample for the same 
common haplotype, and global tests incorporating these SNPs were significant across 
study designs in both samples (see Table 2).  Associations were not detected with the Ser 
or Gly alleles against any other haplotype backgrounds (see Table 3 for all haplotype 
frequencies).  The allele encoding glycine (G) is rarely carried against this haplotype 
background (frequency of Gly-C-G-G-C = .003; Table 3), and the Ser allele was actually 
under-represented in cases as compared to controls against other haplotype backgrounds 
in the U.S. sample.  Taken together, these results could account inconsistencies in studies 
assessing only rs6280. 
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Table 4 Haplotype results incorporating associated intronic and downstream SNPs 
 
U.S. Samples Indian Samples 
Case-Control Families Families 
aSNPs in 
haplotype bAlleles 
cFreqs 
(Case / 
Control) 
Hap    
dp-value
Global   
ep-value T/NT 
TDT      
fp-value 
Global    
gp-value T/NT 
TDT    
p-value
Global 
p-value 
8-9 2-2 0.72/0.72 0.81 0.81 58/34 0.01 0.03 46/28 0.04 0.08 
9-10 2-2 0.47/0.39 0.03 0.04 69/32 0.0002 0.0002 45/38 0.44 0.34 
10-11 2-1 0.50/0.42 0.01 0.05 60/33 0.005 0.04 57/31 0.005 0.002 
8-9-10 2-2-2 0.46/0.38 0.02 0.01 68/31 0.0002 0.0001 44/35 0.31 0.41 
9-10-11 2-2-1 0.39/0.34 0.039 0.002 53/26 0.002 0.009 35/19 0.03 0.006 
8-9-10-11 2-2-2-1 0.39/0.34 0.039 0.002 52/26 0.003 0.009 36/17 0.009 0.005 
7-8-9-10-11 1-2-2-2-1 0.39/0.32 0.01 0.002 50/24 0.002 0.02 31/14 0.01 0.03 
aSNP numbers correspond to numbers provided in Table 1. bAlleles given correspond to reference allele # given in Table 1. 
cFrequency of the over-transmitted haplotype in the U.S. sample for U.S. cases and controls.  dp-value from individual haplotype case-
control comparisons.  eGlobal p-value  incorporating all haplotypes after correction using 1,000 permutations (Cocaphase).  fTDT p-
value is individual haplotype p-value, and gglobal p-value is whole marker results incorporating all haplotypes after 100,000 
permutations (FBAT).   
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Table 5 Frequency of all common haplotypes spanning exon 1 to the DRD3 3' region 
SNPs Alleles 
Case 
Freq 
Control 
Freq 
8-9-10-11 
2221 0.39 0.34 
2212 0.26 0.31 
1122 0.22 0.23 
2222 0.07 0.06 
1121 0.05 0.05 
7-8-9-10-11             
12221 0.39 0.32 
12212 0.26 0.31 
21122 0.17 0.22 
22222 0.03 0.05 
21121 0.04 0.05 
12222 0.04 0.02 
11122 0.05 0.01 
11121 0.01 0 
12211 0 0.01 
22221 0 0 
All common estimated haplotype frequencies (>1%) for SNPs 3’ to exon 1 (8-9-10-11) 
alone and when combined with rs6280 (7-8-9-10-11).  The associated haplotype is given 
in bold and italicized.  Alleles correspond to the reference allele number given in Table 
1.  The Ser allele at rs6280 (SNP 7) corresponds to allele 1, Gly is allele 2. 
3.4.5 Survey of publicly available variations at DRD3  
As these SNPs were identified and genotyped in the initial U.S. sample prior to the first 
release of the International Hapmap Project (IHP) (HapMap, 2003), additional 
information has become available regarding other SNPs in the region.  Thus, we 
conducted post-hoc LD analyses to evaluate the coverage of this region in the current and 
previous studies.  We genotyped the 13 SNPs from the current study in 90 CEPH (Utah 
residents with ancestry from northern and western Europe) individuals and included 
available SNPs from IHP as of June, 2005.  When combined, data was obtained for 50 
SNPs across the 109 kb, 35 of which had an MAF > 5%.  Our analyses indicated 16 tag 
SNPs would reasonably represent all available SNPs with MAF > 5% (r2 > 0.8), 8 of 
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which were genotyped in the current study (50%), and 22 SNPs would be required to tag 
all variations with MAF greater than 1% (42 total SNPs).  We also find that rs6280 was 
highly correlated with 5 SNPs 5’ to the gene, but did not tag any available SNPs 3’ to 
exon 1.  These results suggest previous studies assessing only rs6280, or SNPs 5’ to exon 
1, have not adequately accounted for variants 3’ to exon. 
To determine whether our haplotype results could be a consequence of the 
observed association with rs6280, we estimated LD (r2) between the associated haplotype 
spanning SNPs rs324029 – rs324030 – rs2134655 – rs10934254 and rs6280 in the 
unrelated US controls (n = 278).  We find that rs6280 is not in substantial LD with the 
associated common haplotype (r2 < 0.212), suggesting some degree of independence 
between the associated haplotype and rs6280.     
3.5 DISCUSSION 
Recent simulations have suggested that in the presence of an unidentified liability 
locus, patterns of associations can be complex, depending on the test statistics used.  
Indeed, the liability locus may not produce the maximum test statistic (Roeder et al., 
2005), which is instead found at SNPs in significant or even modest linkage 
disequilibrium (LD) with the liability locus.  It is often beneficial to therefore analyze a 
large set of polymorphisms for candidate gene association studies.  The rapid 
identification of polymorphisms in the human genome, their availability in the public 
domain, and accompanying LD analyses have enabled such studies.  Thus, it is feasible 
and potentially necessary to revisit earlier association studies that typically investigated 
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only one polymorphism at a gene, such as DRD3.  The initial report by Crocq and 
colleagues in two samples suggested associations between schizophrenia and rs6280 with 
a substantial effect size (pooled relative risk in homozygotes = 2.61) (Crocq et al., 1992). 
Replication was pursued in an enormous number of subsequent studies with inconsistent 
results, and the largest in a series of meta-analyses (Jonsson, Flyckt et al., 2003) has 
suggested this association may not be present across populations.  However, since most 
studies investigated only this SNP, it is uncertain whether there are other, more relevant 
associations at this gene.   
Using rigorous quality control measures, we tested associations at DRD3 with two 
different study designs (case-control and family based) and two independent samples.  
These samples have not been investigated in prior reports on DRD3 by our groups 
(Nimgaonkar et al., 1993), (Nimgaonkar et al., 1996), (S. Prasad et al., 1999).  Our 
primary goal was to seek consistency in associations across differing study designs and 
populations.  We also sought explanations for the inconsistencies reported for rs6280.   
Our initial comparisons in the U.S. Caucasian cases and community based 
controls revealed significant associations for three SNPs and related haplotypes.  We did 
not detect increased rates of homozygosity among the cases at rs6280.  Since the 
associations could be confounded by unknown population substructure, we re-evaluated 
our results using a potentially conservative variation of genomic control.  The results 
from two SNPs remained significant, despite this conservative correction.   
We next evaluated approximately half of the U.S. cases for transmission 
distortion using the TDT.  Even in this smaller sample, we detected associations at four 
SNPs.  However, there was no overlap with the associated SNPs from the case-control 
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comparisons.  Inconsistencies in the pattern of associations with different SNPs between 
case-control and family based analyses, similar to those observed here, can result from 
differing assumptions, power, and properties of these tests (Bacanu et al., 2000).  
Supporting our initial results, we detected association with one of the SNPs that displayed 
transmission distortion in the U.S. families (rs10934254) in a second Indian cohort.  
Consistent with the similar patterns of LD observed between variations from the Indian 
and U.S. populations, the same common haplotype was over-transmitted in both samples.  
This haplotype was also over-represented in the entire sample of U.S. cases when 
compared with the U.S. community-based controls.   
Taken together, our analyses indicate an association with a common haplotype in 
both samples.  The results are intriguing as they were replicated through three different 
sets of analyses and two independent populations.  While it is possible that this haplotype 
itself conveys liability to schizophrenia, given the relatively sparse SNP density evaluated 
in this region, we speculate it is more likely that our analyses are suggestive of a risk 
allele(s) carried against this common background.  As our most significant haplotype 
result in the U.S. sample spanned rs324029 – rs2134655, these findings may implicate a 
polymorphism generating schizophrenia susceptibility in the region spanning intron 1 to 
the exon / intron boundary 3’ to exon 4 at DRD3.   
If true, these findings yield a plausible explanation for the inconsistencies 
observed in the past regarding the association between rs6280 and schizophrenia.  We 
observed increased transmission of the Ser allele against the associated haplotype 
background in both the U.S. and Indian samples, but not other haplotypes.  Our analyses 
suggest rs6280 is in modest LD with the common haplotype associated with 
 75
schizophrenia in the current study.  Consistent with results of others regarding association 
tests (Roeder et al., 2005), it is possible that rs6280 could produce the maximum test 
statistic in some, but not all, previous studies due to these LD patterns.  Our analyses bear 
this out, as rs6280 was significantly associated in our U.S. case-control analyses, but not 
our family based analyses. 
Though consistent, our results cannot be considered conclusive for several 
reasons.  First, although 1,332 persons have been analyzed, the sizes of the individual 
samples are still modest.  Second, as in most association studies, a relatively large 
number of individual tests were conducted.  Although some SNPs are correlated and tests 
are not completely independent, the results presented here are not corrected for multiple 
comparisons. On the other hand, we interpreted haplotype results as significant only if 
they were supported in both U.S. study designs, and replicated in the Indian sample.  The 
associations detected remained significant after permutation testing, global analyses were 
conducted for haplotypes showing significant associations using two different types of 
analytical software, and a potentially conservative genomic control correction was used 
to evaluate the case-control SNP results.    Nonetheless, further replication is necessary to 
confirm these findings.   
A third concern is the absence of a clear functional basis for the observed 
associations.  Ser9Gly remains the only known polymorphism that alters the protein 
structure at this gene.  Previous studies seeking exonic mutations have found 
synonymous changes at exon 1 (Griffon et al., 1996) and exon 3 (Asherson et al., 1996), 
but these SNPs are uncommon.  Ashershon and colleagues also found an intronic 5 bp 
deletion polymorphism flanking exon 5 of the gene with similar frequency among cases 
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and controls (7-8%) (Asherson et al., 1996).  These results may warrant further 
investigation given our current findings of association with a common haplotype 
spanning this region.  While it is possible that these SNPs, or SNPs against this common 
background, have a functional effect at this gene, at present there is no clear molecular 
explanation for these results.   The lack of a functional implication is an important hurdle 
and plagues many well accepted genetic associations; e.g., RET gene and Hirschsprung’s 
disease (Emison et al., 2005). 
In conclusion, we report novel, replicable associations with schizophrenia at the 
D3 dopamine receptor (DRD3).  Our results indicate that serine allele of Ser9Gly may not 
be the only susceptibility allele at this gene.  Complete polymorphism screening to 
identify all human variation across this region, comprehensive LD mapping, evaluation 
of conserved regions across species, and analyses in a sufficiently powered cohort are 
necessary in order to provide more convincing evidence for this locus as a susceptibility 
factor in schizophrenia pathogenesis.  These efforts are currently ongoing.   
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4.1 ABSTRACT 
We evaluated the hypothesis that dopaminergic polymorphisms are risk factors 
for schizophrenia.    
Stage I (screening):  Eighteen dopamine-related genes were analyzed in two 
independent US Caucasian samples: 150 trios and 328 cases / 501 controls.  The most 
promising associations were detected with SLC6A3 (alias DAT), DRD3, COMT, and 
SLC18A2 (alias VMAT2).   
Stage II (SNP coverage and epistasis):  To comprehensively evaluate these four genes, 
68 SNPs were genotyped in all 478 cases and 501 controls from stage I.  Fifteen (23.1%) 
significant associations were found (p < 0.05).  We tested for epistasis between pairs of 
SNPs providing main effects and observed 17 significant interactions (169 tests); 41.2% 
of significant interactions involved rs3756450 (5’ near promoter) or rs464049 (intron 4) 
at SLC6A3.      
Stage III (confirmation):  Sixty-five SNPs were genotyped in 659 Bulgarian trios.  Both 
SLC6A3 variants implicated in the US interactions were over-transmitted in this cohort 
(rs3756450, p = 0.035; rs464049, p = 0.011).  Joint analyses from stages II and III 
identified associations at all four genes (pjoint< 0.05).  We tested 29 putative interactions 
from stage II and detected replication between 7 locus pairs (p < 0.05).  Simulations 
suggested our stage II and stage III interaction results were unlikely to have occurred by 
chance (p = 0.008 and 0.001, respectively). 
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Stage IV (function): We tested rs464049 and rs3756450 for functional effects and found 
significant allele specific differences at rs3756450 using EMSA and dual-luciferase 
promoter assays.    
Conclusions: Our data suggest a network of dopaminergic polymorphisms increase risk 
for schizophrenia.     
4.2 INTRODUCTION 
The distribution of schizophrenia  in families and populations is consistent with a 
substantial genetic basis for the disorder.  No obvious genetic model can explain the data, 
but models including multiple interacting loci conferring risk provide a good fit (Risch, 
1990; Schliekelman & Slatkin, 2002).  The disorder is common, with an estimated 
lifetime morbid risk of 1%, and concordance estimates for monozygotic twins (48%) is 
significantly higher than that for dizygotic twins (17%) (I. Gottesman, 1991).  There has 
been long-standing research into the hypothesis that dopamine dysfunction contributes to 
schizophrenia pathogenesis (Laruelle et al., 1999; D. A. Lewis & Lieberman, 2000).  The 
hypothesis originated from observed correlations between the clinical potency of anti-
psychotic drugs and their affinity for dopamine D2 receptors (DRD2) (Carlsson & 
Lindqvist, 1963; Creese et al., 1976; Seeman et al., 1976).  Patients with schizophrenia 
display increased sensitivity to the psychotogenic effects of agents that increase synaptic 
dopamine release (Angrist & van Kammen, 1984; Davidson et al., 1987; Laruelle & Abi-
Dargham, 1999; Laruelle et al., 1999; Lieberman et al., 1984).  In addition, acute 
amphetamine challenge to schizophrenia patients leads to increased dopaminergic 
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transmission in vivo, as measured by radioligand binding to dopamine D2 receptors 
during positron emission tomography (PET) scans (Abi-Dargham et al., 1998; Breier et 
al., 1997; Laruelle et al., 1996).  Therefore, dopamine genes have traditionally been 
prime candidates for genetic studies in schizophrenia. 
Despite the substantial biological evidence implicating dopaminergic dysfunction 
in schizophrenia pathogenesis, it is not precisely known whether genetic polymorphisms 
in dopaminergic genes are associated with dopamine abnormalities.  If such a functional 
link exists, the nature of these variations, the number of genes affected, interactions 
amongst them, and their functional importance is poorly understood.  Associations 
between schizophrenia and many dopaminergic gene variations have been reported, but 
most studies evaluated one or at best a handful of polymorphisms, usually based on 
preliminary evidence of a functional impact (e.g. exonic SNPs or functional repeats).  
Most previous studies were better suited to identify risk factors of substantial effect size 
than multiple interacting loci, for which the marginal effect of an individual locus could 
be small.  Therefore, it appears that many genes in the dopamine pathway have not been 
investigated adequately for their impact on schizophrenia risk.  Our recent review of the 
literature estimated that roughly 5% of representative common SNPs currently available 
in public databases have been considered in association studies of dopaminergic genes 
with at least 50% power to detect modest effect sizes expected (odds ratios from 1.2 – 
1.5) (Talkowski, Bamne, Mansour, & Nimgaonkar, 2007).  For example, a large number 
of studies investigated a single coding variant (rs6280) at the dopamine D3 receptor gene 
(DRD3) with largely inconsistent results (Ioannidis et al., 2001; Jonsson, Flyckt et al., 
2003; Jonsson et al., 2004).  Until recently, studies did not consider other variations 
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within the gene.  Two independent studies of 13 SNPs and 17 SNPs now suggest 
associations with other SNPs / haplotypes might account for past inconsistencies at 
rs6280 (Dominguez et al., 2007; Talkowski, Mansour et al., 2006).  Similar associations 
could be present with common variants yet to be investigated at other dopaminergic 
targets, but alternative strategies may be necessary to jointly evaluate these genes.    
Multi-stage studies can be useful in analyses of a functionally related network of 
genes by initially screening a large group of susceptibility targets and subsequently 
evaluating only the most promising candidates in additional samples, thus maximizing 
power with the resources available (Aplenc, Zhao, Rebbeck, & Propert, 2003; Lowe et 
al., 2004; Satagopan & Elston, 2003).  Skol et al. recently showed that an increase in 
power for multi-stage whole genome studies can be attained by evaluating the joint 
distribution of test statistics from both samples versus independent consideration of each 
sample (Skol et al., 2006).  We reasoned a similar approach could be applied to gene-
based association studies that are restricted to a smaller number of loci, since samples 
from individual studies are almost always underpowered to consistently detect 
associations and interactions of modest effect.  In the present study, we revisited the 
genetic basis for the so called ‘dopamine hypothesis’ of schizophrenia by investigating 
eighteen dopaminergic genes in three independent samples.  We hypothesized that key 
susceptibility variants within the dopaminergic network could be identified if results from 
multiple samples were evaluated jointly.  Our multi-stage strategy progressively pruned 
the list of promising susceptibility candidate genes and culminated in functional analyses 
of associated SNPs. 
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4.3 METHODS 
4.3.1 Samples 
Unrelated patients from the US were recruited at Western Psychiatric Institute and Clinic, 
Pittsburgh, Pennsylvania and surrounding regions (n = 478).  Diagnoses were based on 
the Diagnostic Interview for Genetic Studies (Nurnberger et al., 1994), supplemented by 
medical records and informant interviews. Consensus DSM IV diagnoses of 
schizophrenia (schizophrenia; n = 272) or schizoaffective disorder (schizophreniaA; n = 
206) were assigned by board-certified psychiatrists / psychologists following review of 
all these sources of information.  Both parents of 150 patients were ascertained for family 
based analyses (150 trios).  Control DNA samples were collected from the cord blood of 
501 unscreened Caucasian neonates born at Magee-Women’s Hospital, Pittsburgh, PA.  
Ancestry and gender was available for all samples.   
The Bulgarian patients and their parents were recruited in Bulgaria as part of a 
collection of parent – proband trios described previously (Kirov et al., 2004). Diagnoses 
were made according to DSM-IV criteria, following assessment by a psychiatrist using 
the Schedules for Clinical Assessment in Neuropsychiatry (SCAN, Wing et al 1990) 
which has been validated for use in the Bulgarian language by one of the authors of the 
SCAN instrument, and inspection of hospital discharge summaries. In cases where the 
information collected did not allow a confident diagnosis, the patient was re-interviewed 
by Dr. Kirov or the clinical coordinator of the project. All patients and their parents 
received written information on the project and signed an informed consent form.  The 
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Bulgarian sample included 659 trios (total n = 1,977).  Probands were diagnosed with 
schizophrenia (n = 576) or schizophreniaA (n = 83). 
The University of Pittsburgh Institutional Review Board approved the study.  
Written informed consent was obtained from all participants, except neonatal controls, in 
accordance with IRB guidelines.  Ethics Committee approval was obtained from Ethics 
Committees in all regions of Bulgaria where families were recruited. 
4.3.2 Polymorphism Selection 
We initially selected SNPs from the Celera database (Celera, 2003), the most 
comprehensive source available when stage I analyses were initiated.  SNPs were 
selected based on physical distance (1 SNP / 5 kb attempted).  A denser set of SNPs were 
then chosen for four genes: SLC6A3, SLC18A2, DRD3, and COMT in stage II.  
Polymorphisms for each gene were obtained by surveying the genomic region spanning 
the gene and at least 5 kb of flanking sequence.  For SLC6A3 and SLC18A2 SNPs were 
identified from available HapMap data (HapMap phase I, October 2005 release for 
SLC6A3 and HapMap phase II, June 2006 release for SLC18A2) (HapMap, 2003) and tag 
SNPs were chosen using Hclust software (Rinaldo et al., 2005).  Hclust computes a 
similarity matrix from the square of Pearson’s correlation (r2) between allele counts at 
pairs of loci, then uses hierarchical clustering to group correlated SNPs (minor allele 
frequency > 5%).  Tag SNPs were chosen if the correlation between loci was below an 
arbitrary threshold (r2 < 0.8).  One redundant SNP (rs456082) was also chosen.  At 
COMT and DRD3, additional SNPs were obtained from in-house sequencing.  For DRD3, 
we sequenced overlapping 600 – 800 bp amplicons across the entire gene and 5 kb of 
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flanking sequence in a pool of 200 Caucasian cases to detect common polymorphisms 
(minor allele frequency > 5%).  When polymorphisms were detected that were not 
available in HapMap, we sequenced the same 60 unrelated CEPH individuals used by 
HapMap to investigate patterns of LD.  Sixty-nine polymorphisms were detected, 15 of 
which were novel, and 18 SNPs were selected (see Supplementary Table 4.1).  The 18 
SNPs included tag SNPs (chosen with Hclust as above) and SNPs associated with 
schizophrenia in our previous study (Talkowski, Mansour et al., 2006).  At COMT, 27 
SNPs were identified from directly sequencing coding regions and flanking intronic 
sequence for exons 2-6 as well as the proximal promoter region for S-COMT within 
intron 3.  Sequencing was performed among 60 Caucasian US subjects (data provided by 
R. Weinshilboum, M.D. and J. Zhang, Ph.D., Mayo Clinic, Rochester, MN; see (Shield, 
Thomae, Eckloff, Wieben, & Weinshilboum, 2004) for details).  Individuals used for 
these analyses were different than those used in HapMap.  In sum, we chose 20 SNPs 
from the combination of HapMap and individual sequencing, realizing redundancy in 
SNP selection could result.  It should be noted that for COMT, some SNPs obtained 
within the pre-determined flanking sequence were localized to other genes (ARVCF or 
TXNRD2), however for clarity these SNPs are still referred to as “COMT” SNPs.  In the 
Bulgarian sample, 65 SNPs were genotyped.  Where possible, identical SNPs to stage II 
were analyzed (n = 59 SNPs).  Four additional SNPs were genotyped as surrogates for 
stage II tag SNPs, and two functional synonymous SNPs at COMT were genotyped based 
on work described by Nackley and colleagues during the course of this study (Nackley et 
al., 2006) (Supplementary Table 2).   
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Since a case-control design was used in stage II, we sought evidence for 
population substructure by implementing genomic control (GC) analyses using 31 SNPs 
(Bacanu et al., 2000; Devlin & Roeder, 1999).  We chose a single common SNP (minor 
allele > 10%) from each of the 31 genomic bins least likely to be linked to schizophrenia 
from a meta-analysis of linkage scans by Lewis and colleagues (C. M. Lewis et al., 
2003).   
4.3.3 Genotyping Assays 
4.3.3.1 Stage I 
The screening SNPs (n = 95) were assayed using multiplexed polymerase chain reaction 
(PCR) amplification followed by single base extension (SNaPshot, ABI Biosystems), as 
described elsewhere (Mansour et al., 2005).   
4.3.3.2 Stage II 
SNPs were genotyped using the hybridization based Illumina Golden Gate assay, as 
described elsewhere (Shen et al., 2005).  In sum, 99 SNPs were assayed, including 31 GC 
SNPs.  The median trends test statistic for genomic control was 0.336 (expected median = 
0.456), yielding no evidence for noteworthy sub-structure.  Hence corrections were not 
applied as it would be anti-conservative (Devlin & Roeder, 1999).  
4.3.3.3 Stage III 
Genotyping in the Bulgarian sample was conducted at both Cardiff University (Cardiff, 
Wales, UK) and the University of Pittsburgh (Pittsburgh, PA, US).  At Cardiff, 33 of the 
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SLC6A3 and DRD3 SNPs were genotyped by the Sequenom MassARRAY™ system 
using iPlexTM chemistries according to the recommendations of the manufacturers 
(Sequenom, San Diego, California, USA, http://www.sequenom.com).  At Pittsburgh, 
SNPlex (Tobler et al., 2005) and SNaPshot assays (ABI Biosystems Inc) were utilized to 
type the remaining 32 SNPs.   
4.3.4 Quality control 
In the stage I family based analyses, we sequenced 8 cases for all SNPs (752 sequenced 
genotypes) and one discrepancy was observed between the sequencing data and the 
SNaPshot data.  In stage I and II case-control analyses, there was complete concordance 
between Illumina genotypes and HapMap genotypes for 11 CEPH individuals.  Among 
3,024 duplicated genotypes from positive controls, no discrepancies were found.  The 
overall genotype call rate for stage II was 99.83%.  In stage III, we assayed 31 CEPH 
individuals (n = 2139 genotypes) and found 5 discrepancies.  In addition, four SNPs 
(rs464049, rs463379, rs324030, rs167771) were genotyped in duplicate for all 1977 
Bulgarian samples at Pittsburgh and Cardiff (15,816 total genotypes) and 24 
discrepancies were found (stage III estimated error rate = 0.0015 - 0.0023).   The mean 
genotype call rate was 95.71%. 
Mendelian inconsistencies and deviations from Hardy Weinberg expectations (HWE) 
for individual SNPs were evaluated using PEDCHECK (O'Connell & Weeks, 1998) and 
GENEPOP (version 1.31) software, respectively.  We detected 9 Mendelian errors among 
the 95 SNPs assayed in stage I, and 74 Mendelian errors from analyses of 65 SNPs in 659 
Bulgarian trios.  In sum, 18 families were removed from Bulgarian analyses due to 
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multiple Mendelian errors, and remaining sporadic errors were set to null.  Hardy-
Weinberg Equilibrium (HWE) was tested in each population separately (US cases, US 
controls, US parents, Bulgarian parents, Bulgarian cases.   
4.3.5 Electrophoretic Mobility Shift assay (EMSA) 
Non-radioactive EMSA for rs3756450 was performed using DIG Gel Shift Kit (Roche 
Applied Science) according to manufactures protocol with slight modifications.  
Polyacrylamide gel electrophoresis (PAGE) purified 42-base primers (Integrated DNA 
Technologies, Inc.) encompassing rs3756450 were annealed to complementary 
oligonucleotides by incubating them at 95°C for 5 min, followed by gradual cooling to 
room temperature.  Annealed double stranded oligonucleotides were labeled according to 
the manufacturer’s protocol (Roche Applied Science, Inc).  Nuclear extracts were 
prepared from SHSY-5Y cell lines as described (NC Andrews and DV Faller, Nucleic 
Acids Res. 1991 May 11;19(9):2499).  DIG-labeled oligonucleotides were incubated with 
nuclear extracts (5 μg) in 20 μl reaction containing 5X binding buffer, Poly-L-Lysine, 
poly[d(I-C)], for 30 min at room temperature. Competitive binding was performed by 
including 50X unlabelled oligonucleotides in appropriate control reactions.  DIG-labeled 
oligonucleotide-nuclear extract complexes were resolved on 6% non-denaturing 
polyacrylamide gel for 2 hrs at room temperature and transferred on positively charged 
nylon membranes (Boehringer Mannheim -Roche Applied Science) by electro-blotting.  
Blots were visualized by an enzyme chemiluminescent method (Roche Applied Science, 
Inc).  The experiment was replicated, with two fold excess of the nuclear extract added to 
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reactions having the rs3756450C probes (see Figure 8, lanes 4-6).  The primer sequences 
used for generating allele specific probes are listed with altered bases in red.  
rs3756450 T Allele FWD  5’  TAGCAGCAACCACAATGATAATAAAGCCGACTTGGCATTTAG  3’ 
rs3756450 T Allele REV   5’  CTAAATGCCAAGTCGGCTTTATTATCATTGTGGTTGCTGCTA  3’ 
rs3756450 C Allele FWD  5’  TAGCAGCAACCACAATGATAACAAAGCCGACTTGGCATTTAG  3’ 
rs3756450 C Allele REV   5’  CTAAATGCCAAGTCGGCTTTGTTATCATTGTGGTTGCTGCTA  3’ 
 
4.3.6 Dual Luciferase Assay  
A 2.8 kb genomic region encompassing the 5’ UTR of SLC6A3 (-2783 to +63, spanning 
rs3756450) was amplified from two CEPH samples homozygous for alleles of 
rs3756450, using the Expand High Fidelity PCR System (Roche Applied Science, Inc).  
The PCR amplified fragments were cloned between Kpn1 and HindIII restriction sites in 
a pGL3 Basic vector (Promega, Inc).  Sequence homology for all residues was confirmed 
by sequencing.  Transient transfections of constructs into neuroblastoma cell line SHSY-
5Y (ATCC-CRL-2266) were performed in 24-well plates (0.8 × 106 cells/well) using 
LipofectAMINE (Life Technologies, Inc.), according to the manufacturer's instructions. 
The pRL-TK (Promega, Inc) vector expressing Renilla luciferase by a HSV-TK promoter 
was co-transfected with each construct as an internal control, to normalize for firefly 
luciferase expression.  Cells were harvested 30 h after transfection, and luciferase assays 
performed using the dual luciferase reporter assay system (Promega, Inc).  Relative 
luciferase values were normalized from a promoter-less pGL3 BASIC vector.  Six 
readings were taken for each clone and the entire experiment was conducted in triplicate.   
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4.3.7 Statistical Analysis 
Evidence for transmission distortion was assessed using FBAT software (Horvath, Xu, & 
Laird, 2000).  Differences in genotype distributions between cases and controls were 
evaluated with the Armitage Trends test (SAS software) (Devlin & Roeder, 1999).  
Markers localized to the X chromosome (MAOA and MAOB) were analyzed using 
likelihood ratio tests in a loglinear model, as implemented in the UNPHASED software 
suite (see (Cordell & Clayton, 2002) for review) (Dudbridge, 2003).  We tested for 
gender differences at each of the three COMT SNPs previously described by Shifman and 
colleagues (rs4680, rs737865, rs165599) (Shifman et al., 2002) using logistic regression.  
Gender comparisons were only made for these three SNPs.    
To evaluate results from multiple samples, we computed the joint distribution of 
test statistics (Zjoint), based on the methods of Skol and colleagues (Skol et al., 2006).  
Here, when combining our results from stages II and III, the proportion of markers 
genotyped remained the same, and thus Skol et al.’s adjustment for variable number of 
markers genotyped was not applied.  Z-statistics were derived for both case-control and 
family-based association tests.  To calculate Zjoint, let n1 and n2 be the sample sizes from 
which test statistics Z1 and Z2 were calculated.  The formula for Zjoint is then: 
 
Zjoint = SQRT(π1 (z1)) + SQRT(1-π1 (z2)), for which π1 = n1 / (n1 + n2).  
 
 It should be noted that the sign of the test statistic (i.e. Z positive or negative) was 
accounted for in all analyses, meaning the risk allele was required to be the same in both 
samples.  To determine π1, or the proportion of total samples genotyped in the first stage, 
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we treated a complete case-parent trio (n = 3 individuals) as the equivalent of one case 
and one control.  For stage I we therefore had the equivalent of 478 cases and 651 
controls available, of which the 150 trios represented 26.6% of these samples (i.e. πsamples 
= 0.266).  In this staged design we calculated Zjoint twice, once over the case-control and 
family-based association analyses in stage I (US samples only), and again over the case-
control analyses of stage II and the family-based association analyses of stage III (US and 
Bulgarian samples).  Where surrogates were chosen in the Bulgarian sample to represent 
tag SNPs in the US sample, Zjoint was calculated by combining the test statistic from the 
original SNP with that of the surrogate.  In using this procedure, we are confident that the 
size of the test was not likely to be altered (e.g. p = 0.05 was still at least a 5% type I 
error threshold).  However, a lower correlation between SNPs could result in loss of 
power.   
Epistatic interactions were tested in stages II and III.  Pairs of loci, each of which 
provided a p-value less than 0.10 for a main effect on risk for schizophrenia, were 
analyzed for interaction effects using an unconditional logit model for case-control 
analyses and a conditional logit model for trios (Cordell, Barratt, & Clayton, 2004).  In 
both instances, the “interaction p-value” reported represented the likelihood difference 
between a full model including both main effects and an interaction term from a reduced 
model including only main effects.  When interaction results were significant by 
asymptotic approximation, empirical p-values were determined by permutation testing 
(1,000 permutations; Genetic Association and Interaction Analysis software) (Macgregor 
& Khan, 2006).       
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For the functional analyses, we used a paired t-test to determine differences in 
luciferase activity between the C and T alleles at rs3756450.  To determine significant 
differences between constructs, we conducted analysis of variance.  
4.3.7.1 Simulations 
 Interpretation of the interaction results from the staged design is complicated by the 
design itself and by the LD structure of SNPs in each gene. To facilitate interpretation of 
results from interaction tests, we performed a simulation experiment based on the data 
from these cases and controls. Each simulation consisted of three stages.  
Stage (1): permute the case-control status, thus making affection status 
independent of genotypes while retaining the LD structure of the sample. Test all 68 
SNPs individually for association with affection status at two levels of significance (p ≤ 
0.05 and p ≤ 0.10). If eight or more SNPs are associated at p ≤ 0.05, then record all S 
SNPs with p ≤ 0.10 and proceed to Stage 2; else reject this set of data and rerun the 
permutation until eight or more SNPs are associated at p ≤ 0.05.  Rejection sampling 
ensures this stage is comparable to the results obtained in the original experiment in terms 
of the number of SNPs associated with affection status. 
Stage (2): using the Stage 1 dataset and the list of S SNPs, test for all possible 
SNP-SNP interactions, with the condition that each of the two SNPs be in different genes 
(i.e., gene-gene interaction). As per the original experiment, record all I interactions 
having a p ≤ 0.10 for association. 
Stage (3): do a new permutation of case-control data. With these data, test the I 
interactions found in Stage 2, using a significance level of p ≤ 0.05.  Record the number 
of “replicated interactions” R. 
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We performed this Stage 1 – Stage 3 experiment 10,000 times to obtain the 
distribution of R. This is, in essence, the design of the original experiment. It differs in 
the sense that the original experiment used a family-based sample in Stage 3 and had 
slightly different sample sizes, but neither of these features should be important under the 
null hypothesis evaluated here. 
 
 
 
 
Figure 5 Study Desgin 
Overview of multi-stage study design utilized, including all samples and SNPs analyzed in each 
stage.  In stage I, the 328 cases are independent of the 150 probands from the family based 
samples. dopamine = dopamine, GC = genomic control.  
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4.4 RESULTS 
4.4.1 Design Overview 
An overview of the study design is provided in Figure 5.  Briefly, in stage I we screened 
18 dopamine-related genes using two independent samples from the US; a family-based 
sample and a case-control sample.  To improve the power of our screen, we evaluated the 
joint distribution of test statistics from both samples.  In stage II, in-depth analyses of the 
most promising stage I genes were conducted using tag SNPs and all available case-
control samples from stage I.  Pair-wise epistatic interactions were then modeled for a 
limited number of SNPs where evidence for main effects were detected.  In stage III, we 
analyzed a third independent sample from Bulgaria.  In sum, 3,256 participants were 
genotyped.  Finally, functional effects of key SNPs were examined in stage IV.   
4.4.2 Candidate Genes 
Because the list of genes impacting dopaminergic function is potentially long, subjective, 
and continually expanding, we restricted our evaluation to dopaminergic genes analyzed 
in genetic association studies as of 2003.  The selected genes included those required for 
dopamine synthesis (TH, DDC), transport (SLC6A3, SLC6A2, SLC18A1, SLC18A2), 
metabolism (MAOA, MAOB, COMT), conversion of dopamine to norepinephrine (DBH), 
and all dopamine receptors (DRD1, DRD2, DRD3, DRD4, DRD5) (Table 6).  We also 
chose three genes important for dopamine regulation, namely PPP1R1C (alias 
dopamineRPP-32), DRD1IP (alias CALCYON, a dopamine D1 receptor interacting 
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protein), and NR4A2 (alias NURR1, an orphan nuclear receptor and putative transcription 
factor for the dopamine transporter) (Table 1).  One candidate, DRD3, was analyzed in 
our U.S. sample earlier as part of a collaborative study (Talkowski, Mansour et al., 2006).  
Based on the significant associations detected in that study, DRD3 was retained for stage 
II of this study, which included 501 independent controls.   
 
Table 6  Dopaminergic genes and SNPs analyzed 
 SNPs Genotyped 
Gene Location Gene Name               (alias name) 
Size   
(kb) Stage I Stage II 
Stage 
III 
COMT 22q11.2 catechol-O-methyltransferase 27.2 7 18 17 
DBH 9q34 dopamine beta hydroxylase 23 9   
DDC 7p11 dopamine decarboxylase 102.6 5   
DRD1 5q35.1 dopamine D1 receptor 3.1 3   
DRD1IP 10q26.3 D1 receptor interacting protein (CALCYON) 11.5 5   
DRD2 11q23 dopamine D2 receptor 65.6 5   
DRD3 3q13.3 dopamine D3 receptor 50.2 13a 18 18 
DRD4 11p15.5 dopamine D4 receptor 3.4 3   
DRD5 4p16.1 dopamine D5 receptor 2.1 3   
MAOA Xp11.3 monoamine oxidase A 90.6 10   
MAOB Xp11.3 monoamine oxidase B 115.8 6   
NR4A2 2q24.1 orphin nuclear receptor subunit 4 (NURR1) 8.3 5   
PPP1R1B 17q21.2 
protein phosphatase 1, 
regulatory (inhibitory) subunit 
1B (dopamineRPP-32) 
9.7 4   
SLC18A1 8p21.3 
vessicular monoamine 
transporter, member 1 
(VMAT1) 
38.4 10   
SLC18A2 10q25 
vessicular monoamine 
transporter, member 2 
(VMAT2) 
35.9 3 14 13 
SLC6A2 16q12.2 monoamine transporter, noradrenaline (NET) 46 8   
SLC6A3 5p15.3 dopamine transporter (DAT, DAT1) 52.6 6 18 17 
TH 11p15.5 tyrosine hydroxylase 7.9 3   
Dopamine genes and SNPs analyzed, given in alphabetical order.  The bolded genes were 
further analyzed in Stages II and III.  aThese SNPs were previously analyzed and results from 
those published analyses suggested significant associations in these samples (Talkowski, 
Mansour et al., 2006). 
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4.4.3 Stage I: SNP Screen among two independent US samples  
We conducted 95 tests of association in the US family based sample (150 trios, SNPs 
selected from Celera, 2003 based on physical distance).  The most significant association 
was detected at SLC6A3 (DAT) (rs403636, p = 0.0004, odds ratio = 2.36).  Transmission 
distortion was noted at two other SLC6A3 SNPs (rs27072, p = 0.0009; rs12516948, p = 
0.07).  All trends for association (p < 0.10; n = 9 SNPs) were genotyped in a replicate US 
case-control sample (328 cases, 501 controls).  In this independent sample, significant 
associations were detected with 4 SNPs, including replication of rs403636 (p = 0.04).  
The joint distribution of test statistics from both samples identified SLC6A3, DRD3, 
COMT, and SLC18A2 as the four most promising candidates (pjoint < 0.05) (see Table 7 
for selected significant results).  These four genes were retained for follow-up analyses. 
Table 7 Significant associations from joint analysis of Stage I 
 
Stage I 
Families 
(150 Trios)
Stage I     
Case-
Control  (n 
= 328/501) 
Stage I Joint 
Analysis 
Chr Gene SNP BP Z1 P1 Z2 P2 Zjoint Pjoint 
3 DRD3 rs324030 115364131 2.25 0.024 1.48 0.139 2.48 0.013 
3 DRD3 rs10934256 115368342 2.62 0.009 1.10 0.271 2.36 0.018 
3 DRD3 rs6280 115373505 2.01 0.044 1.70 0.089 2.52 0.012 
3 DRD3 rs1800828 115374239 1.97 0.049 1.20 0.230 2.08 0.038 
5 SLC6A3 rs27072 1447522 3.26 0.001 1.89 0.059 3.37 0.0007
5 SLC6A3 rs403636 1491354 3.53 4E-04 2.46 0.014 4.00 6E-05 
10 SLC18A2 rs3633343 119004938 1.94 0.052 2.09 0.037 2.81 0.005 
22 COMT rs737865* 18310121 1.31 0.190 2.65 0.008 2.93 0.003 
22 COMT rs165815 18334027 1.68 0.090 1.97 0.050 2.55 0.011 
Only SNPs associated based on the joint distribution of test statistics (pjoint < 0.05) are listed.  Z1, 
Z2:  Z scores from analysis of family-based and case-control samples, respectively.  P1, P2:  
Probability of Z score (p values) from association analyses of family-based and case-control 
samples, respectively.  Zjoint, Pjoint: joint analyses and corresponding p-values when considering 
test statistics and proportion of total samples genotyped in each design.  *analyses in 
females, conducted based on previous findings by Shifman et al. (Shifman et al., 2002). 
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4.4.4 Stage II: Comprehensive coverage and epistasis among US samples 
We assayed 68 SNPs among all available cases and controls from stage I (478 cases, 501 
controls) at SLC6A3, DRD3, COMT, and SLC18A2.  SNPs were obtained from HapMap 
(HapMap, 2003) and in-house sequencing for SNP detection. These analyses were not 
intended to replicate the stage I findings, as the samples overlapped.  Instead, they 
enabled us to conduct in-depth analysis of representative common variants (minor allele 
> 5%) from these four genes, over and above what was possible in our initial screen.   
Overall, the distribution of test statistics from these SNPs was skewed towards 
small p-values (median trends test = 1.07; expected median = 0.456).  Significant 
associations (p < 0.05) were found for 15 SNPs (Supplementary Table 4.1).  At SLC6A3, 
6 of 17 SNPs tested were nominally significant (p < 0.05).  Linkage disequilibrium 
analyses (LD) revealed that these associated SNPs were not part of a single cluster 
(Figure 6).  Associations were also detected with six DRD3 SNPs, three SLC18A2 SNPs, 
and one COMT SNP.   
Gender specific analyses were conducted at three COMT SNPs based on a 
previously reported association by Shifman and colleagues (Shifman et al., 2002). 
Consistent with those findings, logistic regression revealed a significant interaction 
between gender and rs737865 genotype (χ2 = 14.14, 2 d.f., p = 0.0007).  The significant 
effect appeared to be attributable to females, and a trends test comparing female patients 
to female controls for this SNP revealed significant differences in genotype distributions 
between groups (p = 0.008; odds ratio = 1.34).  Of note, the frequency of the G allele at 
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rs737865 among female cases (0.38) was different than all three comparison groups, 
namely: female controls (0.29), male cases (0.29), and male controls (0.28).  Gender 
related differences were not consistent with Shifman et al. at the other two SNPs 
(rs165599 and rs4680).   
We next tested epistatic interactions among pairs of SNPs from different genes 
when a main effect was observed (cutoff set at p < 0.10, n = 22 SNPs including rs6347 
based on stage III, see below; total 169 tests).  We identified significant interactions 
between 17 locus pairs (p < 0.05).  Notably, 7 of 17 significant interactions (41.2%) 
involved either rs3756450 in the 5’ upstream region of SLC6A3 or rs464049 within intron 
4 of SLC6A3 (LD between these SNPs: r2 = 0.04 / D’ = 0.56).  In sum, 29 putative 
interactions were detected at p < 0.10. 
4.4.5 Stage III: Corroboration with an independent Bulgarian family sample 
Based on our findings in stages I and II, we tested our hypotheses in a third independent 
sample composed of 659 case-parent trios from Bulgaria (total n = 1,977) using 65 SNPs.  
Significant associations were again detected in this cohort for both consistently 
interacting dopamine transporter SNPs in the stage II epistatic analyses (SLC6A3: 
rs464049, p = 0.011 and rs3756450, p = 0.035).  Trends for transmission bias (p < 0.10) 
were detected at five SLC6A3 SNPs.  Associations were not detected with other SNPs, 
including the three key exonic polymorphisms recently shown to alter COMT mRNA 
secondary structure (rs4680, rs4633, rs4818).  We tested rs737865 for gender related 
differences based on our stage II results and again noted significant transmission 
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distortion to female probands (p = 0.04, OR = 1.47) but not male probands (p = 0.18), 
however the over-transmitted allele was the A allele, in contrast to the US samples.   
The joint distribution of test statistics for SNP analyses from stages II and III (US case-
control and Bulgarian trios, respectively) found individual SNP associations at all four 
genes (pjoint < 0.05), including 7 SLC6A3 loci (Table 9).  
We next tested the putative epistatic interactions from the US sample in this 
cohort.  Interaction tests were limited to the 29 SNP pairs where epistasis was detected in 
the US sample at p < 0.10 or better using a conditional logit model.  Remarkably, 7 of 
these 29 interactions (24.1%) were significant (p < 0.05) in this independent family-based 
cohort.  Consistent with the patterns observed in the US sample, interactions with 
SLC6A3 loci were replicated with each of the other three genes (e.g. p < 0.05 for the same 
locus pairs in both samples when analyzing SLC6A3*DRD3, SLC6A3*SLC18A2, and 
SLC6A3*COMT).  One DRD3*SLC18A2 interaction was also significant in both samples.  
Table 9 lists all pairs of loci where at least a trend (p < 0.10) was detected in both 
samples (Table 9).    
To interpret the results from our interaction tests we performed simulations of our 
analysis design.  Using permutation and rejection sampling methods, we emulated the 
complicated multi-stage design employed here.  The simulation results suggest it would 
be unusual to obtain 7 or more “replicated interactions”, such as in stage III above.  From 
the simulations we estimate the probability of this event to be roughly one in a thousand 
(0.0013 ± 0.00071).  Similarly, we estimate the results of finding the initial 29 interaction 
“trends” (p < 0.10) in stage II to also be rare, despite the much larger number of tests 
(0.0078 ± 0.0055).   
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Table 8  Associated SNPs at SLC6A3, DRD3, SLC18A2, and COMT:  joint analyses of US and Bulgarian samples 
 
US Cases / 
Controls          
(478 / 501) 
Bulgaria Trios       
(659) 
Joint 
Analyses 
Gene SNP Position Nuc
HapMap Freq 
CEU/JPT/YRI Freq Z1 P1 OR Freq Z2 P2 OR Zjoint Pjoint 
SLC6A3 rs12516948 1444369 A .67/.81/.56* 0.67 -2.5 0.01 0.79 0.65 -1.3 0.21 0.90 -2.6 0.009 
SLC6A3 rs6347 1464412 A .72/.93/.38 0.71 1.1 0.26 1.12 0.75 1.7 0.10 1.17 2.0 0.046 
SLC6A3 rs464049 1476905 C .51/.63/.74 0.52 2.5 0.01 1.25 0.53 2.5 0.01 1.22 3.5 0.0004
SLC6A3 rs456082 1483515 T .70/.51/.46 0.77 2.2 0.03 1.27 0.77 1.7 0.09 1.17 2.7 0.007 
SLC6A3 rs463379 1484164 C .70/NA/.47 0.77 2.1 0.04 1.26 0.77 1.8 0.07 1.20 2.7 0.006 
SLC6A3 rs403636 1491354 G .79/.64/.78 0.85 -2.0 0.05 1.27 0.85 -1.5 0.15 0.85 -2.4 0.017 
SLC6A3 rs3756450 1501148 T .84/.57/.50 0.87 1.7 0.09 1.27 0.85 2.1 0.04 1.27 2.7 0.007 
DRD3 rs7625282 115364217 A .73/.76/.72 0.76 2.5 0.01 1.26 0.74 0.6 0.52 1.06 2.1 0.033 
SLC18A2 rs363393 118995757 A .83/1.0/1.0 0.81 1.1 0.28 1.10 0.84 1.9 0.06 1.22 2.1 0.033 
SLC18A2 rs363338 118999379 T .69/.24/.32 0.66 2.2 0.03 1.26 0.67 0.7 0.46 1.06 2.0 0.043 
SLC18A2 rs363227 119016556 C .89/.71/.68 0.87 1.4 0.17 1.15 0.87 1.5 0.13 1.21 2.0 0.041 
COMT rs174696 18327730 T .81/.54/.34 0.79 2.0 0.05 1.24 0.84 1.3 0.19 1.16 2.3 0.029 
COMT rs165815 18334027 T .88/.65/.41 0.83 1.8 0.07 1.26 0.78 1.4 0.15 1.15 2.3 0.017 
 
SNPs listed if joint distribution of test statistics from stages II and III resulted in pjoint < 0.05.  Nuc = nucleotide of common allele.  Allele frequency 
(freq) of the common allele is given.  Allele frequencies from HapMap data for Caucasians (CEU), Asians (JPT), and Africans (YRI) are given.  
Direction (sign) of the Z score is provided for the common allele (e.g. Z = -2.5 indicates that the less common allele confers risk).  OR = odds ratio 
for common allele. *Reference data from Applied Biosystems AoD submission for Caucasian, Japanese, and African-American populations 
(www.ncbi.nlm.nih.gov/SNP).   
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Figure 6 Linkage disequilibrium among SLC6A3 SNPs 
Linkage disequilibrium (LD) patterns among all SLC6A3 SNPs genotyped in the US and 
Bulgarian samples (16 SNPs were common to both samples).  LD values between pairs of SNPs 
(r2) are indicated, and associated SNPs (p < 0.10 and p < 0.05) are shown.   
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Table 9 Noteworthy epistatic interactions at SLC6A3, DRD3, SLC18A2, and COMT 
Stage II:           
US Case-Control 
Stage III:  
Bulgarian Trios 
Combined 
Results 
Genes Loci 
Interaction 
P-value† 
Perm.^   
P-value LLDiff‡ P-value χ24†† P-value
SLC6A3*COMT 
rs464049*rs174696 0.005 0.001 5.2 0.023 18.1 0.001 
rs464049*rs165815 0.001 0.001 2.5 0.101 17.7 0.001 
rs463379*rs174696 0.091 0.013 6.7 0.009 14.1 0.007 
rs456082*rs174696 0.069 0.009 5.9 0.015 13.7 0.008 
SLC6A3*SLC18A2 rs6347*rs363338 0.03 0.023 7.9 0.005 17.6 0.001 
SLC6A3*DRD3 rs463379*rs10934256 0.047 0.063 5.3 0.021 13.8 0.012 
rs12516948*rs6280 0.099 0.005 3.8 0.052 10.5 0.033 
DRD3*SLC18A2 rs1800828*rs363227 0.026 0.017 4.4 0.036 13.9 0.008 
rs1800828*rs929493 0.051 0.021 3.4 0.065 11.4 0.022 
Epistatic interactions results between stages II and III.  The first column lists the pairs of genes at 
which interactions were detected.  The second column lists the corresponding pairs of SNPs.  For 
example, rs464049*rs174696 denotes a SNP at SLC6A3 interacting with a COMT SNP.  Only 
interactions detected from both samples at p < 0.10 are listed.  †P-value for interaction term 
above main effects in logistic regression (see  (Macgregor & Khan, 2006)).  ^Perm. = 
Permutation, p-value from 1,000 iterations permuting case-control status.  ‡Difference in -2* log 
likelihood of full model including an interaction term and a reduced model including only main 
effects (distributed as a χ21.).  ††Test statistic from combining p-values from US and Bulgarian 
analyses (χ24). 
4.4.6 Stage IV: Functional Analysis 
We selected rs3756450 and rs464049 for further analyses of allele specific 
functional effects as these SLC6A3 SNPs were associated individually with risk for 
schizophrenia in both samples and featured prominently in the epistatic analyses.  
We performed electrophoretic mobility shift assays (EMSA) using nuclear 
extracts from SHSY-5Y cell line (Figure 8).  Both allelic probes at rs3756450 generated 
DNA-protein gel shift bands. Addition of 50X fold unlabeled oligonucleotides probes for 
each allele inhibited formation of the gel shift bands, demonstrating specificity for these 
oligonucleotide sequences.  We observed three distinct DNA-protein gel shift bands for 
the T allelic probe at rs3756450.  In contrast, the C allelic probe at rs3756450 annealed to 
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only two of the three bands, indicating allele specific difference in DNA-protein complex 
formation.  The result was replicated in two additional experiments, including one in 
which two fold excess of nuclear extract was added for assays with the C allele (see 
Figure 8).  In contrast, no allele specific DNA-protein gel shift bands were observed at 
rs464049, though bands common to both alleles were noted (data not 
shown).
 
Figure 7 Epistatic interactions at SLC6A3, DRD3, SLC18A2, and COMT. 
The genomic organization of all four genes retained from stage I analyses is shown.  Boxes 
extending below the horizontal line indicate exons and black tick marks represent all SNPs 
analyzed in the US and Bulgarian samples.  The SNPs retained for epistatic interactions (i.e. 
SNPs where p < 0.10 for main effects) are listed.  Gray lines indicate epistatic interactions at p < 
0.10 in both the US and Bulgarian samples, bolded black lines indicate significant interactions in 
the US as well as the Bulgarian samples at p < 0.05. 
 
Since rs3756450 is localized 5’ to the putative promoter region of SLC6A3, we 
also evaluated its effect on transcription.  Dual-luciferase assays were conducted using 
four clones from CEPH individuals whose genotypes were known (two constructs for 
each allele, see Figure 8).  Significant promoter activity was present in all constructs, 
compared with the promoterless construct.  In addition, promoter activity was 
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significantly different between constructs carrying C and T alleles (Student’s t-test, t = 
10.32, 5 d.f., p < 0.0001; Figure 9).   
 
Figure 8 Electorphoretic mobility shift assays of rs3756450 
Nuclear extracts from SHSY-5Y cells were incubated with labeled probes. The labeled probe for 
the T allele was loaded in the first three lanes, and the labeled probe for the C allele in the next 
three lanes.  Unlabeled competitor oligonucleotides were included in 50-fold molar excess in 
lanes 3 and 6. Lanes 1 and 4 indicate the migration of the labeled probe without the nuclear 
extract . * indicates altered band shift pattern for T-allele of rs3756450 (lane 2) with respect to C-
allele (lane 5), despite two fold excess of nuclear extract added to lanes 5 and 6.  
 
Figure 9.  Promoter assays using rs3756450 
 Promoter activity in a dual-luciferase assay system for constructs containing either the C or T 
allele at rs3756450, but identical at all other bases.   
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4.5 DISCUSSION 
Our systematic multi-stage approach yielded novel SNP associations and 
replicated epistasis between four dopaminergic genes, SLC6A3, DRD3, COMT and 
SLC18A2.  We also noted plausible allele specific functional effects in vitro for one of the 
associated SLC6A3 SNPs (rs3756450).  Three of these genes have been frequent targets 
in previous schizophrenia association studies (DRD3, COMT, SLC6A3), yet prior studies 
have not provided definitive evidence for or against associations.  Overall, the SLC6A3 
associations were most striking.  More than a third of test statistics for stage II analyses 
involving SLC6A3 SNPs were significant.  The median trends test statistic among 18 
SNPs was 2.26, indicating a significant shift towards small p-values compared with 
expectations.  When we sought evidence for epistasis, SNPs at SLC6A3 also dominated 
the list.  Two SLC6A3 SNPs (rs3756450 in the 5’ upstream and rs464049 at intron 4) 
were involved in 41.2% of the interactions in the US samples.  When we evaluated an 
independent Bulgarian sample, both these SNPs were again associated.  Though the 
dopamine transporter has long been a target for genetic association studies of 
schizophrenia (reviewed byBannon, Michelhaugh, Wang, & Sacchetti, 2001), most 
reports have focused on a variable number tandem repeat (VNTR) polymorphism 
localized to 15th exon (Gamma et al., 2005), but meta-analysis does not suggest an 
association (Gamma et al., 2005).  A previous analysis of the SLC6A3 3’ VNTR in a 
subset of the Bulgarian families also was not significant (Georgieva et al., 2002).  
Associations with other SLC6A3 polymorphisms have been reported, including 
significant associations in the 5’ region near the promoter (Keikhaee et al., 2005; 
Khodayari et al., 2004; Stober et al., 2006).     
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At DRD3, the present associations are consistent with our previous report, which 
analyzed a smaller set of US cases and a different group of control samples (Talkowski, 
Mansour et al., 2006).  They follow in a long line of studies that have targeted rs6280, a 
non-synonymous functional polymorphism (Jonsson et al., 2004).  More recent studies 
have shown associations with other variants in both the 5’ and 3’ regions of the gene 
(seeTalkowski et al., 2007).   
A functional exonic SNP (rs4680, Val/Met) has been the focus of numerous 
association studies at COMT, but the results have not been replicated consistently (M. D. 
Fallin et al., 2005; J. B. Fan et al., 2005; Glatt et al., 2003a; Munafo, Bowes, Clark, & 
Flint, 2005; H. J. Williams et al., 2005; reviewed byH. J. Williams, Owen, & O'Donovan, 
2007).  Associations with haplotypes including rs4680 have been reported recently 
among Chinese and Ashkenazi Jewish samples (T. Li et al., 2000; Shifman et al., 2002).  
The latter reported on a haplotype of large effect size comprising three SNPs spanning 
the gene (rs737865–rs4680–rs165599), and the association was more significant among 
women.  This haplotype was later found to be associated with decreased COMT mRNA 
levels in the human brain (Bray et al., 2003).  Gender specific associations have also been 
detected with a SNP in this haplotype (rs737865) in late onset Alzheimer’s disease with 
psychosis (Sweet et al., 2005).  Our US samples revealed a gender related association 
between schizophrenia and rs737865 consistent with the Shifman results (OR = 1.34).  
By contrast, our analyses of the Bulgarian sample found over-transmission of the 
opposite risk allele (A allele), matching the results of Sweet et al. (42).  Unlike the other 
three candidates, to date only one small association study of Japanese families at 
SLC18A2 has been conducted (Kunugi et al., 2001). 
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The epistatic interactions suggest a susceptibility model in which variations at 
SLC6A3 are important determinants of schizophrenia susceptibility, with additional risk 
due to variants at SLC18A2, DRD3, and COMT.   This model is appealing because all 
four proteins regulate synaptic dopamine concentrations, and there are plausible 
functional relationships between these genes.  The dopamine transporter (DAT) controls 
both the intensity and duration of dopamine actions at synapses by modulating reuptake 
into the pre-synaptic nerve terminal (Sotnikova, Beaulieu, Gainetdinov, & Caron, 2006; 
Torres, 2006).  Because DRD3 may function as an autoreceptor (Sokoloff et al., 1992; 
Sokoloff, Giros, Martres, Bouthenet, & Schwartz, 1990), it is reasonable to suggest 
molecular interactions between DRD3 and DAT.  Indeed, DRD3, as well as the dopamine 
D2 (DRD2) receptor subtypes can regulate DAT function (Zahniser & Doolen, 2001; 
Zapata & Shippenberg, 2002).  However, the molecular details of this ‘cross talk’ are not 
known.  Since VMAT2, the protein encoded by SLC18A2, mediates the transport of 
dopamine into synaptic vesicles, molecular interactions between VMAT2 and DAT 
following DAT mediated reuptake of dopamine into pre-synaptic terminals are possible 
and require investigation.  Finally, COMT is a key enzyme regulating synaptic dopamine 
levels through catabolism (Napolitano et al., 1995).  Common homeostatic mechanisms 
may thus regulate COMT and DAT.   
EMSA analyses suggest specific bandshift patterns using rs46049 probes in 
neuroblastoma cell lines.  More intriguing allele specific effects were observed with 
rs3756450, which is localized upstream to the core promoter sequences (Kelada et al., 
2005).   Our results suggest a putative transcription factor that either has differential 
affinity for the rs3756450 alleles or binds to rs3756450T, but not rs3756450C.  
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Furthermore, luciferase promoter assays suggest significant differences in promoter 
activity for alleles of this SNP.  Thus sequences flanking rs3756450 may represent a 
novel promoter domain for SLC6A3. 
There are some limitations to our association analyses.  Though the SNP selection 
in stage I was more extensive than past studies, more comprehensive coverage would 
have been desirable for several genes, particularly MAOA, MAOB, and DDC.  The 
samples available for stage I analyses were also limited.  We estimate only 41.3% power 
to detect an effect size of 1.5, so type II errors were possible and undetected liability loci 
could be present at genes that were not carried forward in stage II.  Similarly, our family 
based US samples had limited power to replicate other reported associations.  Our tests of 
epistasis were relatively conservative as we considered only locus pairs with evidence of 
a main effect.  Evaluation of much larger samples would be required to conduct an 
exhaustive analysis of all potential interactions across a larger network of dopaminergic 
genes.   
Our study design was intended to first identify promising susceptibility targets 
and then test these targets as comprehensively as possible.  Spurious associations arising 
from population substructure are unlikely to account for the SLC6A3 results, as 
significant associations were detected in both of the family-based samples.  Genomic 
control analyses also did not detect meaningful population substructure and no 
corrections were necessary.  To limit false positive results, we employed three 
independent samples, analyzing them independently and jointly.  We also simulated our 
study design and empirically determined the probability of obtaining similar results to the 
epistatic interactions.  These simulations suggest that both our stage II and stage III 
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interaction findings are unlikely under the null hypothesis (about eight in one-thousand 
and one in one-thousand for stages II and III, respectively).      
In conclusion, our analyses of eighteen dopaminergic genes among over 3,000 
participants indicate that variants at SLC6A3, DRD3, COMT, and SLC18A2 individually 
and jointly confer risk for schizophrenia.  Our findings propose a model for schizophrenia 
risk in which risk conferred by SLC6A3 variations could be modified by variants at 
DRD3, COMT, and / or SLC18A2.  
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5.1 ABSTRACT 
Recessive mutations in the Phenylalanine hydroxylase (PAH) gene predispose to 
phenylketonuria (PKU) in conjunction with dietary exposure to phenylalanine (Phe). 
Previous linkage and association studies have suggested PAH variations that could confer 
risk for schizophrenia, but comprehensive follow-up studies have not been reported.  We 
analyzed 15 common PAH “tag” SNPs and 3 rare exonic variations among four 
independent samples (total n = 5,414).  The samples included two US Caucasian cohorts 
(260 trios, 230 independent cases, 474 controls), a Bulgarian sample (659 trios), and an 
African-American sample (464 families, 401 controls).  Analyses of both US Caucasian 
samples revealed significant associations with five SNPs (uncorrected p < 0.05); most 
notably the common allele (G) of rs1522305 from case-control analyses (z = 2.99, p = 
0.006).  This SNP was independently replicated in the Bulgarian cohort (z = 2.39, p = 
0.015).  A non-significant trend was also observed among African-American families (z 
= 1.39, p = 0.165), and combined analyses of all four samples were significant 
(rs1522305: χ2 = 23.28, 8 d.f., p = 0.003); rs10860935 was also nominally significant 
from the combined results (p = 0.05).  Case-control analyses in African-Americans were 
restricted to three exonic variants K274E, L321L, and N426N detected an association 
with the common allele of L321L (p = 0.047, OR = 1.46).  Rare alleles were not different 
between groups at these variants.  Our analyses suggest several associations at PAH, with 
consistent evidence for rs1522305.  Further analyses, including additional variations and 
environmental influences such as phenylalanine exposure are warranted. 
 111
5.2 INTRODUCTION 
Phenylalanine hydroxylase (PAH) catalyses the conversion of phenylalanine 
(Phe) to tyrosine.  This reaction is the rate limiting step in the synthesis of catecholamines 
and accounts for approximately 75% of the disposal of dietary Phe. The gene encoding 
PAH is localized to chromosome 12q23.2, contains 13 exons, and the genomic sequence 
spans approximately 79.3 kilobases. PAH is expressed in the liver and kidney. 
Mutations in PAH can lead to phenylketonuria (PKU) in the presence of a diet 
that includes Phe.  PKU manifests as mental retardation (MR), associated with 
peculiarities of gait and posture, eczema, epilepsy, light pigmentation, cataracts, brain 
calcification and a 'mousy' odor (Følling, 1934).  These manifestations have been 
attributed to hyperphenylalaninemia resulting from impaired PAH activity.  Early post-
natal and long term use of a low Phe diet enables near normal cognitive development 
(Donlon, Levy, & Scriver, 2004).  PKU is inherited as an autosomal recessive disorder, 
with an average birth incidence of 1 / 10,000 in European populations.  Despite the 
increased frequency of several rare mutations in African-Americans compared to 
Caucasians, the incidence of PKU in U.S. African Americans is about one-third that in 
Caucasians (National Institute of Child Health and Human Development).  The aggregate 
mutant allele frequency in these groups is estimated at 0.01.  There is considerable allelic 
heterogeneity, with over 500 catalogued mutations leading to a spectrum of disease 
ranging from benign hyperphenylalaninemia to classical PKU (www.pahdb.mcgill.ca) 
(Scriver et al., 2003).  Genetic heterogeneity is also present, as PKU can occur due to 
mutations in tetrahydrobiopterin (BH4), an essential PAH co-factor (Thony & Blau, 
2006).   
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Penrose first suggested co-segregation of psychiatric illnesses and PKU, raising 
the intriguing possibility that PAH mutations may contribute to psychopathology other 
than MR (Penrose, 1935). Studies to explore this hypothesis have been conducted among 
PKU probands and their relatives, as well as psychiatric patients and their relatives, 
particularly schizophrenia patients.  The severe MR observed among individuals with 
untreated PKU would preclude a diagnosis of schizophrenia using current criteria, though 
some case reports with such co-morbidity have been published in the past (Fisch, 
Hosfield, Chang, Barranger, & Hastings, 1979).  More recent case-reports suggesting co-
occurrence of PKU among individuals with psychoses have also been published 
(Shiwach & Sheikha, 1998).  A large scale survey among institutionalized psychotic 
individuals did not detect any individuals with PKU (Cares, 1956).  On the other hand, 
early studies of schizophrenia patients found elevated fasting Phe levels, as well as 
abnormal responses to Phe tolerance tests (Poisner, 1960), suggesting that some 
schizophrenia patients could be carriers of mutant PAH alleles.   
Recent genetic studies have investigated a connection between PAH 
polymorphisms and increased susceptibility to schizophrenia.  Sobell et al. first examined 
two point mutations (R408W and IVS12nt1) known to be associated with PKU in a case-
control study design (190 schizophrenia cases, 336 controls), but did not detect a 
significant association (Sobell, Heston, & Sommer, 1993).  A linkage study of three 
quantitative traits in a sample of European and African-American schizophrenia affected 
siblings identified modest evidence for linkage with a marker at 109.5 cM overlapping 
PAH (LOD = 2.12).  Linkage with negative symptoms bolstered linkage evidence 
somewhat for this sample (LOD score = 2.97 at 104 cM), as well as an association 
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between this marker and schizophrenia (Wilcox, Faraone, Su, Van Eerdewegh, & 
Tsuang, 2002).  A series of studies previously conducted by Dr. Mary Richardson and 
colleagues have suggested associations between several PAH mutations and psychiatric 
illness among African-Americans but not Caucasians (M.A. Richardson et al., 1999a) 
(M.A. Richardson et al., 1999b) (Chao & Richardson, 2002).  Richardson and colleagues 
also reported on 9 exonic variants at PAH among 123 psychiatrically ill individuals and 
34 controls (M. A. Richardson et al., 2003).  One exonic variant (K274E) was noted 
among African-Americans and was over-represented among schizophrenia patients 
(cases: 4/24; controls: 1/13).  The K274E mutation was associated with altered Tyr levels 
following a Phe loading test.  Finally, a recent study detected linkage between short 
tandem repeat polymorphisms near PAH in an island population from Palau when 
mothers of schizophrenia patients were treated as the affected generation (Devlin et al., 
2007). These results are intriguing, because they suggest maternal-fetal interaction in 
schizophrenia genesis.  If true, such a mechanism might account for variability in 
conventional association and linkage analyses. 
Published studies suggest a link between common and / or rare PAH 
polymorphisms and schizophrenia.  To investigate this hypothesis, we evaluated 18 PAH 
variations in four independent samples.  Our analyses included 15 common 
polymorphisms and three additional exonic variations reported on previously (M. A. 
Richardson et al., 2003).     
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5.3 METHODS 
5.3.1 Study design 
We tested the hypothesis that common and/or rare PAH variations increase risk 
for schizophrenia (SZ).  We analyzed 15 single nucleotide polymorphisms (SNPs) that 
tagged common variations in Caucasians (Figure 10, details below).  These SNPs were 
evaluated in four independent samples of either European or African-American ancestry.   
We also selected three variations based on published analyses with psychosis that were 
monomorphic in Caucasians but polymorphic in African-Americans (K274E, N426N, 
and L321L, referred to as ‘rare variants’ herein for clarity) (M.A. Richardson et al., 
1999a), (M.A. Richardson et al., 1999b), (Chao & Richardson, 2002).  Our primary study 
included only SNP based analyses, first in each sample individually then combined 
across samples.  Associations with the ‘rare variants’ were conducted next, followed by 
exploratory analyses to evaluate covariates such as gender and maternal genotypes.   
5.3.2 Samples 
US: Unrelated patients were recruited at Western Psychiatric Institute and Clinic, 
Pittsburgh, Pennsylvania and surrounding regions (n = 490).  Diagnoses were based on 
the Diagnostic Interview for Genetic Studies (Nurnberger et al., 1994), supplemented by 
medical records and informant interviews.  Consensus DSM-IV diagnoses of 
schizophrenia or schizoaffective disorder were assigned by board-certified psychiatrists / 
psychologists following review of all these sources of information.  Both parents of 260 
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patients were ascertained for family based analyses, but diagnostic evaluations were not 
conducted for the parents (260 trios).  Control DNA samples were collected from the 
cord blood of 474 unscreened Caucasian neonates born at Magee-Women’s Hospital, 
Pittsburgh, PA.  Only ancestry and gender was available for these samples.   
Bulgaria:  schizophrenia patients and their parents were recruited in Bulgaria as 
described previously (Kirov et al., 2004).  Diagnoses among probands were made 
according to DSM-IV criteria, following assessment by a psychiatrist using the Schedules 
for Clinical Assessment in Neuropsychiatry (Wing JK, 1990 Jun) , which has been 
validated for use in the Bulgarian language, and inspection of hospital discharge 
summaries. All patients and their parents received written information on the project and 
signed an informed consent form.  The Bulgarian sample included 659 trios (total n = 
1,977).  Probands were diagnosed with schizophrenia (n = 576) or schizophreniaA (n = 
83).  
African Americans:  African-American patients and their parents were ascertained as 
part of an ongoing collaborative study to investigate risks for schizophrenia in an 
African-American sample (Aliyu et al., 2006).  Families were chosen for genotyping 
from the overall consortium and analyses were carried out based on phenotype data as of 
January 19th, 2008.  The sample was composed of 464 total families ascertained for both 
linkage and association studies, including 73 complete trios (proband + 2 parents), 181 
“duo + sibs” (proband + 1 parent + unaffected siblings), 122 “case + sibs” (affected 
proband + unaffected siblings, no parents),  53 affected sibling pairs without parents, 27 
affected sibling pairs with 1 parent, 5 affected sibling pairs + both parents, and 3 “duos” 
(affected proband + 1 parent, no siblings).  From these family configurations, most but 
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not all individuals were informative for family-based association tests.  For the three ‘rare 
variants’ (see below), 551 African-American cases were contrasted with 401 adult 
controls.  The cases included one patient with schizophrenia or schizophreniaA randomly 
chosen from each of the 464 families and 87 singleton cases where no parents were 
available.  The controls were screened for absence of psychoses and current substance 
abuse using the same procedures as the cases (Aliyu et al., 2006).  The University of 
Pittsburgh Institutional Review Board (IRB) approved the study.  Approval from 
appropriate IRBs was also obtained at each collaborating US site.  Ethics committee 
approval was obtained from ethics committees in all regions of Bulgaria where families 
were recruited.  Written informed consent was obtained from all participants, except 
neonatal controls, in accordance with IRB guidelines.   
5.3.3 Polymorphism Selection 
We chose tag SNPs to represent all common variations among 60 unrelated 
Caucasians available in release 20 (phase II, January, 2006) of the International HapMap 
Project (HapMap, 2003).  To accomplish this, we selected all available SNPs within PAH 
and 5 kb of flanking sequence 5’ and 3’ to the gene.  Genotypes were obtained from 
CEPH samples (US residents collected in 1980 by the Centre d'Etude du Polymorphisme 
Humain).  These participants have ancestry from Northern and Western Europe.  Tag 
SNPs were identified to represent common variation with a minor allele frequency 
(MAF) greater than 5% in Caucasians using Hclust software (Rinaldo et al., 2005).  
Hclust computes a similarity matrix from the square of Pearson’s correlation (r2) between 
allele counts at pairs of loci then uses hierarchical clustering to group correlated SNPs.  
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We selected a SNP as a tag if the correlation between loci was below a threshold of r2 < 
0.9.  Thus, 21 SNPs were identified.   When SNPs were initially rejected by Applied 
Biosystems in the assay design (8 SNPs), surrogates were sought.  If no surrogates were 
available, we re-analyzed the dataset to identify another SNP with a lower LD threshold 
to use as a proxy (r2 > 0.8 between surrogate and failed marker).  Using this procedure, 
only two tag SNPs were not represented at a minimum correlation threshold of r2 = 0.8 in 
our analyses (rs1281013 and rs1851381).  .   
Previous research by Richardson et al. suggested associations between several 
exonic variations and psychosis among African-Americans (M. A. Richardson et al., 
2003).  Those analyses indicated that the SNPs had minor allele frequencies (MAF) 
greater than 1% among African-Americans, but had MAF < 0.01 in European Americans.  
We chose three such variants (K274E, L321L, N426N; referred to in this study as ‘rare 
variants’ for clarity) to be genotyped in all of our family samples.  An additional set of 
case-control analyses were conducted for only these SNPs among African-American 
cases not included in the family based analyses and adult African-American control 
sample typed exclusively for these polymorphisms.   
5.3.4 Genotyping Assays 
All 18 variants were included in assays for all four independent samples using the 
hybridization based SNPlex assay (ABI Biosystems Inc), as described elsewhere (Tobler 
et al., 2005).  The assay utilizes custom designed oligonucleotide pools of up to 48 SNPs, 
which can be genotyped in a single reaction.  The three ‘rare variants’ were genotyped 
among the African-American controls using the ABI SNaPshot assay (Applied 
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Biosystems, Inc).  The assay involves a multiplexed PCR reaction followed by single 
base extension (Mansour et al., 2005).  The genomic organization of PAH and the 
selected polymorphisms are shown in Figure 10.  All molecular genetic analyses were 
conducted at the University of Pittsburgh.   
5.3.5 Quality control 
All genotype assays included duplicated samples and/or CEPH individuals genotyped by 
HapMap (HapMap, 2003).   Negative control samples (water) were also included in each 
assay plate.  A random subset of 34 African-American samples were selected from all 
individuals found to carry at least one copy of the rare alleles of K274E, L321L, and 
N426N and individually sequenced to confirm the SNPlex and SNaPshot genotype calls.   
Tests for Mendelian inconsistencies were conducted in all family-based samples using 
PEDCHECK (O'Connell & Weeks, 1998) and tests of Hardy-Weinberg Equilibrium 
(HWE) were carried out for probands, parents, and controls separately in each population 
using GENEPOP software (version 1.31) (Raymond & Rousset, 1995).   
5.3.6 Statistical Analysis   
Transmission distortion was analyzed using FBAT software (Laird, Horvath, & Xu, 
2000), which can appropriately handle families of mixed configuration such as those in 
the African-American sample analyzed here.  Differences in genotype distributions 
between cases and controls were evaluated with the Armitage Trends test (SAS software) 
(Devlin & Roeder, 1999) or Fisher’s exact test, as appropriate.  Test statistics were 
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converted to z scores for case-control analyses for ease of comparison regarding risk 
alleles (i.e. z positive or negative) across samples.  We estimated the effective number of 
independent tests among these SNPs using the statistical package R based on published 
methods (Conneely & Boehnke, 2007).  We estimated the number of effective tests in the 
Caucasians and African-Americans separately due to the expected differences in LD 
patterns between these populations.  Our analyses suggested 7.9 effective tests in the 
Caucasians and 12.6 effective tests in the African-Americans.  We analyzed each SNP for 
association in each sample individually.  To evaluate evidence against the null hypothesis 
across the four independent samples, we combined results based on Fisher’s combined 
probability test (Fisher, 1948).         
5.3.7 Exploratory analyses 
We conducted exploratory analyses to determine if risk conferred by individual 
polymorphisms was modified by gender.  To carry out these analyses, we analyzed allele 
transmissions to male and female probands separately in family based analyses, and 
performed logistic regression among male cases / controls and female cases / controls 
separately.   
Previous analyses in an island population detected linkage to the maternal 
generation of affected schizophrenia cases at 12q23.2 (Devlin et al., 2007).   To test the 
hypothesis of susceptibility due to genetic liability in the maternal generation, we 
compared allele frequencies for all 15 common SNPs between mothers and fathers in all 
three samples (Armitage trends test).   
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5.3.8 Interpretation of statistical significance 
We considered an association with schizophrenia significant if (1) an individual SNP test 
exceeded an alpha threshold of 0.0063 in any Caucasian sample (0.05 / 7.9 tests) or 
0.0040 (0.05 / 12.6 tests) in the African-American samples, (2) a nominally significant 
replication for an individual SNP (and allele) was detected (p < 0.05 in two or more 
samples), or (3) combined analyses provided evidence of an association.  Exploratory 
analyses were considered significant only if replication was detected (p < 0.05).   
5.4 RESULTS 
5.4.1 Quality Control 
All 18 SNPs were genotyped in the Caucasians, but rs124125434 could not be 
assayed in the African-American samples.  The mean genotype call rate was 95% or 
greater in all four samples for the SNPlex assays and 96.8% in the SNaPshot assays.  
Using duplicated samples and CEPH individuals to compare with HapMap, we estimated 
our genotyping accuracy to range between 99.95% - 99.88% in all 4 samples.  These data 
are comparable to HapMap estimates and our previous analyses in these Caucasian 
samples (Talkowski et al., 2008).  We sequenced 34 African-Americans for the three rare 
variations to confirm their genotype.  We found 100% concordance between the 
sequencing genotypes and SNPlex / SNaPshot genotypes for these individuals. 
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5.4.2 Linkage Disequilibrium 
Linkage disequilibrium (LD) was estimated using Haploview software among 
unrelated Caucasian controls from the US (n = 474), unrelated parents from Bulgaria (n = 
1318), and unrelated African-American parents (n = 367).  As expected, pairwise LD (r2) 
was similar between Caucasian samples, but differed among African-Americans (Figure 
11).   
 
 
 
Figure 10 PAH genomic organization and variants analyzed 
The vertical bars represent exons.  The numbers below the line represent the introns.  The 
polymorphisms analyzed are listed above the line. 
 
5.4.3 Primary association analyses 
Caucasians: In the US case-control sample (230 cases independent of the trios, 474 
controls), two SNPs were associated with schizophrenia (rs1522305, z = 2.74, p = 0.006, 
OR = 1.64, 95% CI = 1.15 – 2.32; rs12312872, z = 1.98, p = 0.050, OR = 1.34, 95% CI = 
1.84 – 0.99; all p-values uncorrected).  In the US family sample (260 trios), transmission 
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distortion was detected with three SNPs, including rs1042503 (z = -2.0, p = 0.05), 
rs12425434 (z = -2.2, p = 0.03), and rs10860935 (z = 2.3, p = 0.02).   
In the Bulgarian families (659 trios), the most significant association in the US 
case-control analyses (common G allele of rs1522305) was replicated in this independent 
cohort (z = 2.4, p = 0.015).  Three other SNPs were nominally significant (uncorrected p 
< 0.05; rs2245360, rs937476, rs152296).  Transmission distortion that did not reach 
statistical significance was noted for two SNPs that was consistent with associations in 
the US sample, namely rs12312872 (Bulgarian p = 0.06, US case-control p = 0.05) and 
rs10860935 (Bulgarian p = 0.09, US family-based analyses p = 0.02) (see Table 10).  The 
‘rare variants’ were monomorphic among all Caucasian samples. 
African-Americans: In the African-American family sample, no SNPs were significantly 
associated with schizophrenia but a trend for over-transmission of the G allele at 
rs1522305 was noted (z = 1.39, p = 0.167).  This is the allele associated in the US and 
Bulgarian samples and its frequency was similar across samples (US cases 0.898, US 
cords 0.843, Bulgarian cases 0.875, African-American cases 0.819).  All three ‘rare 
variants’ (K274E, L321L, N426N) were present at a frequency greater than 1% in the 
African-Americans.  None were significantly over-transmitted to probands, however 
minor allele frequencies for K274E (0.014) did not enable meaningful analyses of 
transmission distortion given the size and configuration of the present sample.  Case-
control comparisons in the African-American samples were therefore conducted for only 
these three SNPs (551 cases, 402 controls).  None of the rare alleles were found to be 
associated with schizophrenia risk, however a nominally significant association was 
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detected with the common allele (non-mutant allele) of L321L (p = 0.047, OR = 1.46, 
95% CI = 2.14 – 1.0) (Table 11).   
5.4.4 Combined analyses 
We combined the observed probabilities for each of the four independent samples 
at each of the 14 SNPs tested across all samples (rs12425434 and each of the three ‘rare 
variants’ were not informative for associations in all four samples).  As expected from the 
initial findings in three of the four samples, combined analyses suggested a significant 
association with the common allele of rs1522305 (χ2 = 23.28, 8 d.f., p = 0.003).  A 
nominally significant association was also detected with rs10860935 (χ2 = 15.47, 8 d.f., p 
= 0.05).  Another SNP, rs12312872, was significant among European samples (χ2 = 
12.76, 6 d.f., p = 0.047), but not when African-Americans were included in combined 
analyses (p = 0.072). 
5.4.5 Exploratory analyses 
Gender specific associations were detected in the Bulgarian trios with nine SNPs.  
None were associated in both males and females.  Over-transmission to affected male 
patients was observed for six SNPs, the most significant being rs937476 (p = 0.004, OR 
= 1.4).  Three SNPs were associated among females, most notably rs1522305 (G allele, p 
= 0.002, OR = 1.84) and rs152296 (G allele, p = 0.007, OR = 1.43) (Supplementary Table 
5.1).     
 124
Table 10.  Association analyses of PAH variations 
  
US Cases / Controls      
(n = 230 / 474) 
US Families    
(260 Trios) 
Bulgarian Families   
(659 Trios) 
African-
American 
Families        
(n = 464) 
Combined 
Analysis        
(All samples) 
SNP 
Gene 
Location Nuc 
Case 
Freq. 
Cord 
Freq Z1 P1 
Allele 
Freq Z2 P2 
Allele 
Freq Z3 P3 
Allele 
Freq Z4 P4 χ82 Pall 
rs1522296 Intron- 1 G 0.707 0.686 0.77 0.450 0.691 1.61 0.11 0.682 2.23 0.025 0.49 0.01 1 13.39 0.0991 
rs10778209 Intron-3 G 0.765 0.751 0.58 0.565 0.740 0.76 0.45 0.716 -0.24 0.813 0.92 -0.58 0.56 4.33 0.8262 
rs10860935 Intron-3 T 0.850 0.868 -0.94 0.371 0.856 2.27 0.02 0.837 1.67 0.094 0.66 -0.63 0.53 15.47 0.0506 
rs1522305 Intron-3 G 0.898 0.843 2.99 0.006 0.855 0.46 0.65 0.875 2.39 0.015 0.82 1.39 0.17 23.28 0.0030 
rs1722392 Intron-3 C 0.539 0.558 -0.67 0.528 0.557 -0.20 0.84 0.521 -1.38 0.167 0.57 0.01 0.99 5.22 0.7338 
rs2037639 Intron-3 G 0.733 0.738 -0.23 0.818 0.739 -1.40 0.16 0.770 0.60 0.550 0.87 -0.27 0.79 5.71 0.6797 
rs937476 Intron-6 A 0.586 0.575 0.38 0.722 0.589 0.57 0.57 0.555 -2.07 0.039 0.55 1.39 0.17 11.88 0.1566 
rs12425434 Intron-5 C 0.716 0.723 -0.30 0.769 0.708 -2.20 0.03 0.727 -0.22 0.829 N/A  
rs1126758 Exon-6 A 0.557 0.582 -0.90 0.376 0.561 -1.36 0.17 0.579 1.23 0.218 0.8 -0.07 0.95 8.61 0.3763 
rs12312872 Intron-6 A 0.858 0.818 1.98 0.050 0.844 0.63 0.53 0.863 1.85 0.064 0.63 -0.77 0.44 14.40 0.0719 
N426N Exon-7 T monomorphic  0.86 0.67 0.5  
rs1042503 Exon-7 G 0.714 0.727 -0.51 0.614 0.716 -2.00 0.05 0.737 0.44 0.664 0.95 -0.72 0.47 9.46 0.3050 
K274E Exon-7 A monomorphic  0.98 0.00 1  
rs1722387 Intron-8 G 0.843 0.855 -0.59 0.572 0.845 0.91 0.37 0.841 1.38 0.167 0.85 0.32 0.75 7.29 0.5057 
rs772897 Intron-8 G 0.843 0.848 -0.23 0.822 0.842 1.08 0.28 0.834 1.11 0.269 0.82 1.25 0.21 8.70 0.3682 
L321L Exon-9 C monomorphic  0.94 0.62 0.54  
rs2245360 Exon-11 G 0.642 0.638 0.17 0.870 0.643 0.72 0.47 0.617 -2.18 0.030 0.81 -0.23 0.82 9.24 0.3225 
rs1801153 Intron-11 G 0.811 0.787 1.06 0.312 0.821 0.18 0.86 0.739 0.84 0.399 0.39 0.53 0.6 5.50 0.7030 
Results from association analyses of 18 PAH variations in four independent samples.  SNPs are provided in the direction of PAH transcription 5’ to 
3’. Nuc = nucleotide for which frequency data are listed.  Freq = allele frequency of allele for which nucleotide is provided (common allele).  Z = 
test statistic for common allele (negative = risk conferred by minor allele).  Combined analysis using Fisher’s method of combining probabilities 
from independent tests of significance (distributed as χ22N statistic). 
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Figure 11 Linkage disequilibrium between PAH variants across populations 
Linkage disequilibrium (r2) was estimated between SNPs among (a) unrelated US Caucasian individuals, (b) parents of affected Caucasian 
probands from Bulgaria, and (c) parents of affected African-American probands.   
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Replicate analyses in the US and African-American samples detected a significant 
association with the common allele of rs1522305 when US Caucasian female cases were 
compared with female controls (US case-control p = 0.05).  However, an association was 
not detected among the US Caucasian trios or the African-American family sample.  
Consistent replication was also detected between Bulgarian male patients and US male 
patients (p < 0.05 in both samples) with rs1042503, rs12425434, and rs2037639.  None 
were replicated among US Caucasian male probands or African-American males.  
(Supplementary Table 5.1).   
We compared the allele frequencies of the 18 common polymorphisms between 
the mothers and fathers in all three available family samples.  No significant differences 
were found for any of these comparisons (data not shown).   
 
Table 11 Comparison of three PAH variations among African-Americans 
  Case Genotype 
Control 
Genotype 
Allele Frequencies and 
association tests 
SNP Nuc 11 12 22 11 12 22 
Case 
Freq 
Control 
Freq Y 
p-
value 
K274E 
1 = A 
2 = G 523 16 0 369 17 0 0.985 0.978 1.35 0.246 
L321L 
1 = C 
2 = T 483 52 2 326 57 0 0.948 0.926 3.96 0.047 
N426N 
1 = C 
2 = T 9 138 386 9 83 287 0.146 0.133 0.63 0.428 
Case-control analyses of 3 exonic PAH variations (referred to in text as ‘rare variants’) among an 
African-American case-control sample.  Nuc = nucleotide.  Freq = allele frequency.  Y, p-value: 
results of trends test from distribution of genotypes.  *Fisher’s exact test p-value: K274E, p = 
0.207, L321L, p = 0.017. 
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5.4.6 Interpretation of statistical significance 
Our analyses found the equivalent of 7.9 effective tests in each individual 
Caucasian sample and 12.6 effective tests in the African-American samples.  There were 
thus 36.3 effective tests across all four samples for the primary analyses and 132.6 total 
tests across all primary and exploratory analyses.  The associations at rs1522305 fulfilled 
all three pre-established criteria for significance.  The initial analyses in the US case-
control sample exceeded the individual experiment correction for multiple testing 
(uncorrected p = 0.006, corrected p = 0.047) (criterion #1 above).  This SNP was 
significant in two independent samples (US case-control p = 0.006, Bulgarian p = 0.015) 
(criterion #2), and was associated following combined analyses from all four samples (p 
= 0.003) (criterion #3).  No other SNP associations were robust to correction for multiple 
testing in individual samples, nor were any other SNPs replicated in more than one 
sample, although rs10860935 was significant in combined analysis of all samples (p = 
0.05) (Table 10). 
5.5 DISCUSSION 
We tested associations between PAH variants and schizophrenia by evaluating tag 
SNPs to represent all available common PAH SNPs among Caucasians, as well as three 
‘rare variants’ previously suggested as risk factors for schizophrenia.  We detected 
several associations of modest effect size in individual samples, with one replicated 
association in multiple cohorts.  The magnitude of the effects detected here were similar 
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to those reported with other genes in complex disorders (odds ratios 1.10 – 1.50).  
Simulation studies, as well as analyses of the association between apoE variants and 
Alzheimer disease suggest that variable patterns of association can be observed in 
independent samples of varying size, particularly if the primary risk variant is not 
investigated (Bacanu et al., 2002) (C. E. Yu et al., 2007).  Thus, it is often difficult to 
replicate associations with genetically complex disorders consistently across samples, 
especially if the magnitude of the association is modest.  To reduce the probability of 
rejecting associations prematurely, we conducted analyses in four individual samples, 
followed by combined analyses.  Using this approach, a consistent association was 
detected at rs1522305.  The association was nominally significant in two of the three 
Caucasian samples and combining the results across all four samples revealed a 
significant association.  Similarly, exploratory analyses yielded replicable results related 
to gender between European samples at this locus.  Our analytic strategy combined test 
statistics from multiple independent samples (even those with modest power) in an effort 
to identify meaningful schizophrenia risk conferred by the same allele that may not reach 
nominal significance in individual samples.    
Prior studies have suggested that PAH mutations or exonic polymorphisms may 
be risk factors for schizophrenia among African-Americans (M. A. Richardson et al., 
2003).  We evaluated three such variants in all our samples. We detected one nominally 
significant association with L321L, a synonymous substitution among African-
Americans.  The associated allele is the common allele, consistent with the results of 
Richardson et al., however our results failed to support the findings of risk conferred by 
the rare allele of N426N.  These variants appeared to be monomorphic in the Caucasian 
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samples, although it is possible that rare alleles were present in individuals that failed the 
SNPlex assays for these SNPs.  More comprehensive analyses of other known PAH 
mutations and / or deep sequencing of the region are indicated.   
 It is not known if allelic variation at the associated SNPs alters PAH activity, so 
the functional impact of the associations is uncertain.  It is possible that the associated 
SNPs serve as surrogates for unidentified primary risk allele(s).  There is modest LD 
between rs1522305 and two other SNPs, namely rs12312872 and rs1042503 (Figure 11).  
Analysis of available HapMap data also suggested LD with more remote SNPs, e.g., an 
intergenic region 100.2 kb 3’ to rs1522305 (rs1722400, D’ = 0.75, r2 = 0.52).  If the 
associated SNPs have demonstrable effects on transcription, there are plausible 
mechanisms for the genetic associations.  Hyperphenylalaninemia (HPA) following PAH 
deficiency can enhance competition between phenylalanine and tyrosine for transport 
across the blood brain barrier (BBB) (Pardridge & Choi, 1986).  Reduced transport of 
tyrosine across the BBB may decrease catecholamine synthesis (Fernstrom & Fernstrom, 
2007).  The reduced synthesis may lead to altered dopamine function, a well known 
mechanism proposed for schizophrenia genesis (Carlsson, 1988) (Snyder, 1973) (Seeman 
et al., 1976).  HPA may also increase Phe catabolism through alternative pathways, such 
as increased synthesis of phenylethylamine (PEA), a putative psychotogenic compound 
(Jeste et al., 1981).  This hypothesis has been investigated extensively previously, albeit 
with conflicting results (O'Reilly & Davis, 1994).   
Several other lines of investigations may prove helpful in order to further explore 
the present results.  Since current DSM IV criteria preclude a diagnosis of schizophrenia 
in the presence of MR, it would be of interest to estimate the prevalence of psychoses 
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among PKU patients who have undergone rigid dietary control.  Unfortunately, most 
published follow-up studies have involved children prior to the modal age at onset for 
schizophrenia (Weglage et al., 2000) (Corcoran et al., 2005).  Interestingly, several 
investigators have  reported that frontal lobe dependent cognitive functions are impaired 
into young adulthood even among PKU patients who were treated early and aggressively 
(Welsh, Pennington, Ozonoff, Rouse, & McCabe, 1990) (Diamond, Ciaramitaro, Donner, 
Djali, & Robinson, 1994) (Corcoran et al., 2005).  Similar cognitive impairment has been 
noted among patients with schizophrenia and their relatives (Gur et al., 2007) 
(Greenwood et al., 2007).  Evaluation of cognitive function among patients with the 
putative risk alleles may prove insightful in this regard. To follow up Penrose’s early 
analyses, re-examination of psychiatric disorders among obligate carriers of PAH 
mutations (e.g., parents of individuals with PKU) may also be informative (Penrose, 
1935).  
 The clinical features of PKU are manifested only when individuals with PAH 
mutations consume a diet that includes Phe.  The present study did not evaluate such 
dietary risk factors.  Confirmation of a link between schizophrenia and PAH mutations or 
polymorphisms opens the possibility of use of one of a growing number of therapeutic 
options for treating PKU (including supplementation with biopterin derivatives and large 
neutral amino acids) to examine their effect on the development of psychiatric disease. A 
prior linkage study suggested a role for maternal PAH variation in pathogenesis (Devlin 
et al., 2007).  We did not find differences in allele frequencies between mothers of 
Caucasian probands and controls or fathers of the probands at the associated SNPs.  This 
hypothesis needs to be explored further.  The mechanism for the gender related 
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associations noted here is unclear.  It is possible that gender serves as a proxy for other 
variables.   
Improvement on the current analyses could be made in future studies by 
considering a denser set of polymorphisms in African-American samples.  The tag SNPs 
analyzed in the present study represented common variations in Caucasian samples only.  
Analysis of the Nigerian sample from HapMap suggests that up to 43 SNPs may have 
been required to comprehensively represent all available SNPs in African-Americans 
sample (HapMap, 2003).  Moreover, the power of our African-American samples was 
relatively low, owing to both a smaller number of samples and incomplete family 
configurations.  Therefore, further analyses of African-American samples are required.  
Despite the decreased power in the African-American and US family samples, our 
combined analyses considered the p-values from each independent sample equally and 
could be conservative.  It is noteworthy that analyses of the joint distribution of test 
statistics across groups weighted by sample size also suggested a significant deviation 
from the null hypothesis at rs1522305 (data not shown).   
Our analyses of four independent samples of Caucasian and African-American 
ancestry identified replicable associations between schizophrenia and an intronic PAH 
polymorphism.  The functional role for the associated polymorphisms is unknown.  It 
remains possible that risk is conferred primarily by as yet unidentified polymorphism(s).  
Further analyses of rare exonic variations, population specific tag SNPs for African-
Americans, and additional ethnic groups are warranted, preferably in conjunction with 
environmental risk factors. 
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6.1 ABSTRACT 
Objective:  To determine if dopaminergic gene variations are shared etiological risk 
factors for schizophrenia (SZ), schizoaffective disorder (SZA) and bipolar disorder 
(BP1).  Prior reports suggest dopaminergic dysfunction in SZ/SZA and BP1, as well as a 
shared genetic etiology between disorders.     
 
Method:  We genotyped 431 ‘tag’ SNPs representing all publicly available common 
SNPs from 40 dopamine genes simultaneously among 526 BP1 cases, 531 SZ/SZA cases, 
and 477 screened adult controls.  Analyses to test for population substructure were 
conducted and corrections for multiple testing applied.  
 
Results:  We found that 60% of all nominally significant SZ/SZA associations and 41% 
of all BP1 associations were shared (p < 0.05).  These shared risk loci were from four 
genes: DRD3, DDC, MAOB, and DRD1IP.  The most pronounced results were at DRD3; 
9 of the top 20 ranked SZ/SZA SNPs and 7 of the 20 most significant BP1 associations 
were DRD3 variants.  Gene-based analyses confirmed the DRD3 results (empirical p-
values: SZ/SZA p = 0.007, BP1 p = 0.013).  Diagnosis specific associations were 
detected with 6 other DA genes in SZ/SZA and 8 other genes in BP1.  Several individual 
SNP tests remained significant after gene-wide correction.  No test statistics were robust 
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to experiment-wide Bonferroni correction at the level of individual SNPs or epistatic 
interactions.     
 
Conclusion:  Our results suggest shared dopamine risk factors for BP1 and SZ/SZA, as 
well as disorder related associations.  Adequately powered replicate analyses are required 
to further evaluate these results, as well as possible epistatic interactions. 
6.2 INTRODUCTION 
Since their conception, there has been vigorous debate about the etiological 
relationship between bipolar I disorder (BP1) and schizophrenia (SZ) (see (Crow, 2008a) 
for review).  The arguments for and against a continuum have focused on 
psychopathology and familial aggregation, but the issue is unresolved (Brockington & 
Leff, 1979; Crow, 1990, 2008a; Gershon et al., 1988; Kendell & Brockington, 1980; 
Kendler et al., 1993; Tsuang, Winokur, & Crowe, 1980; Valles et al., 2000).  Recently, 
genetic association studies have been brought to bear on this question (Craddock et al., 
2005, 2006; Craddock & Owen, 2007; Owen et al., 2007).  The proposition that BP1 and 
SZ lie on a phenotypic and etiological continuum, (with schizoaffective disorder, SZA at 
an intermediate position) would be strengthened if variations or identical risk alleles in 
the same genes conferred risk to all three disorders.  Such overlap has been suggested for 
several genes, including dysbindin (DTNBP1), brain derived neurotrophic factor (BDNF), 
catechole-o-methyltransferase (COMT), disrupted in schizophrenia 1 (DISC1), the 
dopamine transporter (SLC6A3), and neuregulin-1 (NRG1), to name a few (Goghari & 
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Sponheim, 2008; Owen et al., 2007; Perlis et al., 2008) (Serretti & Mandelli, 2008).  The 
evidence in support of the shared etiological hypothesis comes from different studies that 
evaluated overlapping sets of polymorphisms in either BP1 or SZ samples compared to 
different control groups.  The hypothesis could be more comprehensively tested if the 
same genetic variants were evaluated systematically and simultaneously among BP1, SZ, 
and SZA cases compared against the same set of control individuals.   
Dysfunction in brain dopaminergic (DA) neurotransmission may have a 
pathogenic role for SZ as well as BP1 (Carlsson, 1988) (Seeman, 1995) (Crow, 1980b) 
(Crow, 1987) (Goldberg et al., 1999) (Berk et al., 2007).  The ‘dopamine hypothesis’ of 
SZ / SZA suggests that ‘positive symptoms’ such as delusions and hallucinations result 
from DA dysfunction in the mesolimbic and striatal regions, while negative symptoms 
are a consequence of DA deficits in the prefrontal regions of the brain (Lang et al., 2007).  
A DA model of BP1 pathogenesis has also been proposed (Berk et al., 2007).  The model 
predicts a cyclical dysregulation of DA transmission, with DA increases during manic 
phases followed by secondary down regulation and consequent decreased DA 
neurotransmission during depressive episodes (Berk et al., 2007).  These models could 
implicate a common pathogenic pathway for both disorders, and thus a possible common 
genetic etiology. 
Numerous DA polymorphisms have been investigated in SZ/SZA, and to a lesser 
extent in BP1, with inconsistent results.  Our recent review of DA gene association 
studies in SZ suggested relatively low power and sparse coverage of common variants in 
most publications (Talkowski et al., 2007).  Since different DA gene variants have 
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typically been evaluated in each study, it has often been difficult to conduct meaningful 
meta-analyses (Allen et al., 2008).   
We recently proposed a model of SZ/SZA susceptibility centered on four 
interacting DA genes, namely SLC6A3 (DAT), DRD3, SLC18A2 (VMAT2), and COMT 
(Talkowski et al., 2008).  The findings were derived from an initial screen of eighteen 
DA genes and the results were replicable in two large Caucasian samples.  To address the 
BP1-SZ continuum hypothesis, it would be necessary to evaluate the same genes for BP1.  
Our initial screen of DA genes did not adequately represent common polymorphisms that 
are currently available in public databases (e.g., HapMap), nor did it investigate the entire 
list of DA genes.  Hence we have extended our analysis from the initial set of 18 DA 
genes to 22 other DA interacting proteins.  To comprehensively consider common 
variants, we selected representative tag SNPs from all publicly available SNPs within 
these 40 genes.  We simultaneously compared BP1 and SZ/SZA samples to an adult 
control sample that was screened for absence of these disorders.   We sought plausible 
individual and overlapping risk loci for each disorder, with appropriate corrections for 
multiple comparisons applied.  
6.3 METHODS 
6.3.1 Samples 
BP1 cases:  We obtained genomic DNA from 526 patients with BP1 recruited through the 
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), a 
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longitudinal study aimed at improving the treatment for BP1, (Sachs et al., 2003) (Sklar 
et al., 2008).  STEP-BD used a network of eighteen U.S. treatment centers for 
standardized evaluation and treatment of patients including interview schedules based on 
the Structured Clinical Interview for DSM-IV (SCID), as well as the Mini-International 
Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) (Spitzer, Williams, & Gibbon, 
1996).   
 
SZ/SZA cases:  Unrelated patients were recruited at Western Psychiatric Institute and 
Clinic, Pittsburgh, PA and surrounding regions (n = 527).  Diagnoses were based on the 
Diagnostic Interview for Genetic Studies (DIGS)(Nurnberger et al., 1994), supplemented 
by medical records and informant interviews.  All participants met consensus DSM-IV 
diagnosis of SZ or SZA by board-certified psychiatrists / psychologists.  Of these, 213 
(40.4%) met diagnostic criteria for SZA.  Most of these SZ/SZA patients (n = 460) were 
genotyped in our previous analyses of DA SNPs (Talkowski et al., 2008).     
  
Screened adult controls:  An adult control sample, screened for absence of BP1, SZ or 
SZA was selected (n = 477).  As the STEP-BD BP1 sample was recruited across the 
USA, we utilized control individuals from the Pittsburgh region, as well as a national 
sample obtained from the publicly available samples deposited with the National Institute 
of Mental Health Genetics Research Initiative repository (NIMH-GRI). 
Pittsburgh controls (n = 168)  Members of the community were recruited through 
random digit dialing by the Pittsburgh University Center for Social and Urban Research 
(UCSUR), or through web-based advertisements.  All participants were self-identified as 
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Caucasian and screened using DSM IV criteria through the DIGS and other screening 
tools for absence of BP1, SZ, SZA, substance abuse disorder within the past month, 
serious medical or neurological illnesses, and mental retardation as defined in the DSM 
IV.  Individuals who reported a first-degree relative with psychoses or BP1 were also 
excluded.  All participants provided written informed consent, according to the guidelines 
of the University of Pittsburgh Institutional Review Board (IRB). 
NIMH-GRI controls (n = 309) Adult controls were obtained from the ongoing genetic 
analysis and information network (GAIN) initiative project “Linking Genome Wide 
Association Study of Schizophrenia” (Suarez et al., 2006) (Manolio et al., 2007).  Control 
individuals were screened for ancestry and asked a series of questions regarding medical 
history, including any previous treatment and/or diagnosis of schizophrenia and/or 
schizoaffective disorder, any previous treatment and/or diagnosis of bipolar disorder 
and/or manic depression, and any previous treatment and/or presence of auditory 
hallucinations and/or delusions (Sanders et al., 2008).  Complete details are available on 
the study website: (www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000021.v2.p1). 
6.3.2 Gene selection 
We previously identified 15 genes important in DA neurotransmission that had also been 
evaluated in SZ association studies, as well as 3 genes known to interact with the DA 
pathway (Talkowski et al., 2007) (Talkowski et al., 2008).   In addition to these genes, 22 
additional genes that interact with the DA pathway were selected (see Supplementary 
Table 6.1 for gene descriptions). 
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6.3.3 SNP selection 
We considered all available common HapMap phase II SNPs (rel 22) (HapMap, 2003) 
from each of the 40 genes, including 5 kilobases (kb) upstream and downstream of the 
coding sequence (minor allele frequency > 0.05).   Additional SNPs were obtained from 
the SeattleSNPs project where possible (www.pga.gs.washington.edu).  We analyzed 
linkage disequilibrium (LD) among CEPH individuals and selected tag SNPs at a 
minimum correlation threshold of r2 = 0.9 using a combination of Haploview software 
(Barrett, Fry, Maller, & Daly, 2005), Hclust software (Rinaldo et al., 2005), and the 
genome variation server (www.gvs.gs.washington.edu/GVS).  For SNPs did not pass the 
initial Illumina screen for assay design, we identified suitable surrogates, while 
maintaining the 0.9 correlation threshold.  If no such surrogates were available, the 
correlation threshold was lowered to 0.8.  If possible, we chose multiple surrogates for 
SNPs previously associated with SZ/SZA or BP1, allowing for a level of redundancy at 
key genes. 
6.3.4 Genotyping and quality control 
All polymorphisms were genotyped using the hybridization based Illumina GoldenGate 
Assay (www.Illumina.com) (Steemers & Gunderson, 2007).  We included blind 
duplicates, negative controls (distilled water) and positive controls (17 CEPH individuals 
genotyped by HapMap) in all assays.  Additional confirmation about genotype calls was 
obtained from 460 SZ/SZA cases previously genotyped for 64 SNPs (Talkowski et al., 
2008).  Deviations from Hardy-Weinberg Equilibrium (HWE) were evaluated for each 
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SNP using a global significance threshold of p > 0.005, well above what would be 
expected by chance from analysis of all SNPs.   
6.3.5 Statistical analyses 
We tested for individual SNP associations, then obtained a summary statistic for all SNPs 
within a gene, and finally conducted exploratory analyses for epistatic interactions and 
potentially important covariates such as diagnosis, gender, and age at onset of illness.     
We estimated the effective number of independent tests among SNPs within each 
gene using the statistical package R, based on published methods (Conneely & Boehnke, 
2007).  Differences in genotype distributions for individual SNPs among cases and 
controls were evaluated using the Armitage trends test.  Gene based tests were used to 
evaluate all SNPs within each gene simultaneously.  The optimal procedure for 
evaluating multiple single locus tests of association within a gene can vary depending on 
the number of SNPs genotyped and the correlation structure within the gene (Roeder et 
al., 2005).   Our genes differed widely by the number of SNPs genotyped (n = 1 - 47) and 
the correlation structure between SNPs was high.  For these analyses we conducted the 
Hotelling’s T2 multilocus association test (R. Fan & Knapp, 2003).  Both the asymptotic 
p-value and empirical permutation p-values are reported.  Analyses were carried out 
using PLINK, version 0.99r (http://pngu.mgh.harvard.edu/purcell/plink) (Purcell et al., 
2007).  Analysis of epistasis was conducted for all possible gene-gene SNP pairs in each 
disorder using logistic regression, as previously described (Talkowski et al., 2008).  
Exploratory analyses were conducted for each SNP to test for meaningful phenotypic 
covariates of diagnosis (SZ or SZA), gender, and age at onset of illness.   
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Corrections for multiple tests:  Our analyses included some genes with a strong a priori 
hypothesis (e.g. DRD3, DRD2, COMT, and SLC6A3, among others) and other 
exploratory genes such as the dopamine interacting proteins, many of which have never 
been tested in association studies.  We therefore performed corrections for multiple 
comparisons in our SNP based analyses at two levels: 1) at the gene level, applying 
correction for the effective number of independent tests within each gene and 2) at an 
experiment wide level, correcting for all effective independent tests conducted in both 
disorders (164.5 independent tests per disorder, 329 total tests; uncorrected threshold p < 
0.0003 per disorder, p < 1.5 x 10-4 for all tests).  For gene-based analyses, empirical p-
values for each gene were determined by permutation, and Bonferroni correction for 40 
independent gene-based tests was applied.    Interaction results were also corrected for all 
effective independent interactions tested (26,024 tests per disorder, 52,048 total; 
uncorrected threshold p < 9.6 x 10-7).  All exploratory analyses were corrected for the 
total number of effective tests conducted (164.5 tests x 3 variables x 2 disorders = 987 
tests).   
     
Genomic control:  We tested for population substructure by comparing SZ/SZA cases to 
controls as well as BP1 cases to controls using a variation of the genomic control (GC) 
method (Devlin & Roeder, 1999) (Bacanu et al., 2000) (Devlin, Bacanu, & Roeder, 
2004).  Briefly, these samples were previously genotyped for the current report and 
another study investigating variations from the circadian pathway (Mansour et al., in 
preparation).  In sum 768 SNPs were genotyped from 64 different genes, i.e. 64 
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generally independent genomic regions.  Next, we performed 10,000 iterations of 
randomly choosing a single SNP from each of the 64 genes to compare between cases 
and controls, obtaining a distribution of median chi-square tests.  The mean value of this 
distribution was calculated and was divided by the expected median of a chi-square 
distribution with 1 degree of freedom (0.456).  Since control samples were obtained from 
two different geographic regions, we conducted identical analyses between the two 
control groups to assess within-group substructure.     
 
Power analysis 
We evaluated the power of our sample to detect an odds ratio of 1.5 under a 
dominant model, or the maximum expected effect size based on previous studies of DA 
gene variations using similar sample sizes (Talkowski et al., 2007).  We tested the 
assumptions that the risk allele was actually analyzed in our sample or that a surrogate 
was genotyped at r2 of 0.9 with the risk loci (similar to our primary analyses).  We 
assessed power using risk allele frequencies of 0.15, 0.4, and 0.9 in the population, and 
varied the type I error threshold between 0.05 and 0.00015 (i.e., nominal significance and 
our corrected significance for all tests).   
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6.4 RESULTS 
6.4.1 Quality control 
Of 431 SNPs genotyped, 422 were retained for association analysis (9 SNPs failed QC 
criteria or were rare, i.e. minor allele frequency less than 0.01).  The mean genotype call 
rate was 99.96% across samples.  The discrepancy rate in all positive controls (duplicated 
samples, overlapping samples from previous studies, and CEPH individuals compared 
with HapMap) was less than  0.01%, a rate comparable to HapMap (HapMap, 2003).     
6.4.2 Association tests 
Thirty-seven of the 422 SNPs tested reached nominal significance for BP1 (8.8%, 
uncorrected p < 0.05).  Tweny-five SNPs were associated with SZ/SZA (6.2%).  Of these 
25 nominally significant SZ/SZA associations, 15 SNPs (60%) were also associated with 
BP1.  These shared associations occurred at DRD3 (8 SNPs), DDC (5 SNPs), DRD1IP (1 
SNP), and MAOB (1 SNP).  These shared loci accounted for 44.7% of all nominally 
significant associations observed with BP1.   
The top ranked association signal was the same DRD3 SNP / allele in both 
disorders, rs9868039 (uncorrected p = 0.0017 and 0.0032 in BP1 and SZ/SZA, 
respectively).  Nominally significant associations with BP1 were detected following 
gene-wide correction for the following genes (number of nominally significant 
associations in parentheses): DDC (11 SNPs), DRD3 (8 SNPs), DRD1IP (2 SNPs), 
SLC18A1 (2 SNPs), DRD4 (1 SNP), and PPP1R9B (1 SNP).  Associations with SZ/SZA 
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remained significant following gene-wide correction at DRD3 (10 SNPs), DRD1IP (1 
SNP), and SP4 (1 SNP).  Nominally significant associations with SZ/SZA were also 
detected at DDC (6 SNPs) and DRD2 (2 SNPs).  These SNPs were not significant after 
gene-wide correction (40 and 22 SNPs were tested in DDC and DRD2, respectively), 
however both DRD2 associations were direct replications of risk alleles detected by 
Sanders et al. (rs17529477: p = 0.039, rs7131056: p = 0.048; Sanders et al. p = 0.018 and 
0.012, respectively) (Sanders et al., 2008).  No SNPs exceeded our experiment-wide 
significance threshold of p < 1.5 x 10-4.  Gene based tests supported the SNP associations, 
DRD3 was significantly associated with both SZ/SZA (p = 0.007) and BP1 (p = 0.013) 
following permutation when all SNPs were considered.  No other gene based tests were 
significant, nor did the DRD3 results survive Bonferroni correction.  
Our previous analyses suggested associations between SZ/SZA and DRD3, 
SLC6A3 (DAT), SLC18A2 (VMAT2), and COMT.  In the present analysis, individual 
SNPs at DRD3, SLC6A3 and SLC18A2 were nominally significant with SZ/SZA, but not 
COMT.  Only the DRD3 associations remained significant after correction.      
6.4.3 Exploratory analyses 
We tested all possible gene-gene SNP pairs in each disorder separately (i.e., only 
pairs across genes were tested, but not pairs of SNPs within genes).  In sum, 175,818 
interaction tests were conducted for each disorder (351,636 total tests), the equivalent of 
26,024.3 effective tests for each disorder (52,048 total).  No pair-wise interactions were 
significant at this threshold (p < 9.61 x 10-7).  The top ranked shared interactions (p < 
0.001 in each disorder) and disorder specific results (p < 0.001) are found in 
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Supplementary Tables 6.4. and 6.5.  Despite a number of nominally significant results, 
particularly between DRD3 variants, gender, and psychotic symptoms, none of our 
analyses of phenotypic variables exceeded chance expectations (Supplementary Table 
6.6). 
 
 
 
Table 12 Nominally significant gene-based associations 
      SNP Associations Hotelling's T2 
Significant 
Association Gene 
Tag 
SNPs 
Effective 
tests 
# SNPs 
p<0.05 
(SZ) 
Best SZ 
p-value
# SNPs 
p<0.05 
(BP1) 
Best BP1 
p-value 
 
Empiricalp-
value (SZ)
Empiricalp-
value (BP1)
SZ / SZA 
and BP1 
DRD3 20 6.7 10 0.003* 8 0.002* 0.007 0.013 
DDC 40 11.9 6 0.029 11 0.002* 0.391 0.708 
MAOB 8 3.3 2 0.019 2 0.042 0.268 0.296 
DRD1IP 4 1.9 1 0.012* 2 0.008* 0.090 0.063 
SZ / SZA 
Only 
DRD2 22 8.3 3 0.037 0 0.261 0.433 0.813 
SLC6A3 47 16.9 1 0.045 0 0.118 0.479 0.818 
NEF3 8 3.5 1 0.044 0 0.075 0.342 0.286 
Sp4 3 1.1 1 0.016* 0 0.687 0.105 0.963 
SLC18A2 18 7.7 2 0.041 0 0.095 0.420 0.393 
GRB2 8 3.4 1 0.037 0 0.208 0.373 0.715 
BP1 Only 
FREQ 21 8.1 0 0.056 5 0.011 0.776 0.376 
SLC18A1 22 8.7 0 0.233 2 0.005* 0.761 0.113 
SNAP25 34 13.3 0 0.064 2 0.012 0.334 0.375 
COMT 31 10.6 0 0.217 1 0.050 0.804 0.518 
SNCA 12 4.9 0 0.128 1 0.038 0.753 0.614 
DBH 29 11.2 0 0.124 1 0.045 0.617 0.878 
PPP1R9B 5 1.9 0 0.068 1 0.019* 0.396 0.095 
EPB41 15 4.9 0 0.138 1 0.022 0.818 0.109 
Chr = chromosome.  Effective tests = effective number of independent tests.  *Significant 
after Bonferroni correction for 40 gene-based tests.  *Significant after gene-wide 
correction.  No SNPs were significant at a level of experiment-wide correction.    
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6.4.4 Testing for possible confounds  
A series of tests were conducted to see if the overlapping associations described above 
arose from biased control selection or comparison groups.  Based on our genomic control 
analysis, no meaningful inflation in the test statistics was observed between SZ/SZA 
cases and controls (λ = 1.08), nor were differences found between BP1 cases and controls 
(λ = 0.85).  We also compared our SZ cases to our SZA cases to determine if meaningful 
differences existed, which they did not (λ = 0.938).  Since our controls were obtained 
from two different sources, we performed similar genomic control analyses (10,000 
iterations comparing SNPs from 64 different genomic regions, see Methods) between 
controls from Pittsburgh and the NHGRI controls.  Nearly identical results to the case / 
control comparisons were found between the two sets of controls (λ = 1.08).    
Nominally significant associations with both diagnostic groups were detected at 
15 SNPs (p < 0.05, see Table 13).  Two non-significant trends were also observed.  To 
determine if these results were an artifact of the control group, we compared these 17 
SNPs between the two control groups.  No significant differences were detected (p > 0.1 
in all analyses; data not shown).  To further interrogate our control sample, we obtained 
allele frequencies for these SNPs from other sources, where available, including: 1) our 
previously reported association study with SZ/SA using population based neonatal 
control samples (Talkowski et al., 2008), 2) HapMap (ref), and 3) available Caucasian 
populations in dbSNP (build 129).  Allele frequencies are available in Supplementary 
Table 6.7.   In general, we found that our case frequencies comported well with the 
independent control frequencies.  Qualitative differences were obvious between our 
control sample and the independent control samples for some, but not all SNPs.
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Figure 12 Individual SNP association results across 40 dopaminergic genes 
Trends test p-values for individual SNPs across the 40 genes.  The y-axis is -2 x the natural log of the p-value (-2*LN(p)), and the x-
axis contains all genes.  SNP results are provided in genomic order.  **Figure to be updated in color or with different symbols, 
depending on journal specificity.  Dotted line p = 0.05.   
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Table 13 Nominally significant associations between individual SNPs and both diagnostic groups 
Genomic Data SNP Association Results Allele Frequencies 
Gene SNP Position 
SZ/SZAp-
value 
SZ 
OR 
BP1    
p-
value
BP1 
OR N 
SZ 
Case 
BD 
Case Control
DDC rs4947535 50499175 0.036 0.82 0.033 0.82 A 0.296 0.295 0.340 
DDC rs745043 50511449 0.029 0.78 0.004 0.73 A 0.206 0.195 0.248 
DDC rs4470989 50530192 0.029 0.81 0.028 0.81 A 0.297 0.297 0.343 
DDC rs3807558 50538516 0.043 0.80 0.008 0.75 A 0.207 0.198 0.246 
DDC rs3779078 50578412 0.042 0.80 0.004 0.74 A 0.205 0.193 0.244 
DRD1IP rs11101694 134996704 0.012 0.73 0.008 0.72 G 0.129 0.127 0.169 
DRD3 rs2046496 115317621 0.031 1.21 0.017 1.24 G 0.494 0.502 0.448 
DRD3 rs12636133 115322414 0.023 0.81 0.009 0.79 C 0.424 0.416 0.475 
DRD3 rs10934254 115324324 0.035 0.83 0.009 0.79 G 0.428 0.417 0.475 
DRD3 rs9868039 115329232 0.003 1.30 0.002 1.34 A 0.451 0.458 0.387 
DRD3 rs9817063 115329798 0.011 0.79 0.003 0.77 G 0.456 0.447 0.514 
DRD3 rs3732790 115329973 0.033 0.82 0.012 0.79 A 0.383 0.374 0.431 
DRD3 rs2134655 115340891 0.007 1.31 0.005 1.33 A 0.277 0.280 0.226 
DRD3 rs963468 115345577 0.030 0.82 0.008 0.78 A 0.381 0.370 0.429 
DRD3 rs7625282 115364217 0.057 0.83 0.073 0.84 G 0.248 0.250 0.284 
MAOB rs2283729 43562986 0.026 1.26 0.042 1.34 A 0.274 0.286 0.231 
MAOB rs6651806 43573908 0.058 1.23 0.052 1.36 C 0.284 0.304 0.243 
All SNP based associations that were nominally significant in both SZ/SZA and BP1 are 
provided.  P-values are uncorrected results from Armitage trends test.  OR = odds ratio of 
rare allele.  N = nucleotide of rare allele assayed in this study.  Allele frequencies for 
SZ/SZA cases, BP1 cases, and controls provided. 
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6.4.5 Power analysis  
Under a dominant model, the sample had 80.9% power to detect a nominally significant 
association (OR 1.5) for a risk allele with 15% MAF in the population, using a type I 
error threshold of 5%.  For a risk allele with MAF 40%, power declined to 70.3% under 
the same assumptions.  The sample had approximately 12% power to detect a 
significance level of p < 0.00012, the threshold required to exceed correction for all SNP 
based analyses. 
6.5 DISCUSSION 
We systematically evaluated associations between representative, common 
dopaminergic (DA) gene variants and bipolar disorder (BP1), schizophrenia (SZ) and 
schizoaffective disorder (SZA).  The catalogue of DA genes is dynamic and likely to 
grow.  We included a core group of genes that unambiguously impact DA function, as 
well as additional DA interacting proteins.  Thus, our analyses provided more intensive 
interrogation of common DA pathway genes and SNPs than previous efforts.  We 
adopted a relatively conservative gene based approach in the present controversy over the 
type of correction needed for multiple comparisons (WTCCC, 2007).   
Our analyses detected multiple associations between dopamine D3 receptor gene 
(DRD3) variants and BP1 as well as SZ/SZA.  Both individual SNP and gene based tests 
were associated with both disorders.  Although no single SNP association exceeded 
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correction for multiple comparisons, 7 of the 20 most significant BP1 associations and 9 
of the top 20 SZ/SZA associations were DRD3 variants.  Among the 20 DRD3 SNPs 
evaluated, 8 SNPs were associated with BP1 and 10 SNPs were associated with SZ/SZA.   
The same allele at rs9868039 of DRD3 was the most significant SNP in both 
diagnostic groups across all 422 SNP tests.  This SNP was part of a cluster of 8 nominally 
significant SNPs in both SZ/SZA and BP1 spanning intron 4 to the 3’ region of the gene.  
Linkage disequilibrium between all 8 SNPs was modest (minimum r2 > 0.2, D’ > 0.65 
between all SNP pairs).  Like several previous DRD3 associations, rs9868039 has 
unidentified biological function but is localized in the 3’ region of the gene 
approximately 1 kb from the transcription stop site in exon 7 (previously named exon 
6)(www.ncbi.nlm.nih.gov).  Two SNPs significantly associated with both SZ/SZA and 
BP1 from this cluster in the current analyses are consistent with our previous findings, 
however rs9868039 is not among them (rs10934254, rs2134655) (Talkowski, Mansour et 
al., 2006) (Talkowski et al., 2008).  Haplotypes spanning this region were also 
significantly associated with SZ in an independent study (Dominguez et al., 2007).  No 
SNPs spanning this region were associated with BP1 in two large GWAS studies; 
however none of our associated SNPs were included in those studies (WTCCC, 2007) 
(Sklar et al., 2008).  Two SNPs within intron 2 (and one additional trend) independent of 
this 8 SNP cluster were nominally significant in SZ/SZA (rs10934256, rs7633291, 
rs7625282), but not BP1, consistent with our previous findings (Figure 13) (Talkowski, 
Mansour et al., 2006) (Talkowski et al., 2008).  The second ranked gene in our analyses 
was dopamine decarboxylase (DDC), in which 6 SNPs were associated with SZ/SZA and 
 152
11 SNPs were associated with BP1.  These results merit replication, as previous studies 
have not investigated DDC extensively (see (Talkowski et al., 2007) for review).   
In addition to the shared risk factors, there were diagnostic specific associations 
detected with some genes, consistent with the possibility that the different 
psychopathology in these disorders is modulated by some DA genes.  Supporting a 
number of prior reports, we found nominally significant associations between two DRD2 
SNPs and SZ/SZA, but not BP1 (Glatt et al., 2008; Monakhov, Golimbet, Abramova, 
Kaleda, & Karpov, 2008) (Dubertret et al., 2004).  Both associations replicated risk 
alleles detected by Sanders and colleagues (Sanders et al., 2008).  We also detected a 
trend for association with a SNP that was a surrogate for another associated SNP 
(rs4245147) in that study (rs4274224, uncorrected p = 0.09; see supplementary Table 
6.2).  None of these SNPs met significance thresholds in our study or Sanders et al. after 
corrections for multiple testing were applied.  These results highlight the inherent 
difficulty with interpreting nominally significant results in large scale studies, where 
sample sizes are rarely sufficient to detect replicable associations of small effect.  We did 
not find an association with two surrogates for rs6277 (C957T) (Hanninen et al., 2006; 
Hoenicka et al., 2006; Lawford et al., 2005; H. Xu et al., 2007).  Glatt et al. also reported 
associations with SNPs and haplotypes spanning most regions of DRD2 in an Asian 
population.  While a non-significant trend in that study was consistent with our observed 
association (rs7131056), the most significant SNPs did not overlap with our results, 
lending credence to the argument that the primary DRD2 risk alleles remain unidentified 
(Glatt et al., 2008).  In BP1, we detected association with five FREQ SNPs.  A number of 
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other strong BP1 candidate such as MAOB and SLC18A1 (VMAT1) were nominally 
significant in BP1 but not SZ/SZA (see Table 12).   
 
 
 
Figure 13 Linkage disequilibrium (r2) between DRD3 SNPs and association statistics 
 
Linkage disequilibrium (r2), SNP locations, and tests of association in both diagnostic groups for 
all DRD3 SNPs provided.  IN = intron, EX = exon.  Genomic locations based on dbSNP build 129, 
which includes an exon 5’ to previously described exon 1.  P-values based on Armitage trends 
test.  All p-values are uncorrected for multiple comparisons. 
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Our results support the null hypothesis for several traditional susceptibility 
candidates.  At COMT previous studies suggested associations with SZ and multiple 
SNPs / haplotypes spanning the gene, including our own (H. J. Williams et al., 2007) 
(Talkowski et al., 2008).  In the current study, we tested 31 variations and found no 
probabilities lower than p = 0.217.  At DBH, we evaluated 29 SNPs with p > 0.12 for all 
tests (refs).  MAOA was similarly negative in SZ, as well as BP1.  As discussed, the 
power of our study was relatively low to detect small effects, but our study provides 
compelling evidence against individual SNPs of major effect within these genes. 
We previously reported on associations between SZ/SZA at four DA genes (DRD3, 
SLC6A3, SLC18A2, COMT).  Nominally significant associations with individual SNPs 
were detected with three these genes (not COMT), an expected result given the overlap 
between SZ/SZA samples in the present and prior studies (Talkowski et al., 2008).  Most 
of the associated SNPs differed between studies, althought non-significant trends were 
noted for some alleles (e.g. rs3756450).  Still, only the DRD3 findings provided 
significant overlap with prior studies, and no results were significant after corrections for 
multiple testing.  Such variation might be expected in view of the different control groups 
utilized, the possibility of over-inflation of the effect size in the initial study, or stochastic 
variation if the primary risk alleles are not analyzed.   
There are limitations to this study.  The associations identified here may not represent 
primary risk alleles, so analysis of additional common and / or rare variants may be 
needed.  Independent samples, preferably large Caucasian cohorts, are critical to 
strengthen support for a shared etiology between BP1 and SZ/SZA.  Additional studies to 
investigate the biological function of the associated SNPs are also required.  Owing to 
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limitations imposed by power in the available samples, rare variants or structural 
variations within DA genes were not investigated.  Such efforts are worthy, in view of 
recent suggestions regarding the role of rare variations in SZ genesis (Walsh et al., 2008; 
B. Xu et al., 2008).   
The present sample was adequately powered to detect associations with odds 
ratios of 1.5 or greater when individual genes were considered independently, but power 
to detect associations when all loci were considered was inadequate.  In addition, our 
analytic strategy was conservative and could limit interpretation of these results.  
Previously investigated DA genes were equally weighted with novel DA interacting 
genes, raising the possibility of type II errors.  For example, DRD2 had strong a priori 
evidence as an SZ/SZA susceptibility candidate, and both our study and Sanders et al. 
(Sanders et al., 2008) identified associations at DRD2, however neither set of associations 
were significant when corrected for all other genes considered.   Similarly, the epistatic 
interactions entailed a considerable number of tests, so our power was limited to detect 
only very large effect sizes after correcting for multiple tests.  None of the interactions 
results were significant after such corrections.   
We previously suggested interactions between four DA genes and SZ/SZA 
(SLC6A3*COMT, SLC6A3*DRD3, SLC6A3*SLC18A2, and DRD3*SLC18A2) 
(Talkowski et al., 2008).  When we evaluated those genes here, we found 198 nominally 
significant interactions for SZ/SZA vs control comparisons, which were present in each 
of gene of the pairs (198 / 1457 tests = 13.59%), consistent with our earlier report using a 
different set of controls.  When BP1 cases were compared with the controls, 188 of these 
SNP pairs were also significantly associated with risk (12.9%).  Despite considerable 
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effect sizes for some of these analyses (Supplementary Table 6.5), none of these results 
exceeded chance expectations when all interactions were considered.   
In conclusion, we conducted a comprehensive evaluation of the DA pathway for 
common variants conferring risk for BP1 and SZ/SZA.  Our analyses identified DRD3 as 
the strongest susceptibility gene for both groups.  We found additional support for other 
overlapping and disease specific risk loci in each disorder (approximately 60% of 
nominally significant SZ/SZA associations were also associated with BP1).  Our analyses 
suggest the overlapping risk loci could not be entirely attributed to population 
substructure or variation due to control selection.  Other associations were significant for 
BP1 or SZ/SZA, suggesting modulatory DA influences that could impact differences in 
psychopathology between these disorders.  Our findings could provide a genetic 
epidemiological basis for a shared etiology between SZ, SZA, and BP1,  
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7.0  SUMMARY AND CONCLUSIONS 
7.1 SUMMARY OF STUDIES 
This series of studies was aimed at evaluating a genetic basis for the commonly cited 
hypothesis that the dopaminergic neurotransmitter pathway is dysregulated in the 
pathogenesis of schizophrenia.  The initial review of the literature suggested a clear 
pattern in which strong claims and subsequent conclusions have been drawn regarding 
dopaminergic gene variations despite a paucity of information for most genes.  
Paralleling the technological advances in molecular genetics that has taken place over a 
remarkably short period of time, each of the studies presented incrementally grew in 
terms of molecular and analytic sophistication, culminating with analysis of a 
considerable portion of representative common variation in the dopaminergic network.   
 The initial study of DRD3 addressed a significant gap in the literature regarding 
this important autoreceptor in the dopaminergic pathway.  Prior to 2006, nearly all 
studies of DRD3 evaluated only a single coding variant, rs6280 (Ser9Gly) in exon 1 (now 
exon2) of the gene.  Our linkage disequilibrium analyses showed that this variant was 
independent of other regions in the gene, and the vast majority of sequence variation 
remained uncovered.  Our study considered SNPs over a 109 kb region and was the first 
to suggest associations between schizophrenia and SNPs / haplotypes 3’ to rs6280.  Our 
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study was also one of the few to seek evidence of replication as part of the initial 
investigation.  Despite the incremental advances of this study over previous efforts, the 
analyses shared many of the limitations of its predecessors.  Representative variations 
spanning the gene were not yet publicly available, power was limited, and a large number 
of tests were conducted without correcting for multiple comparisons.  Nonetheless, 
associations were subsequently replicated in an independent population (Dominguez et 
al., 2007), indicating more comprehensive analyses were warranted. 
Study #2 was motivated by similar logic to study #1.  The majority of genes 
central to the dopaminergic pathway had been previously studied, but usually in small 
samples with no more than one or two putatively functional variations.  This study 
employed a multi-stage design.  The first stage was conducted in a small trio sample just 
prior to availability of the International HapMap Project (HapMap, 2003), so the initial 
screen was limited to detecting test statistics falling on the extreme end of the 
distribution.  Still, an internal replication in the US cohort identified several consistent 
associations.  Follow-up analyses using a more comprehensive set of polymorphisms 
validated the initial screen, and consistencies with a replicate Bulgarian cohort were also 
encouraging.  To our knowledge, this was the first study to report replicated interactions 
between dopaminergic variations and schizophrenia.  Our simulations suggested these 
findings were unlikely under the null hypothesis.  Results at the dopamine transporter 
were particularly consistent, and functional analyses suggested a novel transcription 
factor binding sites and effects on promoter activity with an associated SNP 5’ to the 
transcription start site.  This combination of statistical and functional associations 
suggested the dopamine transporter was a promising target for future studies; however 
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detection of a primary risk allele for the disorder was not obvious as the associations 
spanned several independent genomic regions.    
Study #3 was an effort peripheral to the series of investigations on the 
neurobiological impact of dopaminergic genes on schizophrenia risk.  Phenylalanine 
hydroxylase catalyzes the hydroxylation of phenylalanine to tyrosine, a dopamine 
precursor, in the kidney, liver, and melanocytes (Lichter-Konecki, Hipke, & Konecki, 
1999; S. C. Richardson & Fisher, 1993; Schallreuter et al., 1995; Solstad, Stokka, 
Andersen, & Flatmark, 2003).  Mutations in PAH combined with phenylalanine in the 
diet can cause phenylketunuria (PKU), a severe neurological disorder.  Co-segregation of 
PKU with psychiatric illness has been reported (Fisch et al., 1979; Penrose, 1935), and a 
series of studies suggested association with several PKU causing variants and 
schizophrenia in small cohorts of Caucasian and African-American subjects (M. A. 
Richardson et al., 2003).  Our study extended these previous results to evaluate both the 
common and rare variant hypotheses of schizophrenia in four independent samples of 
Caucasian and African-American ancestry.  One common PAH SNP was associated with 
schizophrenia in two independent samples (rs1522305).  The association was with an 
intronic variant, and functional analyses are necessary in future studies.  
Study #4, was a natural endpoint to these surveys of common dopaminergic 
polymorphisms and their role in schizophrenia etiology.  This study addressed the 
limitations in coverage of studies #1 and #2, as well as the narrow view of the 
dopamienrgic network considered in study #2.  Motivated by an extensive literature 
suggesting shared etiological risk factors for schizophrenia, schizoaffective disorder, and 
bipolar disorder, this study simultaneously evaluated SNPs reporesentative of all publicly 
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available common variation within 40 genes and compared these disorders to a common 
set of screened adult controls.  The results provided strong evidence for DRD3 as a 
shared genetic risk locus for both schizophrenia and bipolar disorder.  Since case samples 
overlapped between studies #2 and 4, the results are not an independent replication.  
However the findings bolster the argument that DRD3 is a credible risk locus since each 
of the three studies in this series evaluating DRD3 detected significant associations 
despite comparisons with independent control subjects in each study.  The results 
pertaining to bipolar disorder are novel.  The overlap in associations included a cluster of 
8 SNPs spanning intron 4 to the 3’ region of the gene.  Replications of previous findings 
at other genes were noted.  None of the results were significant after corrections for 
multiple comparisons were applied.  Although additional associations were observed at 
our at our three other primary schizophrenia targets (SLC18A2, SLC6A3, and COMT), 
none of these results exceeded chance expectations, a result that should raise caution in 
interpretation of study #2 given the overlap in case samples between studies.   In 
summary, these findings support a shared etiological basis for schizophrenia and bipolar 
disorder at DRD3 and several other targets.  Although additional common variations are 
not required in future studies of Caucasians, replication of these findings in additional 
samples is essential.  The absence of replication precludes firm conclusions regarding the 
nominally significant associations and interactions detected.   
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7.2 LIMITATIONS 
Genetic association studies in psychiatric genetics have had considerable limitations, 
many of which hindered more conclusive interpretation of the studies conducted herein.  
Primary among these is the heterogeneous phenotype and individual risk variants of 
presumably very small effect.  Owing to the combination of these two factors, the two 
primary goals of these studies (comprehensive evaluation and statistically conservative 
interpretation) may be fundamentally unrealistic in sample sizes such as these.  This issue 
has been widely debated in the literature regarding genomewide association studies.  The 
primary limitation is power.  As detailed above, these sampled were reasonably powered 
to detect an odds ratio of 1.5 under ideal circumstances (including genotyping the actual 
risk allele).  This effect size is almost certainly inflated based on credible large scale 
studies, and considers only an individual test (i.e. an alpha of 0.05).  If one were to 
consider detection of a true association under the realistic circumstances of these studies 
(maximum OR of 1.31, r2 < 0.9 between risk allele and surrogate marker, 422 SNPs / 
disorder, 339 effective tests), over 8,000 cases would be required to detect statistical 
significance after correction.  The threshold for significance is more stringent in a GWAS 
study, a factor likely contributing to the lack of consistency between such psychiatric 
genetic studies to date.  Statistical weighting may be an optimal strategy, but the nebulous 
nature of determining what constitutes a significant association in the existing literature 
complicates such designs.    
Another limitation was the inability to draw conclusions regarding primary risk 
causing variants.  The functional analyses in study #2 were intriguing but not conclusive.  
The validity of an in vitro assay system to model in vivo effects in the brain is always a 
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concern.  The majority of the associations detected were with intronic variations of yet 
unknown function.  Finally, these results raise the question of statistical thresholds for 
interpreting replication between independent samples.  These studies relied on strategies 
such as joint analyses and summary statistics to identify multiple independent small 
effects in the same direction (i.e. the same risk allele).  This strategy is defensible given 
the power limitations discussed above, but could be interpreted as anti-conservative. 
7.3 ONGOING AND FUTURE STUDIES  
These studies represent a reasonable evaluation of the common variant hypothesis of 
genetic risk to schizophrenia (and bipolar disorder).  If the common variant hypothesis 
were to be evaluated further, comprehensive sequencing for novel SNP detection might 
provide the most benefit in identifying true liability loci.  Our ongoing study has taken 
this approach to exhaustively evaluate the dopamine transporter.  In conjunction with the 
SeattleSNPs project, we have conducted focused sequencing to cover roughly 90% of the 
genomic region spanning the gene, cataloguing all common and rare variations detected.  
To date, 375 variations have been catalogued, 164 of which are common.  We have 
genotyped 88 tag SNPs in both the US and Bulgarian samples.  We find that consistent 
associations persist between samples within introns 3 and 4 of the gene.  In collaboration 
with Dr. Javier Lopez at Carnegie Mellon University, novel splice variants are being 
investigated in this region to determine a plausible functional basis for the associations.   
Replicate studies on substantially powered samples are critically needed to 
validate the associations reported here.  These studies would be particularly useful in 
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interpretation of the most significant interactions detected in study #4.  Alternative 
strategies such as multifactor dimensionality reduction may be of benefit provided 
replicate samples are available.  Additional common variants would be required for 
individuals of African descent, but replicate studies in Caucasian and Asian populations 
would likely choose to focus on the subset of noteworthy SNPs already detected (e.g. the 
top 10% of SNP associations).  Additional studies of diagnostic sub-phenotypes would 
also be of interest given the results of exploratory analyses in study #4.  Parallel studies 
to identify causative rare and structural variations are also desirable.  Finally, functional 
analyses of patient specific cell lines, post-mortem brain tissue, and neuroimaging 
variables could all yield further lines of inquiry into the genetic epidemiological results 
reported here.    
7.4 CONCLUSION 
Taken together, thes analyses failed to conclusively support or reject the null hypothesis 
of no association between dopaminergic variation and schizophrenia.  No obvious 
individual risk loci arose.  The statistical results are compelling that an individual 
common variant of significant effect on schizophrenia risk (odds ratio greater than 1.5) is 
unlikely likely to be present within the dopmaniergic network studied here.  Instead, a 
series of small but consistent effects in several genes, as well as replicable epistatic 
interactions, suggest a plausible genetic basis for the dopamine hypothesis of 
schizophrenia could exist.  The results of these studies require further replication before 
an alternative hypothesis can be confidently accepted.  
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APPENDEX A: SUPPLEMENT TO CHAPTER 4 
Supplementary Table numbers include chapter and table (e.g. 4.1 = supplementary table 
1 from chapter 4). 
Table 14 Supplementary Table 4.1: All SNP association tests 
          
US samples                
(478 cases / 501 controls) 
Bulgaria           (659 
trios) Joint 
Gene BP SNP Group N
Case 
Freq 
Cord 
Freq 
p-
value Z1 Freq Z2 P2 Zjoint
DRD3 115313209 rs7631540 ALL C 0.517 0.520 0.884 -0.14 0.547 -0.80 0.422 -0.70
DRD3 115317621 rs2046496 ALL C 0.507 0.505 0.916 0.10 0.526 -1.04 0.300 -0.71
DRD3 115319654 MT_4* ALL A 0.949 0.954 0.572 -0.56 0.96 0.10 0.922 -0.29
DRD3 115322414 rs12636133 ALL G 0.571 0.564 0.747 0.32 0.549 0.16 0.872 -0.09
DRD3 115324324 rs10934254 ALL A 0.570 0.562 0.694 0.39 0.547 0.41 0.685 0.56
DRD3 115329232 rs9868039 ALL C 0.558 0.550 0.572 0.33 0.572 -0.38 0.707 -0.07
DRD3 115329798 rs9817063 ALL A 0.538 0.547 0.686 -0.41 0.524 0.20 0.839 -0.11
DRD3 115329973 rs3732790 ALL T 0.608 0.625 0.438 -0.77 0.599 0.58 0.564 -0.07
DRD3 115337545 rs13061336 ALL A 0.996 0.997 0.160 -1.41 0.997 1.27 0.206 0.03
DRD3 115340891 rs2134655 ALL G 0.727 0.762 0.066 -1.88 0.74 0.18 0.857 1.32
DRD3 115345577 rs963468 US G 0.612 0.628 0.462 -0.74     
DRD3 115352768 rs3773678 ALL C 0.845 0.848 0.690 -0.60 0.851 0.85 0.393 0.52
DRD3 115358965 rs167771 ALL T 0.818 0.801 0.348 0.94 0.801 -0.54 0.589 0.20
DRD3 115364131 rs324030 ALL C 0.724 0.675 0.016 2.40 0.688 0.75 0.455 2.14
DRD3 115364217 rs7625282 ALL T 0.760 0.710 0.039 2.51 0.744 0.64 0.524 2.13
DRD3 115367825 rs11706283 BGT C     0.883 -0.74 0.459  
DRD3 115368342 rs10934256 ALL G 0.820 0.775 0.014 2.46 0.8 0.68 0.494 -1.10
DRD3 115373505 rs6280 ALL A 0.680 0.627 0.012 2.48 0.667 0.04 0.966 0.08
DRD3 115374239 rs1800828 ALL G 0.775 0.729 0.015 2.39 0.776 -0.48 0.630 1.20
SLC6A3 1436550 rs27074 ALL G 0.908 0.905 0.829 0.21 0.912 0.28 0.782 0.07
SLC6A3 1444369 rs12516948 ALL T 0.619 0.673 0.015 -2.47 0.65 -1.27 0.205 -2.58
SLC6A3 1447522 rs27072 ALL G 0.834 0.808 0.133 1.50 0.82 0.78 0.436 -0.40
SLC6A3 1447815 rs1042098 BGT T     0.687 0.68 0.500  
SLC6A3 1448077 rs40184 ALL C 0.530 0.507 0.289 1.04 0.505 0.00 1.000 0.68
SLC6A3 1457548 rs6869645 ALL C 0.926 0.936 0.392 -0.87 0.922 0.40 0.686 0.88
SLC6A3 1464412 rs6347 ALL A 0.732 0.710 0.257 1.12 0.745 1.67 0.095 1.99
SLC6A3 1465645 rs27048 ALL G 0.582 0.582 0.991 -0.01 0.536 0.86 0.392 0.64
SLC6A3 1468629 rs37022 ALL A 0.833 0.801 0.073 1.81 0.842 0.93 0.354 1.89
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Table 14 Continued 
 
SLC6A3 1469646 rs2042449 US G 0.777 0.763 0.438 0.78     
SLC6A3 1476905 rs464049 ALL A 0.579 0.524 0.013 2.46 0.53 2.55 0.011 3.54
SLC6A3 1483515 rs456082 ALL A 0.806 0.766 0.027 2.16 0.771 1.70 0.090 2.70
SLC6A3 1484164 rs463379 ALL C 0.805 0.767 0.035 2.07 0.772 1.82 0.069 2.73
SLC6A3 1491354 rs403636 ALL G 0.815 0.848 0.045 -1.98 0.846 -1.45 0.146 -2.39
SLC6A3 1495521 rs2617605 ALL HWE Flag_removed   0.685 -0.45 0.655 -0.98
SLC6A3 1496199 rs6350 US G 0.937 0.932 0.636 0.47     
SLC6A3 1501148 rs3756450 ALL A 0.893 0.868 0.080 1.70 0.848 2.12 0.035 2.70
SLC6A3 1503506 rs2550947 ALL C 0.584 0.572 0.570 0.56 0.559 1.07 0.286 0.44
SLC6A3 1505280 rs2078247 ALL G 0.721 0.763 0.030 -2.16 0.769 -0.15 0.882 -1.53
SLC18A2 118995757 rs363393 ALL A 0.812 0.793 0.315 1.09 0.839 1.89 0.059 2.14
SLC18A2 118998861 rs363399 ALL T 0.769 0.749 0.319 1.02 0.773 -0.37 0.713 0.39
SLC18A2 118999379 rs363338 ALL T 0.707 0.660 0.029 2.23 0.666 -0.74 0.458 2.02
SLC18A2 119004938 rs363343 ALL A 0.824 0.786 0.046 2.09 0.799 -0.28 0.782 1.16
SLC18A2 119008669 rs2283138 ALL A 0.892 0.895 0.839 -0.21 0.887 -0.48 0.635 -0.49
SLC18A2 119009116 rs929493 ALL T 0.840 0.808 0.068 1.86 0.815 -0.06 0.956 1.18
SLC18A2 119009680 rs4752045 ALL G 0.603 0.542 0.009 2.72 0.515 0.43 0.665 -1.46
SLC18A2 119011397 rs10082463 ALL A 0.909 0.894 0.260 1.15 0.894 -0.28 0.784 0.54
SLC18A2 119012563 rs363224 ALL A 0.551 0.528 0.341 1.03 0.512 1.62 0.106 1.90
SLC18A2 119015202 rs363226 ALL C 0.668 0.646 0.324 1.03 0.608 0.70 0.486 1.20
SLC18A2 119016556 rs363227 ALL C 0.891 0.868 0.184 1.40 0.87 1.51 0.130 2.02
SLC18A2 119027061 rs14240 US C 0.536 0.523 0.702 0.15     
SLC18A2 119028361 rs363236 ALL T 0.859 0.843 0.352 0.98 0.835 -0.57 0.570 0.21
SLC18A2 119029149 rs363285 ALL A 0.712 0.718 0.800 -0.27 0.678 1.25 0.210 0.77
COMT 18303438 rs2020917 ALL C 0.684 0.712 0.160 -1.18 0.673 1.04 0.296 1.56
COMT 18305961 rs933271 ALL A 0.723 0.723 0.972 0.04 0.775 1.58 0.113 1.22
COMT 18310121 rs737865 ALL A 0.684 0.712 0.163 -1.39 0.679 0.88 0.379 -0.80
COMT 18319731 rs740603 ALL C 0.603 0.584 0.317 0.84 0.547 0.59 0.552 -0.10
COMT 18322680 rs7290221 BGT G     0.53 0.75 0.456  
COMT 18322891 rs4646312 ALL A 0.584 0.613 0.185 -1.31 0.6 -0.45 0.654 -1.19
COMT 18323417 rs165656 ALL C 0.515 0.504 0.634 0.47 0.512 1.48 0.140 1.43
COMT 18324506 rs6269 US T 0.581 0.609 0.198 -1.29     
COMT 18324982 rs2239393 US T 0.582 0.609 0.212 -1.25     
COMT 18325825 rs4680 US A 0.510 0.500 0.642 0.47     
COMT 18326451 rs4646315 ALL G 0.831 0.828 0.898 0.13 0.836 -1.38 0.169 -0.95
COMT 18326686 rs4646316 ALL C 0.756 0.755 0.967 0.04 0.777 0.29 0.775 0.25
COMT 18327115 rs165774 ALL C 0.682 0.689 0.738 -0.33 0.667 -0.79 0.431 -0.81
COMT 18327730 rs174696 ALL T 0.794 0.757 0.048 1.99 0.782 1.43 0.154 2.38
COMT 18330235 rs4633 BGT C     0.501 -0.04 0.965  
COMT 18330246 rs9332377 ALL C 0.836 0.858 0.172 -1.32 0.835 -0.41 0.685 -1.17
COMT 18330763 rs740601 BGT A     0.584 -0.99 0.323  
COMT 18331107 rs9332381 ALL G 0.956 0.954 0.833 0.21 0.986 0.23 0.819 0.31
COMT 18331207 rs4818 BGT C     0.588 -0.88 0.380  
COMT 18331335 rs165599 US T 0.689 0.688 0.943 0.07     
COMT 18333223 rs165849 US A 0.688 0.687 0.936 0.08     
COMT 18334027 rs165815 ALL T 0.862 0.833 0.076 1.81 0.84 1.31 0.189 2.18
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Table 14. BP = genomic location in base pairs.  N = nucleotide of common allele.  Freq = 
frequency of common allele provided. Z scores are test statistics with reference to  common 
allele.  allele.  p-value = p-value obatined from Armitage Trends test comparing case and control 
genotype distributions.  BGT = Bulgarian trios.  Frequency of common allele for parents of 
probands in Bulgarian families provided.  Joint = joint analysis.  Zjoint derived from the joint 
distribution of test statistics from stages II and III, weighted for sample size. *Novel SNP 
discovered from sequencing.           
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APPENDIX B: SUPPLEMENT TO CHAPTER 5 
Table 15 Supplementary Table 5.1: Nominally significant gender based analyses 
  Associations in Females only Associations in Males only 
SNP 
Gene 
Location 
Bulgarian  
p-value 
US C-C  
p-value 
US 
Trio  
p-value
AFAM   
p-value
Bulgarian  
p-value 
US C-C  
p-value 
US 
Trio  p-
value 
AFAM  
p-value
rs2245360 Exon-11         0.02       
rs1042503 Exon-7     0.05  0.01  
rs1126758 Exon-6     0.02  0.07  
rs12425434 Intron-5 0.03    0.07  0.004  
rs937476 Intron-6     0.004    
rs2037639 Intron-3     0.03  0.03  
rs1722392 Intron-3     0.04    
rs1522305 Intron-3 0.002 0.05    0.04   
rs1522296 Intron- 1 0.007               
Nominally significant SNP tests for gender based analyses.  P-values provided for unconditional 
(case-control) or conditional (family based) logistic regression among male or female participants 
separately.. All p-values are uncorrected for multiple comparisons.  C-C = case-control.  AFAM = 
African-American families.  SNPs where nominally significant replication (p < 0.05) was detected 
are highlighted.  No SNPs were significant after correction.  
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APPENDIX C: SUPPLEMENT TO CHAPTER 6 
Table 16 Supplementary Table 6.1: All gene descriptions 
  
SNP Analyses 
(Trends Test) 
Gene-based test 
(Hotelling's T2) 
Chr Gene Name 
Tag 
SNPs
Effective 
tests 
Best SZ 
p-value
Best BD  
p-value 
 Empirical 
p-value 
(SZ) 
 Empirical 
p-value 
(BP1) 
22 ADRBK2 
adrenergic, beta, receptor kinase 
2 3 1.0 0.516 0.269 0.756 0.700 
22 CACNG2 
calcium channel, voltage-
dependent, gamma subunit 2 6 2.7 0.063 0.175 0.247 0.374 
21 CLIC6 chloride intracellular channel 6 6 2.4 0.280 0.2085 0.881 0.734 
22 COMT catechol-O-methyltransferase 31 10.6 0.217 0.050 0.804 0.518 
7 COPG2 Gamma COP 6 2.7 0.408 0.260 0.801 0.615 
17 DARPP32 
protein phosphatase 1, regulatory 
(inhibitor) subunit 1B 1 1.0 0.144 0.855 0.179 0.849 
9 DBH dopamine beta-hydroxylase 29 11.2 0.124 0.045 0.617 0.878 
7 DDC dopa decarboxylase 40 11.9 0.029 0.002* 0.391 0.708 
5 DRD1 dopamine receptor 1 5 1.8 0.095 0.536 0.400 0.988 
10 DRD1IP 
dopamine receptor D1 interacting 
protein 4 1.9 0.012* 0.008* 0.090 0.063 
11 DRD2 dopamine receptor D2 22 8.3 0.037 0.261 0.433 0.813 
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3 DRD3 dopamine receptor D3 20 6.7 0.003* 0.002* 0.007 0.013 
11 DRD4 dopamine receptor D4 2 1.0 0.613 0.052 0.745 0.095 
4 DRD5 dopamine receptor D5 1 1.0 0.646 0.600 0.597 0.577 
12 DRIP78 
dopamine receptor interacting 
protein  3 1.0 0.428 0.978 0.496 1.000 
1 EPB41 
erythrocyte membrane protein 
band 4.1 15 4.9 0.138 0.022 0.818 0.109 
X FLNA Filamin A 2 1.0 0.396 0.340 0.060 0.208 
9 FREQ frequenin homolog 21 8.1 0.056 0.011 0.776 0.376 
5 GNB2L1 Receptor for activated C kinase1 4 1.9 0.234 0.245 0.150 0.419 
17 GRB2 
growth factor receptor-bound 
protein 2 8 3.4 0.037 0.208 0.373 0.715 
11 GRK2 
adrenergic, beta, receptor kinase 
1 2 1.0 0.467 0.223 0.671 0.447 
8 Hey1 Hesr1/Hey1 7 2.6 0.530 0.083 0.992 0.156 
16 HIC5 Focal adhesion protein 2 1.0 0.657 0.154 0.828 0.360 
X MAOA monoamine oxidase A 8 3.1 0.228 0.318 0.336 0.481 
X MAOB monoamine oxidase B 8 3.3 0.019 0.042 0.268 0.296 
3 NCK1 NCK adaptor protein 6 2.6 0.316 0.565 0.826 0.977 
8 NEF3 Neurofilament M 8 3.5 0.044 0.075 0.342 0.286 
2 NR4A2 
nuclear receptor subfamily 4, 
group A, member 2 2 1.0 0.384 0.431 0.682 0.643 
22 PICK1 
Protein interacting with C 
Kinase1 6 2.6 0.150 0.319 0.697 0.931 
17 PPP1R9B Spinophilin 5 1.9 0.068 0.019* 0.396 0.095 
5 PPP2CA Protein Phosphatase 1 1.0 0.486 0.994 0.566 1.000 
8 SLC18A1 
solute carrier family 18 (vesicular 
monoamine), member 1 22 8.7 0.233 0.005* 0.761 0.113 
10 SLC18A2 
solute carrier family 18 (vesicular 
monoamine), member 2 18 7.7 0.041 0.095 0.420 0.393 
5 SLC6A3 Dopamine Transporter 47 16.9 0.045 0.118 0.479 0.818 
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20 SNAP25 synaptosomal-associated protein 34 13.3 0.064 0.012 0.334 0.375 
4 SNCA Synuclein 12 4.9 0.128 0.038 0.753 0.614 
7 Sp4 Sp4 transcription factor 3 1.1 0.016* 0.687 0.105 0.963 
7 STX1A Syntaxin1A 2 1.0 0.455 0.771 0.572 0.956 
16 SYNGR3 synaptogyrin 3 2 1.0 0.468 0.662 0.650 0.885 
11 TH tyrosine hydroxylase 7 2.7 0.098 0.106 0.247 0.252 
*Significant after gene-wide correction. 
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Table 17 Supplementary Table 6.2: All SNP associations in both diagnostic groups 
Genomic Information Minor Allele Information Test Statistics  
Gene Position SNP Nuc SZ/SZA
Freq 
BP1 
Freq
Control 
Freq 
SZ/SZA
p-value
SZ 
OR 
BP1    
p-value 
BP1 
OR
EPB41 29092857 rs126013 A 0.355 0.347 0.376 0.3185 0.91 0.1734 0.88
EPB41 29101418 rs150093 G 0.138 0.142 0.141 0.8521 0.98 0.9473 1.01
EPB41 29114784 rs203278 G 0.333 0.336 0.363 0.1723 0.88 0.2036 0.89
EPB41 29117993 rs157208 G 0.217 0.231 0.220 0.8791 0.98 0.5486 1.07
EPB41 29131901 rs150089 G 0.303 0.305 0.324 0.3223 0.91 0.3623 0.92
EPB41 29141303 rs12038347 G 0.088 0.105 0.091 0.8187 0.96 0.2951 1.17
EPB41 29182405 rs2762682 A 0.286 0.281 0.278 0.6996 1.04 0.8698 1.02
EPB41 29183661 rs12021667 G 0.409 0.412 0.397 0.6053 1.05 0.5015 1.06
EPB41 29205312 rs11581096 A 0.097 0.094 0.108 0.4145 0.89 0.2889 0.85
EPB41 29207950 rs2985331 G 0.142 0.141 0.132 0.5040 1.09 0.5820 1.08
EPB41 29229250 rs10915216 A 0.498 0.483 0.491 0.7438 1.03 0.2339 0.90
EPB41 29269534 rs12130351 A 0.060 0.049 0.052 0.4781 1.15 0.7094 0.93
EPB41 29316310 rs2249138 A 0.121 0.109 0.133 0.4013 0.89 0.0977 0.80
EPB41 29317814 rs12120422 G 0.168 0.164 0.165 0.8406 1.03 0.9476 0.99
EPB41 29319434 rs575675 G 0.086 0.075 0.104 0.1825 0.82 0.0216 0.70
NR4A2 156890171 rs12803 A 0.474 0.476 0.494 0.3793 0.93 0.4312 0.93
NR4A2 156891881 rs834834 G 0.308 0.316 0.321 0.5524 0.94 0.8362 0.98
DRD3 115317621 rs2046496 G 0.494 0.502 0.448 0.0345 1.21 0.0151 1.24
DRD3 115322414 rs12636133 C 0.424 0.416 0.475 0.0239 0.81 0.0080 0.79
DRD3 115324324 rs10934254 G 0.428 0.417 0.475 0.0367 0.83 0.0091 0.79
DRD3 115329232 rs9868039 A 0.451 0.458 0.387 0.0039 1.30 0.0013 1.34
DRD3 115329798 rs9817063 G 0.456 0.447 0.514 0.0123 0.79 0.0031 0.77
DRD3 115329973 rs3732790 A 0.383 0.374 0.431 0.0334 0.82 0.0094 0.79
DRD3 115340891 rs2134655 A 0.277 0.280 0.226 0.0080 1.31 0.0059 1.33
DRD3 115345577 rs963468 A 0.381 0.370 0.429 0.0302 0.82 0.0074 0.78
DRD3 115351544 rs324035 A 0.210 0.200 0.197 0.4879 1.08 0.8611 1.02
DRD3 115357749 rs2630351 A 0.065 0.070 0.053 0.2630 1.24 0.1304 1.33
DRD3 115358965 rs167771 G 0.187 0.183 0.174 0.4593 1.09 0.6161 1.06
DRD3 115360518 rs324032 G 0.069 0.072 0.053 0.1492 1.32 0.0935 1.37
DRD3 115362252 rs167770 G 0.277 0.277 0.301 0.2323 0.89 0.2448 0.89
DRD3 115363703 rs226082 G 0.278 0.278 0.301 0.2537 0.89 0.2647 0.90
DRD3 115364131 rs324030 G 0.278 0.278 0.301 0.2537 0.89 0.2647 0.90
DRD3 115364217 rs7625282 G 0.248 0.250 0.284 0.0575 0.83 0.0808 0.84
DRD3 115368342 rs10934256 A 0.178 0.188 0.215 0.0355 0.79 0.1389 0.85
DRD3 115369758 rs7633291 C 0.180 0.189 0.215 0.0463 0.80 0.1541 0.85
DRD3 115373505 rs6280 G 0.325 0.329 0.338 0.5569 0.95 0.6817 0.96
DRD3 115374239 rs1800828 G 0.226 0.239 0.252 0.1651 0.87 0.5140 0.93
NCK1 138069807 rs9845460 A 0.222 0.214 0.206 0.3733 1.10 0.6333 1.05
NCK1 138101599 rs9867325 C 0.235 0.229 0.237 0.9338 0.99 0.6938 0.96
NCK1 138102256 rs6783508 A 0.317 0.298 0.296 0.3055 1.11 0.8957 1.01
NCK1 138109387 rs1347209 C 0.397 0.380 0.380 0.4242 1.08 0.9968 1.00
NCK1 138150095 rs1048145 G 0.095 0.084 0.089 0.6538 1.07 0.6930 0.94
NCK1 138154451 rs7648198 C 0.453 0.442 0.441 0.6065 1.05 0.9863 1.00
DRD5 9397033 rs2867383 A 0.323 0.324 0.312 0.5966 1.05 0.5614 1.06
SNCA 90862167 rs168552 G 0.280 0.286 0.253 0.1618 1.15 0.0945 1.18
SNCA 90865909 rs356165 G 0.383 0.369 0.351 0.1284 1.15 0.3935 1.08
SNCA 90910560 rs356188 G 0.221 0.238 0.203 0.3337 1.11 0.0620 1.22
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SNCA 90912499 rs356164 C 0.132 0.146 0.128 0.7939 1.04 0.2330 1.17
SNCA 90924387 rs356186 A 0.206 0.225 0.195 0.5402 1.07 0.1037 1.20
SNCA 90931534 rs10002435 A 0.121 0.108 0.120 0.9454 1.01 0.4194 0.89
SNCA 90950732 rs1866995 G 0.058 0.048 0.055 0.7385 1.07 0.4959 0.87
SNCA 90955540 rs3822095 G 0.377 0.373 0.402 0.2378 0.90 0.1893 0.89
SNCA 90959901 rs2737020 G 0.285 0.298 0.269 0.4449 1.08 0.1527 1.15
SNCA 90964953 rs6532191 G 0.484 0.503 0.457 0.2136 1.11 0.0404 1.20
SNCA 90976758 rs2619361 A 0.262 0.266 0.252 0.5999 1.06 0.4690 1.08
SNCA 90980380 rs17016274 A 0.067 0.061 0.069 0.8587 0.97 0.4611 0.87
SLC6A3 1436550 rs27074 A 0.091 0.081 0.087 0.7472 1.05 0.6439 0.93
SLC6A3 1443349 rs12516758 G 0.224 0.207 0.207 0.3495 1.11 0.9999 1.00
SLC6A3 1444161 rs11133762 A 0.014 0.023 0.019 0.4105 0.75 0.5254 1.22
SLC6A3 1445711 rs3863145 A 0.262 0.274 0.272 0.6318 0.95 0.8848 1.02
SLC6A3 1447522 rs27072 A 0.160 0.166 0.165 0.7663 0.96 0.9315 1.01
SLC6A3 1447815 rs1042098 G 0.272 0.276 0.275 0.9088 0.99 0.9340 1.01
SLC6A3 1448077 rs40184 A 0.458 0.431 0.457 0.9569 1.01 0.2483 0.90
SLC6A3 1451007 rs11564772 A 0.081 0.071 0.082 0.9278 0.99 0.3532 0.86
SLC6A3 1452431 rs11564769 G 0.083 0.069 0.080 0.8368 1.04 0.3541 0.85
SLC6A3 1457548 rs6869645 A 0.067 0.056 0.066 0.9058 1.02 0.3687 0.85
SLC6A3 1457704 rs11564767 T 0.079 0.065 0.068 0.3653 1.17 0.7794 0.95
SLC6A3 1458694 rs28363119 G 0.065 0.056 0.066 0.9590 0.99 0.3687 0.85
SLC6A3 1458806 rs11564764 A 0.066 0.054 0.064 0.8238 1.04 0.3704 0.84
SLC6A3 1459036 rs6876225 A 0.067 0.056 0.065 0.8317 1.04 0.4212 0.86
SLC6A3 1460129 rs3776511 A 0.205 0.196 0.206 0.9753 1.00 0.5812 0.94
SLC6A3 1461979 rs11133770 C 0.215 0.203 0.211 0.7990 1.03 0.6583 0.95
SLC6A3 1463472 rs2617577 G 0.286 0.266 0.277 0.6577 1.05 0.5999 0.95
SLC6A3 1463613 rs11564762 A 0.207 0.197 0.208 0.9684 1.00 0.5551 0.94
SLC6A3 1464256 rs2550936 C 0.289 0.267 0.281 0.6770 1.04 0.4770 0.93
SLC6A3 1464412 rs6347 G 0.270 0.270 0.274 0.8700 0.98 0.8413 0.98
SLC6A3 1468629 rs37022 A 0.164 0.178 0.174 0.5669 0.93 0.8229 1.03
SLC6A3 1469142 rs40358 C 0.175 0.151 0.147 0.0868 1.23 0.7873 1.04
SLC6A3 1469646 rs2042449 A 0.227 0.240 0.224 0.8971 1.01 0.4081 1.09
SLC6A3 1472932 rs2975292 G 0.370 0.361 0.351 0.3687 1.09 0.6378 1.05
SLC6A3 1473268 rs2735917 A 0.057 0.055 0.056 0.8949 1.03 0.9917 1.00
SLC6A3 1473346 rs28382247 A 0.231 0.237 0.231 0.9976 1.00 0.7322 1.04
SLC6A3 1473476 rs28382245 A 0.390 0.391 0.408 0.4112 0.93 0.4450 0.93
SLC6A3 1473588 rs11564758 G 0.392 0.390 0.414 0.3073 0.91 0.2744 0.91
SLC6A3 1476905 rs464049 G 0.423 0.449 0.431 0.7293 0.97 0.4049 1.08
SLC6A3 1483244 rs464061 A 0.193 0.212 0.200 0.6684 0.95 0.5069 1.08
SLC6A3 1483616 rs11737901 A 0.336 0.348 0.362 0.2202 0.89 0.5241 0.94
SLC6A3 1484164 rs463379 C 0.194 0.212 0.200 0.7218 0.96 0.5265 1.07
SLC6A3 1489408 rs420422 G 0.436 0.450 0.438 0.9379 0.99 0.5855 1.05
SLC6A3 1491354 rs403636 A 0.181 0.158 0.153 0.0924 1.23 0.7719 1.04
SLC6A3 1495732 rs2981359 C 0.432 0.445 0.471 0.0764 0.85 0.2419 0.90
SLC6A3 1495842 rs13189021 A 0.200 0.226 0.237 0.0487 0.81 0.5501 0.94
SLC6A3 1495974 rs2254408 C 0.441 0.440 0.456 0.4952 0.94 0.4573 0.94
SLC6A3 1496498 rs2455391 A 0.269 0.233 0.262 0.7415 1.03 0.1360 0.86
SLC6A3 1496728 rs2937639 A 0.414 0.415 0.405 0.6764 1.04 0.6399 1.04
SLC6A3 1497427 rs2963238 A 0.406 0.405 0.398 0.7153 1.03 0.7487 1.03
SLC6A3 1498616 rs2975226 T 0.413 0.410 0.408 0.8086 1.02 0.9071 1.01
SLC6A3 1499389 rs2652511 A 0.405 0.407 0.401 0.8557 1.02 0.7847 1.03
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SLC6A3 1501148 rs3756450 G 0.107 0.128 0.131 0.0986 0.80 0.8318 0.97
SLC6A3 1505280 rs2078247 G 0.279 0.242 0.268 0.5861 1.06 0.1827 0.87
PPP2CA 133593991 rs4246019 G 0.115 0.124 0.124 0.5266 0.92 0.9679 1.01
DRD1 174800505 rs4867798 G 0.286 0.317 0.321 0.0890 0.85 0.8723 0.98
DRD1 174801306 rs686 G 0.373 0.382 0.371 0.9342 1.01 0.6012 1.05
DRD1 174802802 rs5326 A 0.140 0.153 0.158 0.2380 0.86 0.7431 0.96
DRD1 174811672 rs267416 G 0.425 0.406 0.420 0.8341 1.02 0.5246 0.94
DRD1 174813251 rs267418 C 0.463 0.440 0.450 0.5550 1.06 0.6558 0.96
GNB2L1 180595641 rs2261114 G 0.384 0.383 0.408 0.2880 0.91 0.2651 0.90
GNB2L1 180598539 rs13160776 A 0.076 0.074 0.079 0.8148 0.96 0.6733 0.93
GNB2L1 180598882 rs2287716 G 0.133 0.139 0.152 0.2111 0.85 0.3964 0.90
GNB2L1 180602857 rs1279738 C 0.265 0.261 0.262 0.8773 1.02 0.9753 1.00
Sp4 21429057 rs10245440 A 0.234 0.238 0.245 0.5646 0.94 0.7058 0.96
Sp4 21498416 rs12668354 C 0.328 0.278 0.282 0.0239 1.24 0.8513 0.98
Sp4 21516416 rs1018954 A 0.429 0.455 0.448 0.4068 0.93 0.7371 1.03
DDC 50492617 rs11575564 A 0.050 0.036 0.034 0.0602 1.53 0.7349 1.09
DDC 50492914 rs4947510 A 0.277 0.274 0.298 0.2989 0.90 0.2489 0.89
DDC 50493713 rs11575553 A 0.076 0.093 0.075 0.9700 1.01 0.1656 1.25
DDC 50497803 rs11575548 A 0.094 0.115 0.087 0.5770 1.09 0.0403 1.36
DDC 50498481 rs11575542 A 0.025 0.015 0.019 0.3810 1.32 0.5371 0.81
DDC 50499175 rs4947535 A 0.296 0.295 0.340 0.0339 0.82 0.0337 0.82
DDC 50499488 rs11575535 A 0.033 0.020 0.024 0.2255 1.39 0.5392 0.83
DDC 50503248 rs730092 G 0.416 0.425 0.449 0.1248 0.87 0.2764 0.91
DDC 50504704 rs11575500 A 0.069 0.083 0.061 0.4383 1.15 0.0539 1.40
DDC 50511449 rs745043 A 0.206 0.195 0.248 0.0243 0.78 0.0043 0.73
DDC 50511808 rs4490786 A 0.184 0.213 0.181 0.8721 1.02 0.0742 1.22
DDC 50515359 rs11575453 A 0.089 0.097 0.093 0.7460 0.95 0.8035 1.04
DDC 50520392 rs11575441 T 0.013 0.010 0.012 0.7219 1.15 0.6659 0.83
DDC 50520545 rs1451371 G 0.454 0.457 0.428 0.2400 1.11 0.1876 1.13
DDC 50520718 rs11575438 A 0.089 0.097 0.093 0.7460 0.95 0.8035 1.04
DDC 50521365 rs1451372 G 0.392 0.410 0.432 0.0622 0.85 0.3254 0.91
DDC 50530192 rs4470989 A 0.297 0.297 0.343 0.0275 0.81 0.0294 0.81
DDC 50530315 rs4602840 A 0.096 0.117 0.090 0.6406 1.07 0.0526 1.33
DDC 50531681 rs6957607 G 0.083 0.088 0.085 0.8475 0.97 0.8086 1.04
DDC 50533884 rs3807563 A 0.410 0.425 0.405 0.8091 1.02 0.3679 1.09
DDC 50534165 rs3807562 A 0.476 0.469 0.446 0.1768 1.13 0.3032 1.10
DDC 50534929 rs11575387 C 0.081 0.084 0.084 0.7925 0.96 0.9825 1.00
DDC 50538516 rs3807558 A 0.207 0.198 0.246 0.0365 0.80 0.0091 0.75
DDC 50539273 rs11575375 A 0.338 0.347 0.324 0.5059 1.07 0.2739 1.11
DDC 50540203 rs4947584 A 0.340 0.351 0.325 0.4817 1.07 0.2213 1.12
DDC 50540384 rs6592961 A 0.201 0.217 0.193 0.6377 1.05 0.1820 1.16
DDC 50562006 rs10274275 G 0.238 0.253 0.225 0.4946 1.07 0.1434 1.17
DDC 50563851 rs11575342 A 0.136 0.122 0.124 0.4253 1.11 0.9285 0.99
DDC 50564124 rs3735274 G 0.240 0.255 0.228 0.5039 1.07 0.1472 1.16
DDC 50564358 rs3735273 A 0.232 0.206 0.262 0.1262 0.85 0.0028 0.73
DDC 50572526 rs11575322 A 0.082 0.107 0.080 0.8701 1.03 0.0359 1.39
DDC 50574882 rs998850 C 0.471 0.461 0.491 0.3734 0.92 0.1831 0.89
DDC 50578412 rs3779078 A 0.205 0.193 0.244 0.0357 0.80 0.0056 0.74
DDC 50579382 rs11575288 G 0.025 0.017 0.013 0.0570 1.99 0.3949 1.38
DDC 50579579 rs11575286 A 0.082 0.106 0.080 0.8701 1.03 0.0424 1.37
DDC 50580056 rs2044859 G 0.380 0.339 0.395 0.4794 0.94 0.0097 0.79
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DDC 50580400 rs7786398 G 0.461 0.444 0.475 0.5428 0.95 0.1732 0.88
DDC 50597258 rs3829897 A 0.374 0.371 0.383 0.6724 0.96 0.5831 0.95
STX1A 72752376 rs867500 C 0.347 0.348 0.346 0.9490 1.01 0.9331 1.01
STX1A 72759283 rs3793243 A 0.440 0.429 0.424 0.4422 1.07 0.7943 1.02
COPG2 129947065 rs10954272 G 0.228 0.226 0.215 0.4955 1.08 0.5629 1.07
COPG2 129955068 rs6967801 A 0.233 0.232 0.223 0.5900 1.06 0.6302 1.05
COPG2 129965829 rs13241924 A 0.461 0.462 0.442 0.4162 1.08 0.3837 1.08
COPG2 129984917 rs10954274 A 0.052 0.047 0.059 0.5230 0.88 0.2351 0.79
COPG2 129992573 rs3857855 G 0.158 0.152 0.150 0.6007 1.07 0.8952 1.02
COPG2 129993518 rs11763462 G 0.152 0.147 0.147 0.7554 1.04 0.9760 1.00
SLC18A1 20046706 rs1497020 G 0.319 0.287 0.303 0.4496 1.08 0.4456 0.93
SLC18A1 20049580 rs1018079 G 0.302 0.324 0.295 0.7315 1.04 0.1536 1.15
SLC18A1 20049719 rs10102779 C 0.252 0.263 0.256 0.8630 0.98 0.7159 1.04
SLC18A1 20049834 rs17092104 C 0.103 0.075 0.111 0.5277 0.91 0.0047 0.64
SLC18A1 20049996 rs903997 C 0.231 0.233 0.218 0.5072 1.08 0.4157 1.09
SLC18A1 20050350 rs4921692 G 0.096 0.088 0.111 0.2563 0.85 0.0833 0.77
SLC18A1 20052292 rs2270650 A 0.374 0.385 0.362 0.5712 1.05 0.2751 1.11
SLC18A1 20052435 rs17092107 A 0.100 0.076 0.103 0.8165 0.97 0.0395 0.72
SLC18A1 20063898 rs1390942 A 0.169 0.173 0.168 0.9439 1.01 0.7653 1.04
SLC18A1 20073883 rs13258461 A 0.457 0.461 0.464 0.7547 0.97 0.8735 0.99
SLC18A1 20076383 rs3779672 G 0.194 0.179 0.196 0.8894 0.98 0.3233 0.89
SLC18A1 20076626 rs3779673 A 0.167 0.155 0.177 0.5470 0.93 0.1807 0.85
SLC18A1 20080513 rs2279709 A 0.450 0.439 0.457 0.7478 0.97 0.4134 0.93
SLC18A1 20080993 rs1390938 A 0.248 0.248 0.258 0.6000 0.95 0.5981 0.95
SLC18A1 20081107 rs2270637 C 0.184 0.181 0.187 0.8858 0.98 0.7337 0.96
SLC18A1 20082746 rs2270641 C 0.353 0.374 0.349 0.8663 1.02 0.2500 1.11
SLC18A1 20082870 rs2270642 A 0.349 0.372 0.343 0.7770 1.03 0.1851 1.13
SLC18A1 20084992 rs1390939 A 0.472 0.457 0.476 0.8493 0.98 0.3971 0.93
SLC18A1 20085581 rs988713 G 0.247 0.249 0.256 0.6407 0.95 0.7111 0.96
SLC18A1 20086029 rs7836907 T 0.134 0.137 0.139 0.7410 0.96 0.8611 0.98
SLC18A1 20087205 rs2173114 C 0.497 0.491 0.479 0.4222 1.08 0.5807 1.05
SLC18A1 20088916 rs7820517 A 0.189 0.172 0.204 0.3739 0.91 0.0644 0.81
NEF3 24823733 rs11782211 G 0.073 0.096 0.073 0.9773 1.00 0.0750 1.34
NEF3 24824747 rs10096842 A 0.081 0.064 0.062 0.1077 1.33 0.8391 1.04
NEF3 24825500 rs196868 G 0.122 0.110 0.104 0.1804 1.20 0.6558 1.07
NEF3 24825757 rs1457266 A 0.358 0.366 0.335 0.2945 1.10 0.1506 1.15
NEF3 24830588 rs196864 C 0.068 0.074 0.074 0.6000 0.91 0.9449 0.99
NEF3 24832328 rs12515 A 0.165 0.152 0.159 0.7283 1.04 0.6518 0.95
NEF3 24834861 rs13251967 G 0.370 0.353 0.327 0.0448 1.21 0.2252 1.12
NEF3 24836483 rs2975180 G 0.365 0.361 0.341 0.2500 1.11 0.3327 1.10
Hey1 80836175 rs2461056 A 0.174 0.182 0.177 0.8405 0.98 0.7936 1.03
Hey1 80836720 rs6473177 G 0.092 0.075 0.095 0.7906 0.96 0.0946 0.76
Hey1 80837832 rs6986945 C 0.198 0.205 0.188 0.5451 1.07 0.3404 1.11
Hey1 80839084 rs1046472 A 0.271 0.294 0.264 0.7154 1.04 0.1441 1.16
Hey1 80841420 rs960978 A 0.312 0.316 0.318 0.7925 0.98 0.9188 0.99
Hey1 80845876 rs2467779 A 0.165 0.172 0.166 0.9749 1.00 0.7000 1.05
Hey1 80846477 rs2920950 A 0.255 0.240 0.267 0.5517 0.94 0.1679 0.87
FREQ 131975772 rs3780708 A 0.327 0.299 0.330 0.8921 0.99 0.1363 0.87
FREQ 131976625 rs1017112 G 0.196 0.218 0.194 0.8895 1.02 0.1844 1.16
FREQ 131984366 rs7849345 A 0.495 0.470 0.491 0.8351 1.02 0.3671 0.92
FREQ 131987341 rs4424362 A 0.322 0.340 0.289 0.1164 1.17 0.0142 1.27
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FREQ 131988371 rs3824544 A 0.239 0.259 0.225 0.4441 1.08 0.0742 1.21
FREQ 131995274 rs10819611 G 0.326 0.353 0.301 0.2171 1.13 0.0135 1.27
FREQ 131996050 rs1009502 A 0.310 0.353 0.301 0.6439 1.05 0.0135 1.27
FREQ 132003939 rs11793619 C 0.125 0.127 0.116 0.5408 1.09 0.4611 1.11
FREQ 132008905 rs870811 A 0.427 0.470 0.432 0.8225 0.98 0.0840 1.17
FREQ 132012650 rs947514 A 0.069 0.054 0.058 0.2833 1.22 0.7589 0.94
FREQ 132013809 rs947513 G 0.475 0.473 0.448 0.2260 1.11 0.2668 1.11
FREQ 132014745 rs10819615 A 0.326 0.313 0.335 0.6730 0.96 0.2761 0.90
FREQ 132018298 rs4240447 A 0.302 0.328 0.274 0.1606 1.15 0.0094 1.29
FREQ 132024932 rs3829905 A 0.407 0.420 0.377 0.1659 1.13 0.0535 1.19
FREQ 132028530 rs2277200 C 0.330 0.360 0.315 0.4453 1.08 0.0301 1.23
FREQ 132032983 rs7873936 A 0.211 0.196 0.176 0.0524 1.25 0.2542 1.14
FREQ 132034981 rs7852859 G 0.140 0.142 0.117 0.1335 1.23 0.1096 1.24
FREQ 132035589 rs1054879 A 0.495 0.498 0.503 0.7261 0.97 0.9561 1.01
FREQ 132036468 rs6478954 A 0.311 0.316 0.298 0.5240 1.06 0.3698 1.09
FREQ 132037596 rs13710 G 0.312 0.278 0.299 0.4997 1.07 0.3110 0.90
FREQ 132038378 rs11552451 G 0.146 0.141 0.157 0.4940 0.92 0.2942 0.88
DBH 135486529 rs3025373 G 0.141 0.142 0.148 0.6858 0.95 0.7342 0.96
DBH 135487964 rs1076153 A 0.176 0.200 0.180 0.7954 0.97 0.2581 1.14
DBH 135488582 rs1076150 A 0.468 0.512 0.483 0.4957 0.94 0.2070 1.12
DBH 135490336 rs1611115 A 0.198 0.229 0.217 0.2945 0.89 0.5369 1.07
DBH 135491762 rs2797849 G 0.353 0.327 0.336 0.4338 1.08 0.6635 0.96
DBH 135492142 rs3025382 A 0.131 0.119 0.133 0.8891 0.98 0.3257 0.88
DBH 135493077 rs3025388 G 0.186 0.167 0.177 0.6227 1.06 0.5601 0.93
DBH 135493640 rs2007153 A 0.380 0.393 0.393 0.5419 0.95 0.9975 1.00
DBH 135494744 rs1611118 A 0.053 0.061 0.065 0.2528 0.81 0.7265 0.94
DBH 135494935 rs1108580 A 0.439 0.479 0.442 0.8937 0.99 0.1014 1.16
DBH 135495062 rs1108581 G 0.216 0.205 0.225 0.6335 0.95 0.2582 0.88
DBH 135498795 rs3025399 C 0.044 0.049 0.030 0.1160 1.46 0.0364 1.64
DBH 135498904 rs1611123 A 0.503 0.453 0.489 0.5240 1.06 0.1140 0.87
DBH 135500715 rs2797855 G 0.429 0.392 0.434 0.8203 0.98 0.0567 0.84
DBH 135501206 rs1541333 G 0.438 0.470 0.443 0.8274 0.98 0.2266 1.12
DBH 135501337 rs1541332 A 0.448 0.454 0.428 0.3806 1.09 0.2343 1.11
DBH 135502096 rs2519154 G 0.415 0.425 0.397 0.4514 1.08 0.2170 1.12
DBH 135502336 rs2797853 A 0.324 0.332 0.347 0.2786 0.90 0.4726 0.93
DBH 135504489 rs6479643 G 0.402 0.404 0.382 0.3466 1.09 0.2962 1.10
DBH 135505151 rs2283124 A 0.132 0.115 0.123 0.5348 1.09 0.5842 0.93
DBH 135507918 rs77905 A 0.470 0.491 0.502 0.1484 0.88 0.6326 0.96
DBH 135510103 rs2073833 G 0.436 0.421 0.413 0.3182 1.10 0.7288 1.03
DBH 135512008 rs1611131 G 0.285 0.287 0.281 0.8548 1.02 0.7707 1.03
DBH 135512749 rs2073837 A 0.295 0.305 0.294 0.9393 1.01 0.5759 1.06
DBH 135513490 rs129882 A 0.187 0.201 0.211 0.1765 0.86 0.5898 0.94
DBH 135514632 rs129883 G 0.307 0.311 0.306 0.9500 1.01 0.8229 1.02
DBH 135514739 rs129915 G 0.288 0.292 0.277 0.5690 1.06 0.4659 1.08
DBH 135514907 rs129884 A 0.179 0.192 0.189 0.5592 0.94 0.8608 1.02
DBH 135518542 rs129886 A 0.193 0.205 0.214 0.2280 0.88 0.6114 0.95
SLC18A2 118995757 rs363393 T 0.182 0.186 0.195 0.4670 0.92 0.6270 0.95
SLC18A2 118998861 rs363399 G 0.239 0.243 0.268 0.1313 0.86 0.1997 0.88
SLC18A2 118999379 rs363338 G 0.302 0.319 0.326 0.2262 0.89 0.7494 0.97
SLC18A2 119004013 rs2072362 G 0.090 0.098 0.118 0.0390 0.74 0.1671 0.82
SLC18A2 119004938 rs363343 C 0.171 0.173 0.201 0.0769 0.82 0.1136 0.83
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SLC18A2 119008669 rs2283138 G 0.102 0.108 0.121 0.1606 0.82 0.3791 0.88
SLC18A2 119009116 rs929493 G 0.158 0.169 0.190 0.0578 0.80 0.2320 0.87
SLC18A2 119009457 rs363251 G 0.367 0.398 0.394 0.2120 0.89 0.8703 1.02
SLC18A2 119009648 rs11197936 G 0.393 0.352 0.366 0.2139 1.12 0.5140 0.94
SLC18A2 119011397 rs10082463 C 0.089 0.093 0.091 0.8735 0.98 0.9053 1.02
SLC18A2 119012563 rs363224 C 0.445 0.420 0.432 0.5598 1.06 0.5824 0.95
SLC18A2 119015202 rs363226 G 0.324 0.301 0.315 0.6526 1.04 0.5191 0.94
SLC18A2 119027061 rs14240 A 0.492 0.449 0.486 0.8229 1.02 0.0972 0.86
SLC18A2 119027658 rs363282 G 0.143 0.140 0.146 0.8746 0.98 0.6956 0.95
SLC18A2 119028361 rs363236 G 0.143 0.140 0.145 0.9127 0.99 0.7309 0.96
SLC18A2 119028749 rs363238 A 0.110 0.114 0.103 0.5841 1.08 0.4278 1.12
SLC18A2 119029149 rs363285 C 0.273 0.248 0.268 0.8048 1.03 0.2895 0.90
SLC18A2 119033544 rs363294 A 0.072 0.059 0.072 0.9845 1.00 0.2386 0.81
DRD1IP 134990001 rs7475905 A 0.026 0.023 0.030 0.5044 0.84 0.2963 0.75
DRD1IP 134991562 rs2298122 C 0.189 0.179 0.219 0.1035 0.83 0.0261 0.78
DRD1IP 134996704 rs11101694 G 0.129 0.127 0.169 0.0141 0.73 0.0087 0.72
DRD4 626399 rs3758653 G 0.185 0.194 0.177 0.6412 1.05 0.3482 1.11
DRD4 633568 rs936465 C 0.470 0.500 0.456 0.5338 1.06 0.0487 1.19
TH 2137971 rs3842748 C 0.232 0.240 0.234 0.9260 0.99 0.7841 1.03
TH 2142911 rs2070762 G 0.509 0.487 0.472 0.1105 1.16 0.5048 1.06
TH 2147527 rs6356 A 0.354 0.391 0.354 0.9848 1.00 0.0900 1.17
TH 2150751 rs10743149 A 0.127 0.123 0.106 0.1419 1.23 0.2413 1.18
TH 2150966 rs10840491 A 0.156 0.118 0.134 0.1751 1.19 0.2636 0.86
TH 2151386 rs7119275 A 0.379 0.382 0.381 0.8998 0.99 0.9594 1.01
TH 2154012 rs4929966 C 0.270 0.265 0.277 0.7247 0.97 0.5302 0.94
GRK2 66789652 rs11605263 A 0.045 0.038 0.049 0.6197 0.90 0.2273 0.77
GRK2 66806868 rs2071007 G 0.082 0.077 0.072 0.4372 1.14 0.6647 1.08
DRD2 112783693 rs2234689 G 0.188 0.177 0.178 0.5767 1.07 0.9537 0.99
DRD2 112783974 rs1554929 G 0.474 0.459 0.472 0.9027 1.01 0.5663 0.95
DRD2 112786283 rs6279 G 0.289 0.295 0.298 0.6816 0.96 0.9111 0.99
DRD2 112787485 rs1124492 A 0.101 0.116 0.120 0.1705 0.82 0.7911 0.96
DRD2 112788022 rs1079594 C 0.183 0.160 0.173 0.5487 1.07 0.4246 0.91
DRD2 112792088 rs2440390 A 0.131 0.123 0.121 0.4916 1.10 0.8494 1.03
DRD2 112797422 rs2587548 G 0.419 0.401 0.416 0.8826 1.01 0.4792 0.94
DRD2 112812339 rs4586205 C 0.242 0.250 0.247 0.7768 0.97 0.9118 1.01
DRD2 112814829 rs4620755 A 0.099 0.117 0.122 0.1005 0.79 0.7323 0.95
DRD2 112815079 rs11214606 A 0.058 0.038 0.048 0.3414 1.21 0.2719 0.78
DRD2 112815891 rs7125415 A 0.081 0.089 0.102 0.0986 0.78 0.3308 0.86
DRD2 112822277 rs17529477 A 0.295 0.326 0.337 0.0389 0.83 0.6191 0.95
DRD2 112822955 rs17601612 C 0.347 0.377 0.387 0.0607 0.84 0.6417 0.96
DRD2 112823618 rs4936270 A 0.106 0.099 0.102 0.7343 1.05 0.8672 0.98
DRD2 112824662 rs4274224 G 0.449 0.474 0.486 0.0908 0.86 0.5829 0.95
DRD2 112829684 rs4581480 G 0.103 0.097 0.102 0.8971 1.02 0.7018 0.94
DRD2 112834984 rs7131056 A 0.471 0.428 0.428 0.0476 1.19 0.9775 1.00
DRD2 112836742 rs4648317 A 0.137 0.140 0.128 0.5696 1.08 0.4431 1.11
DRD2 112839419 rs4630328 A 0.344 0.372 0.382 0.0708 0.85 0.6561 0.96
DRD2 112846601 rs4938019 G 0.138 0.141 0.129 0.5731 1.08 0.4481 1.11
DRD2 112852165 rs12364283 G 0.080 0.080 0.067 0.2855 1.20 0.2593 1.21
DRIP78 54502337 rs12308277 A 0.023 0.029 0.028 0.4436 0.80 0.9594 1.01
syngr3 1979309 rs2283476 A 0.147 0.148 0.156 0.5688 0.93 0.6186 0.94
syngr3 1983819 rs3183175 A 0.063 0.071 0.070 0.4954 0.88 0.9642 1.01
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HIC5 31391123 rs11646911 A 0.466 0.436 0.467 0.9430 0.99 0.1577 0.88
HIC5 31396534 rs13143 A 0.259 0.264 0.248 0.5865 1.06 0.4298 1.08
dopamineR
PP32 
35035375 rs879606 A 0.193 0.166 0.169 0.1676 1.18 0.8550 0.98
PPP1R9B 45563273 rs847682 A 0.475 0.479 0.490 0.5250 0.94 0.1591 0.88
PPP1R9B 45571943 rs1569116 A 0.142 0.144 0.136 0.6905 1.05 0.6030 1.07
PPP1R9B 45575583 rs4794103 A 0.180 0.177 0.164 0.3314 1.13 0.4281 1.10
PPP1R9B 45576919 rs12453363 A 0.157 0.179 0.139 0.2768 1.15 0.0156 1.35
PPP1R9B 45579074 rs847680 G 0.147 0.166 0.177 0.0701 0.80 0.4977 0.92
GRB2 70825380 rs17490675 G 0.049 0.061 0.067 0.0935 0.72 0.5902 0.91
GRB2 70826963 rs7219 G 0.239 0.253 0.274 0.0817 0.83 0.3045 0.90
GRB2 70839969 rs12600908 A 0.117 0.126 0.135 0.2113 0.84 0.5495 0.92
GRB2 70853307 rs4789172 G 0.454 0.486 0.491 0.1145 0.86 0.8265 0.98
GRB2 70855674 rs12950752 A 0.230 0.233 0.255 0.1944 0.87 0.2643 0.89
GRB2 70864463 rs4789176 A 0.159 0.165 0.187 0.1123 0.83 0.2134 0.86
GRB2 70867364 rs4350602 G 0.264 0.275 0.287 0.2446 0.89 0.5409 0.94
GRB2 70905054 rs2053158 A 0.169 0.184 0.206 0.0387 0.79 0.2162 0.87
SNAP25 10142678 rs8119844 A 0.293 0.274 0.304 0.5921 0.95 0.1444 0.87
SNAP25 10143433 rs6104567 C 0.263 0.245 0.244 0.3283 1.10 0.9790 1.00
SNAP25 10145086 rs1889189 A 0.323 0.355 0.326 0.8738 0.98 0.1764 1.14
SNAP25 10156748 rs3787303 G 0.174 0.188 0.161 0.4647 1.09 0.1141 1.21
SNAP25 10164902 rs363026 A 0.079 0.065 0.077 0.8665 1.03 0.3090 0.84
SNAP25 10165336 rs363011 G 0.089 0.118 0.083 0.6134 1.08 0.0104 1.47
SNAP25 10167799 rs363012 G 0.345 0.351 0.349 0.8660 0.98 0.9327 1.01
SNAP25 10168496 rs363039 A 0.358 0.317 0.343 0.4698 1.07 0.2280 0.89
SNAP25 10169467 rs363040 A 0.240 0.240 0.256 0.4091 0.92 0.4275 0.92
SNAP25 10174146 rs363043 A 0.288 0.288 0.325 0.0735 0.84 0.0714 0.84
SNAP25 10179174 rs363016 G 0.449 0.426 0.414 0.1067 1.15 0.5803 1.05
SNAP25 10183426 rs363052 A 0.207 0.215 0.214 0.6984 0.96 0.9450 1.01
SNAP25 10183926 rs3025866 A 0.029 0.023 0.024 0.4656 1.23 0.8637 0.95
SNAP25 10189811 rs363021 A 0.435 0.453 0.433 0.9422 1.01 0.3628 1.09
SNAP25 10191251 rs362563 G 0.049 0.064 0.041 0.3513 1.22 0.0209 1.61
SNAP25 10192626 rs362564 G 0.391 0.403 0.398 0.7346 0.97 0.8495 1.02
SNAP25 10193139 rs362547 A 0.422 0.425 0.447 0.2507 0.90 0.3236 0.91
SNAP25 10194091 rs362567 A 0.144 0.115 0.127 0.2493 1.16 0.4060 0.89
SNAP25 10194864 rs362570 A 0.196 0.180 0.166 0.0740 1.23 0.4046 1.10
SNAP25 10202475 rs362584 A 0.277 0.268 0.286 0.6478 0.96 0.3561 0.91
SNAP25 10217040 rs3025873 G 0.205 0.231 0.207 0.9306 0.99 0.1798 1.16
SNAP25 10217890 rs362549 G 0.476 0.495 0.491 0.5189 0.94 0.8347 1.02
SNAP25 10218925 rs362588 C 0.138 0.155 0.153 0.3174 0.88 0.8951 1.02
SNAP25 10224716 rs362993 A 0.089 0.101 0.081 0.4935 1.12 0.1101 1.28
SNAP25 10225621 rs362998 A 0.066 0.075 0.055 0.2659 1.23 0.0691 1.40
SNAP25 10228505 rs6108463 G 0.174 0.165 0.153 0.2033 1.16 0.4511 1.10
SNAP25 10229370 rs362988 A 0.480 0.436 0.451 0.1744 1.13 0.5061 0.94
SNAP25 10231950 rs6108464 G 0.409 0.378 0.380 0.1714 1.13 0.9330 0.99
SNAP25 10232418 rs3787283 G 0.360 0.328 0.348 0.5824 1.05 0.3426 0.91
SNAP25 10235742 rs8636 A 0.323 0.353 0.348 0.2356 0.89 0.8235 1.02
SNAP25 10238703 rs6074121 G 0.374 0.339 0.332 0.0531 1.20 0.7369 1.03
SNAP25 10239487 rs4813927 T 0.271 0.288 0.296 0.2313 0.89 0.7002 0.96
SNAP25 10239812 rs362599 C 0.340 0.352 0.352 0.5560 0.95 0.9856 1.00
SNAP25 10240769 rs6032846 G 0.398 0.413 0.414 0.4469 0.93 0.9622 1.00
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CLIC6 34982538 rs2236610 G 0.186 0.181 0.202 0.3520 0.90 0.2193 0.87
CLIC6 34991708 rs2834590 A 0.167 0.179 0.169 0.9147 0.99 0.5552 1.07
CLIC6 35002160 rs6517254 A 0.379 0.393 0.402 0.3184 0.91 0.6966 0.97
CLIC6 35002268 rs2070368 G 0.405 0.392 0.397 0.7235 1.03 0.8084 0.98
CLIC6 35007972 rs2834600 A 0.140 0.153 0.144 0.8385 0.97 0.5567 1.08
CLIC6 35010924 rs2834601 A 0.060 0.060 0.071 0.2999 0.83 0.3185 0.84
COMT 18307146 rs5748489 A 0.410 0.412 0.413 0.9170 0.99 0.9788 1.00
COMT 18308022 rs1800706 A 0.302 0.298 0.286 0.4392 1.08 0.5374 1.06
COMT 18310002 rs9306231 G 0.232 0.241 0.252 0.3167 0.90 0.5980 0.95
COMT 18310121 rs737865 G 0.304 0.301 0.284 0.3201 1.10 0.3897 1.09
COMT 18311407 rs933271 G 0.285 0.295 0.302 0.3949 0.92 0.7519 0.97
COMT 18313048 rs8185002 C 0.306 0.304 0.285 0.3256 1.10 0.3644 1.09
COMT 18313687 rs9332325 A 0.284 0.293 0.300 0.4262 0.93 0.7229 0.97
COMT 18314051 rs174675 A 0.284 0.293 0.300 0.4421 0.93 0.7229 0.97
COMT 18322484 rs9332347 A 0.121 0.130 0.136 0.2961 0.87 0.6810 0.95
COMT 18322997 rs5746849 A 0.468 0.465 0.464 0.8756 1.01 0.9851 1.00
COMT 18328337 rs4646312 G 0.407 0.396 0.415 0.7212 0.97 0.3845 0.92
COMT 18329644 rs3810595 G 0.411 0.400 0.423 0.5735 0.95 0.2822 0.91
COMT 18329952 rs6269 G 0.410 0.400 0.423 0.5451 0.95 0.2822 0.91
COMT 18330235 rs4633 G 0.485 0.492 0.496 0.6288 0.96 0.8781 0.99
COMT 18330428 rs2239393 G 0.410 0.400 0.423 0.5503 0.95 0.2857 0.91
COMT 18330763 rs740601 C 0.410 0.399 0.424 0.5189 0.94 0.2466 0.90
COMT 18331207 rs4818 C 0.406 0.392 0.416 0.6608 0.96 0.2747 0.91
COMT 18331271 rs4680 G 0.483 0.490 0.497 0.5373 0.95 0.7751 0.97
COMT 18331897 rs4646315 C 0.163 0.165 0.172 0.5967 0.94 0.6818 0.95
COMT 18332132 rs4646316 A 0.245 0.228 0.251 0.7680 0.97 0.2282 0.88
COMT 18332561 rs165774 A 0.332 0.315 0.308 0.2421 1.12 0.7358 1.03
COMT 18333176 rs174696 G 0.203 0.216 0.202 0.9679 1.01 0.4502 1.09
COMT 18333832 rs174697 A 0.054 0.055 0.049 0.6209 1.10 0.5358 1.13
COMT 18334458 rs174699 G 0.054 0.056 0.046 0.4024 1.18 0.2986 1.24
COMT 18335692 rs9332377 A 0.160 0.175 0.179 0.2738 0.88 0.8322 0.98
COMT 18336553 rs9332381 G 0.046 0.046 0.040 0.5238 1.15 0.4991 1.16
COMT 18336781 rs165599 G 0.306 0.340 0.304 0.9501 1.01 0.0847 1.18
COMT 18337023 rs165728 G 0.053 0.055 0.045 0.3924 1.19 0.2899 1.24
COMT 18337631 rs9265 C 0.306 0.339 0.305 0.9658 1.00 0.0969 1.17
COMT 18338669 rs165849 G 0.307 0.339 0.304 0.9046 1.01 0.0907 1.18
COMT 18339473 rs165815 G 0.138 0.156 0.125 0.3841 1.12 0.0441 1.30
ADRBK2 24261580 rs576895 G 0.259 0.252 0.275 0.4288 0.92 0.2591 0.89
ADRBK2 24264721 rs558934 G 0.280 0.290 0.296 0.4373 0.93 0.7712 0.97
ADRBK2 24280750 rs5761116 A 0.166 0.159 0.170 0.8031 0.97 0.4895 0.92
CACNG2 35288854 rs4820239 A 0.247 0.233 0.259 0.5309 0.94 0.1833 0.87
CACNG2 35306921 rs2267341 G 0.315 0.326 0.344 0.1721 0.88 0.3991 0.92
CACNG2 35316038 rs2283981 G 0.325 0.328 0.335 0.6020 0.95 0.7214 0.97
CACNG2 35322433 rs3788521 G 0.100 0.100 0.102 0.8741 0.98 0.9235 0.99
CACNG2 35338874 rs738977 A 0.226 0.227 0.246 0.2791 0.89 0.2987 0.90
CACNG2 35449746 rs738518 G 0.298 0.290 0.262 0.0740 1.20 0.1678 1.15
PICK1 36785415 rs713729 T 0.278 0.248 0.266 0.5575 1.06 0.3404 0.91
PICK1 36786544 rs3952 G 0.317 0.330 0.331 0.4923 0.94 0.9467 0.99
PICK1 36793598 rs2076369 A 0.373 0.394 0.375 0.9126 0.99 0.3927 1.08
PICK1 36803652 rs2012859 A 0.309 0.279 0.293 0.4427 1.08 0.4739 0.93
PICK1 36804642 rs2076371 A 0.256 0.272 0.263 0.7242 0.96 0.6714 1.04
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PICK1 36806222 rs8135665 A 0.193 0.217 0.219 0.1444 0.85 0.9112 0.99
MAOA 43411492 rs6520894 C 0.296 0.300 0.297 0.6536 0.99 0.9228 1.01
MAOA 43432254 rs5906957 A 0.255 0.255 0.243 0.8485 1.07 0.5921 1.07
MAOA 43436265 rs5906974 G 0.297 0.302 0.297 0.6861 1.00 0.8220 1.03
MAOA 43436344 rs3027392 A 0.045 0.029 0.030 0.2154 1.50 0.9044 0.96
MAOA 43438146 rs909525 G 0.328 0.326 0.324 0.8932 1.02 0.9211 1.01
MAOA 43477666 rs3027399 C 0.058 0.072 0.055 0.7881 1.05 0.1769 1.33
MAOA 43488335 rs1137070 A 0.301 0.302 0.308 0.5271 0.97 0.7863 0.97
MAOA 43489785 rs3027407 A 0.301 0.299 0.307 0.5718 0.97 0.7359 0.96
MAOB 43512943 rs1799836 G 0.455 0.445 0.421 0.0623 1.15 0.3602 1.10
MAOB 43536139 rs3027450 G 0.215 0.242 0.203 0.2903 1.07 0.0707 1.25
MAOB 43536455 rs2311013 A 0.043 0.052 0.044 0.4611 0.98 0.4519 1.20
MAOB 43559979 rs736944 A 0.165 0.151 0.178 0.9332 0.91 0.1593 0.82
MAOB 43562986 rs2283729 A 0.274 0.286 0.231 0.0255 1.26 0.0136 1.34
MAOB 43573908 rs6651806 C 0.284 0.304 0.243 0.0570 1.23 0.0079 1.36
MAOB 43588734 rs4824562 G 0.156 0.140 0.166 0.7147 0.93 0.1634 0.82
MAOB 43611338 rs5905512 G 0.505 0.495 0.475 0.0189 1.13 0.4448 1.08
FLNA 153231493 rs2070819 G 0.090 0.105 0.119 0.5685 0.73 0.3762 0.87
FLNA 153248612 rs2070816 G 0.196 0.211 0.199 0.4019 0.98 0.5663 1.08
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Table 18 Supplementary Table 6.3: Hotellings T2 for all Genes 
  Schizophrenia Bipolar Disorder 
Gene SNPs T2 DF1 DF2 P_Hotel
EMP-
P T2 DF1 DF2 P_Hotel 
EMP-
P 
ADRBK2 3 0.39 3 1000 0.757 0.756 0.48 3 996 0.694 0.700 
CACNG2 6 1.33 6 997 0.242 0.247 1.07 6 993 0.379 0.374 
CLIC6 6 0.35 5 998 0.879 0.881 0.55 5 994 0.736 0.734 
COMT 31 0.68 15 988 0.804 0.804 0.94 14 985 0.511 0.518 
COPG2 6 0.47 5 998 0.801 0.801 0.72 5 994 0.610 0.615 
DARPP32 1 1.90 1 1002 0.168 0.179 0.03 1 998 0.855 0.849 
DBH 29 0.88 20 983 0.616 0.617 0.65 20 979 0.877 0.878 
DDC 38 0.99 15 988 0.465 0.391 0.77 15 984 0.712 0.708 
DRD1 5 1.02 4 999 0.395 0.400 0.13 5 994 0.985 0.988 
DRD1IP 3 2.20 3 1000 0.086 0.090 2.40 3 996 0.067 0.063 
DRD2 21 1.01 12 991 0.438 0.433 0.63 12 987 0.819 0.813 
DRD3 20 2.35 9 994 0.013 0.007 2.09 10 989 0.023 0.013 
DRD4 2 0.29 2 1001 0.750 0.745 2.36 2 997 0.095 0.095 
DRD5 1 0.28 1 1002 0.596 0.597 0.32 1 998 0.572 0.577 
DRIP78 1 0.59 1 1002 0.444 0.496 0.00 1 998 0.962 1.000 
EPB41 15 0.60 10 993 0.811 0.818 1.55 10 989 0.115 0.109 
FLNA 2 2.93 2 1001 0.054 0.060 1.63 2 997 0.197 0.208 
FREQ 21 0.74 18 985 0.774 0.776 1.08 18 981 0.373 0.376 
GNB2L1 4 1.71 4 999 0.145 0.150 0.99 4 995 0.412 0.419 
GRB2 8 0.92 7 996 0.489 0.373 0.58 5 994 0.715 0.715 
GRK2 2 0.40 2 1001 0.668 0.671 0.80 2 997 0.451 0.447 
Hey1 7 0.16 7 996 0.993 0.992 1.52 7 992 0.158 0.156 
HIC5 2 0.19 2 1001 0.828 0.828 1.03 2 997 0.356 0.360 
MAOA 8 1.17 5 998 0.323 0.336 0.93 5 994 0.463 0.481 
MAOB 8 1.28 6 997 0.266 0.268 1.24 6 993 0.283 0.296 
NCK1 6 0.37 4 999 0.832 0.826 0.11 4 995 0.977 0.977 
NEF3 8 1.14 8 995 0.337 0.342 1.21 8 991 0.288 0.286 
NR4A2 2 0.39 2 1001 0.680 0.682 0.43 2 997 0.649 0.643 
PICK1 6 0.61 5 998 0.694 0.697 0.26 5 994 0.937 0.931 
PPP1R9B 5 1.04 5 998 0.394 0.396 1.89 5 994 0.093 0.095 
PPP2CA 1 0.40 1 1002 0.527 0.566 0.00 1 998 0.967 1.000 
SLC18A1 22 0.72 14 989 0.754 0.761 1.46 14 985 0.119 0.113 
SLC18A2 18 1.03 16 987 0.425 0.420 1.06 16 983 0.388 0.393 
SLC6A3 44 1.00 24 979 0.470 0.479 0.73 23 976 0.820 0.818 
SNAP25 34 1.10 25 978 0.333 0.334 1.06 25 974 0.381 0.375 
SNCA 12 0.62 8 995 0.759 0.753 0.77 7 992 0.615 0.614 
Sp4 3 2.05 3 1000 0.106 0.105 0.09 3 996 0.965 0.963 
STX1A 2 0.57 2 1001 0.564 0.572 0.05 2 997 0.951 0.956 
syngr3 2 0.43 2 1001 0.652 0.650 0.13 2 997 0.881 0.885 
TH 7 1.29 7 996 0.254 0.247 1.28 7 992 0.258 0.252 
Test statistics for all gene-based tests provided.  P_Hotel = asymptotic p-value, EMP_P = 
empirical p-value from permutation. 
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Table 19 Supplementary Table 6.4: Most significant shared interactions 
Gene Pair SNP pair 
SZ/SZA 
Ineraction 
p-value 
SZ/SZA 
OR 
BP1 
Interaction 
p-value 
BP1 
OR 
SLC6A3*COMT rs1042098*rs9332347 0.004102 1.86 0.005004 1.83 
SLC6A3*COMT rs37022*rs5746849 0.008311 0.64 0.004138 0.61 
SLC6A3*COMT rs37022*rs3810595 0.008486 1.60 0.000169 1.95 
SLC6A3*DDC rs27072*rs1451372 0.001076 1.85 0.001355 1.80 
SLC6A3*DDC rs27072*rs730092 0.002693 1.75 0.002664 1.71 
SLC6A3*DDC rs11133770*rs1451372 0.003083 0.60 0.008423 0.64 
SNCA*SLC6A3 rs2737020*rs40184 0.000918 1.68 0.000096 1.81 
SNCA*SLC6A3 rs2737020*rs2963238 0.006455 1.54 0.009120 1.47 
SNCA*SLC6A3 rs2737020*rs2937639 0.006456 1.55 0.005345 1.51 
DDC*DRD2 rs4602840*rs6279 0.000067 0.33 0.002460 0.48 
DDC*DRD2 rs11575548*rs6279 0.000116 0.34 0.001245 0.45 
DDC*DRD2 rs4490786*rs6279 0.000774 0.53 0.001788 0.57 
DDC*DRD2 rs11575500*rs6279 0.000826 0.35 0.008439 0.48 
DDC*DRD2 rs11575500*rs1124492 0.001188 0.23 0.005118 0.36 
DDC*DRD2 rs11575553*rs6279 0.001324 0.39 0.002275 0.43 
DDC*DRD2 rs11575500*rs4620755 0.001455 0.23 0.005583 0.37 
DDC*DRD2 rs11575322*rs6279 0.002127 0.43 0.002607 0.47 
DDC*DRD2 rs11575286*rs6279 0.002127 0.43 0.003174 0.48 
DDC*DRD2 rs4602840*rs4620755 0.002152 0.31 0.000542 0.31 
DDC*DRD2 rs11575548*rs4586205 0.002337 0.42 0.008537 0.52 
DDC*DRD2 rs11575548*rs4620755 0.003006 0.32 0.000272 0.28 
DDC*DRD2 rs4602840*rs1124492 0.003031 0.33 0.000835 0.32 
DDC*DRD2 rs11575548*rs1124492 0.004239 0.34 0.000433 0.29 
DDC*DRD2 rs4602840*rs7125415 0.004374 0.30 0.000870 0.26 
DDC*DRD2 rs11575500*rs7125415 0.005641 0.24 0.007194 0.30 
DDC*DRD2 rs11575548*rs7125415 0.006342 0.31 0.000390 0.21 
DDC*DRD2 rs3807558*rs4274224 0.007916 1.50 0.000106 1.88 
DDC*DRD2 rs745043*rs4274224 0.008410 1.50 0.000082 1.90 
DDC*DRD2 rs2044859*rs4274224 0.008429 1.41 0.009260 1.40 
DRD3*SLC18A1 rs12636133*rs1390939 0.001761 0.67 0.009201 0.72 
DRD3*SLC18A1 rs2046496*rs1390939 0.009455 1.40 0.005784 1.41 
DRD3*SNCA rs324035*rs356165 0.007760 1.59 0.005575 1.60 
COPG2*DBH rs3857855*rs1108580 0.001617 1.73 0.001275 1.81 
COPG2*DBH rs3857855*rs1541333 0.002250 1.70 0.004060 1.69 
COPG2*DBH rs3857855*rs2519154 0.002430 1.69 0.009847 1.62 
COPG2*DBH rs10954272*rs1076150 0.006521 1.53 0.004382 1.59 
COPG2*DBH rs10954272*rs1108580 0.007224 1.50 0.004646 1.55 
COPG2*DBH rs3857855*rs1541332 0.007514 1.59 0.007709 1.61 
COPG2*DBH rs3857855*rs1076150 0.007574 1.61 0.006381 1.70 
COPG2*DBH rs10954272*rs1541333 0.007772 1.49 0.009245 1.50 
DBH*COMT rs129884*rs4633 0.004273 0.62 0.008398 0.64 
DBH*COMT rs129884*rs4680 0.004626 0.62 0.007568 0.64 
DBH*GRK2 rs1108580*rs2071007 0.004761 0.49 0.001629 0.44 
DBH*SNAP25 rs129884*rs362549 0.000790 1.79 0.003504 1.64 
 182
Table 19 Continued 
DDC*DBH rs1451372*rs77905 0.000458 1.61 0.001339 1.54 
DDC*DBH rs1451372*rs129883 0.000769 1.64 0.005606 1.49 
DDC*DBH rs3807558*rs77905 0.001997 1.63 0.000812 1.72 
DDC*DBH rs3779078*rs77905 0.002108 1.63 0.003823 1.61 
DDC*DBH rs745043*rs77905 0.002535 1.61 0.001556 1.66 
DDC*DBH rs3807558*rs6479643 0.004665 0.63 0.002786 0.62 
DDC*DBH rs4470989*rs77905 0.005641 1.48 0.006906 1.47 
DDC*DBH rs745043*rs6479643 0.006343 0.64 0.005084 0.64 
DDC*DBH rs3735273*rs77905 0.007694 1.50 0.007153 1.52 
DDC*DBH rs3779078*rs6479643 0.008044 0.65 0.008674 0.65 
DRD2*PPP1R9B rs2234689*rs4794103 0.003995 0.54 0.001841 0.50 
DRD2*SNAP25 rs4274224*rs3025873 0.000224 0.56 0.001435 0.61 
DRD2*SNAP25 rs17601612*rs3025873 0.000824 0.56 0.006590 0.64 
DRD2*SNAP25 rs4630328*rs362588 0.001034 0.51 0.006193 0.58 
DRD2*SNAP25 rs4274224*rs362584 0.001533 1.58 0.002642 1.55 
DRD2*SNAP25 rs4630328*rs3025873 0.001698 0.59 0.005333 0.63 
DRD2*SNAP25 rs17529477*rs3025873 0.006320 0.62 0.001273 0.58 
EPB41*COMT rs203278*rs174696 0.001033 0.58 0.000444 0.56 
EPB41*COMT rs150089*rs174696 0.002086 0.59 0.001959 0.60 
EPB41*COMT rs575675*rs4646312 0.007096 1.86 0.003522 2.02 
EPB41*COMT rs575675*rs4818 0.008664 1.83 0.007585 1.89 
EPB41*COPG2 rs150093*rs10954272 0.000775 0.46 0.009857 0.56 
EPB41*COPG2 rs126013*rs10954272 0.004940 0.65 0.000676 0.60 
EPB41*COPG2 rs10915216*rs10954272 0.006974 1.51 0.009130 0.67 
EPB41*DBH rs2762682*rs1611118 0.003655 0.36 0.007147 0.41 
FREQ*TH rs3829905*rs3842748 0.006040 0.65 0.000185 0.56 
GNB2L1*syngr3 rs2261114*rs3183175 0.000727 2.47 0.007557 1.96 
GRK2*COMT rs2071007*rs174696 0.002992 0.43 0.001723 0.41 
HIC5*SNAP25 rs11646911*rs362998 0.005128 2.34 0.000700 2.76 
HIC5*SNAP25 rs11646911*rs362563 0.005143 2.71 0.002875 2.75 
NCK1*SLC18A2 rs9845460*rs363226 0.006039 0.62 0.004956 0.60 
NEF3*SLC18A2 rs196868*rs363238 0.001658 3.82 0.006270 3.13 
NEF3*SLC18A2 rs196868*rs363224 0.007843 1.78 0.003565 1.89 
NR4A2*SNAP25 rs12803*rs8636 0.002733 0.67 0.000473 0.61 
SLC18A1*ADRBK2 rs2270641*rs558934 0.007900 0.67 0.004438 0.65 
SLC18A1*ADRBK2 rs2270642*rs558934 0.008610 0.67 0.002566 0.63 
SLC18A1*DBH rs3779672*rs3025373 0.000273 2.30 0.005648 1.94 
SLC18A1*DRD2 rs2270642*rs12364283 0.004614 2.21 0.007881 2.05 
SLC18A1*FREQ rs3779672*rs4424362 0.000105 2.05 0.002116 1.83 
SLC18A1*FREQ rs17092104*rs2277200 0.005870 1.86 0.008970 1.89 
SLC18A1*FREQ rs3779672*rs3824544 0.006086 1.71 0.004677 1.81 
SNCA*TH rs3822095*rs6356 0.000052 1.84 0.000119 1.70 
SNCA*TH rs3822095*rs7119275 0.000215 0.58 0.001377 0.64 
TH*PICK1 rs3842748*rs3952 0.000271 0.56 0.003976 0.64 
SNP pairs provided where interaction p < 0.001 in both disorders.  OR = odds ratio. No 
interaction tests significant after corrections for multiple comparisons
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Table 20 Supplementary Table 6.5: Most significant diagnosis specific interactions 
SCHIZOPHRENIA 
gene-pair SNP pair 
Main 
Effect 
SNP1 
Main 
Effect 
SNP2 
SZ/SZA 
Ineraction 
p-value 
SZ/SZA 
OR 
SLC18A2*COMT rs11197936*rs5748489 0.249 0.975 0.000234 0.60 
SLC6A3*DBH rs37022*rs129915 0.518 0.610 0.000343 1.92 
SLC6A3*DBH rs37022*rs1611131 0.518 0.901 0.000505 1.92 
SLC6A3*DBH rs11564764*rs1611123 0.729 0.524 0.000593 2.54 
SLC6A3*DBH rs28363119*rs2797855 0.942 0.839 0.000598 2.62 
SLC6A3*DBH rs11564764*rs2797855 0.729 0.839 0.000750 2.59 
SLC6A3*DBH rs11564764*rs1108580 0.729 0.845 0.000786 0.41 
SLC6A3*DBH rs28363119*rs1611123 0.942 0.524 0.000854 2.44 
SLC6A3*DBH rs6869645*rs1611123 0.810 0.524 0.000902 2.43 
SLC6A3*DBH rs6876225*rs1611123 0.738 0.524 0.000918 2.43 
SLC6A3*HIC5 rs2078247*rs13143 0.662 0.657 0.000133 0.52 
SLC6A3*HIC5 rs2455391*rs13143 0.821 0.657 0.000252 0.54 
SLC6A3*TH rs6347*rs10743149 0.826 0.098 0.000537 2.29 
DDC*DRD2 rs4602840*rs6279 0.628 0.705 0.000067 0.33 
DDC*DRD2 rs11575548*rs6279 0.564 0.705 0.000116 0.34 
DDC*DRD2 rs11575453*rs17529477 0.705 0.037 0.000279 0.36 
DDC*DRD2 rs11575438*rs17529477 0.705 0.037 0.000279 0.36 
DDC*DRD2 rs4490786*rs6279 0.893 0.705 0.000774 0.53 
DDC*DRD2 rs11575500*rs6279 0.416 0.705 0.000826 0.35 
DDC*COMT rs2044859*rs9265 0.505 0.981 0.000108 0.57 
DDC*COMT rs2044859*rs165599 0.505 0.997 0.000109 0.57 
DDC*COMT rs2044859*rs165849 0.505 0.957 0.000177 0.58 
DDC*COMT rs3735273*rs9265 0.141 0.981 0.000184 0.52 
DDC*COMT rs3735273*rs165599 0.141 0.997 0.000223 0.53 
DDC*COMT rs3735273*rs165849 0.141 0.957 0.000354 0.54 
DDC*COMT rs7786398*rs9265 0.551 0.981 0.000893 0.62 
DDC*COMT rs7786398*rs165599 0.551 0.997 0.000990 0.62 
DDC*DBH rs11575322*rs2797853 0.911 0.286 0.000239 2.75 
DDC*DBH rs11575286*rs2797853 0.911 0.286 0.000239 2.75 
DDC*DBH rs1451372*rs77905 0.067 0.177 0.000458 1.61 
DDC*DBH rs1451372*rs129883 0.067 0.931 0.000769 1.64 
COPG2*SLC18A2 rs3857855*rs363343 0.652 0.073 0.000631 0.44 
DBH*SNAP25 rs129884*rs362549 0.618 0.496 0.000790 1.79 
DDC*ADRBK2 rs4602840*rs558934 0.628 0.518 0.000346 2.61 
DDC*ADRBK2 rs11575548*rs558934 0.564 0.518 0.000427 2.61 
DRD1*DBH rs5326*rs2007153 0.234 0.541 0.000638 0.51 
DRD1*PICK1 rs267416*rs8135665 0.847 0.150 0.000112 0.53 
DRD1*PICK1 rs4867798*rs2012859 0.095 0.455 0.000838 0.61 
DRD1*TH rs5326*rs2070762 0.234 0.110 0.000166 0.51 
DRD1IP*PICK1 rs11101694*rs2076371 0.012 0.722 0.000250 0.45 
DRD2*SNAP25 rs4274224*rs3025873 0.078 0.987 0.000224 0.56 
DRD2*SNAP25 rs17601612*rs362588 0.055 0.376 0.000640 0.50 
DRD2*SNAP25 rs17601612*rs3025873 0.055 0.987 0.000824 0.56 
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DRD3*SLC18A1 rs12636133*rs2270642 0.023 0.770 0.000616 1.59 
DRD3*SLC18A1 rs12636133*rs2270641 0.023 0.860 0.000639 1.58 
DRD3*SLC18A1 rs963468*rs2270642 0.030 0.770 0.000783 1.57 
DRD3*SLC18A1 rs963468*rs2270641 0.030 0.860 0.000878 1.56 
DRD3*SLC18A1 rs10934254*rs2270642 0.035 0.770 0.000956 1.56 
DRD3*SLC18A1 rs3732790*rs2270642 0.033 0.770 0.000998 1.55 
DRD3*SLC18A1 rs10934254*rs2270641 0.035 0.860 0.000999 1.56 
EPB41*CACNG2 rs575675*rs2267341 0.165 0.164 0.000805 0.43 
EPB41*CACNG2 rs150089*rs2267341 0.272 0.164 0.000870 0.62 
EPB41*COPG2 rs150093*rs3857855 0.847 0.652 0.000387 0.37 
EPB41*COPG2 rs150093*rs10954272 0.847 0.521 0.000775 0.46 
EPB41*COPG2 rs150093*rs10954274 0.847 0.497 0.000888 0.18 
EPB41*DBH rs10915216*rs129882 0.713 0.203 0.000604 1.74 
EPB41*DBH rs126013*rs129882 0.322 0.203 0.000817 0.56 
FREQ*COMT rs10819611*rs9332377 0.226 0.242 0.000564 1.96 
FREQ*DBH rs4424362*rs1611131 0.122 0.901 0.000174 0.56 
FREQ*DBH rs4424362*rs2073837 0.122 0.989 0.000302 0.58 
FREQ*DBH rs4424362*rs129915 0.122 0.610 0.000620 0.59 
FREQ*PICK1 rs11552451*rs2012859 0.487 0.455 0.000090 0.44 
FREQ*PICK1 rs11552451*rs713729 0.487 0.532 0.000613 0.49 
FREQ*SNAP25 rs3824544*rs4813927 0.440 0.265 0.000605 1.79 
FREQ*SNAP25 rs11552451*rs362549 0.487 0.496 0.000994 1.84 
GNB2L1*syngr3 rs2261114*rs3183175 0.327 0.468 0.000727 2.47 
GNB2L1*TH rs2261114*rs3842748 0.327 0.854 0.000750 1.62 
Hey1*DRD2 rs2461056*rs7131056 0.952 0.037 0.000930 1.82 
SLC18A1*DBH rs3779672*rs3025373 0.824 0.636 0.000273 2.30 
SLC18A1*DBH rs3779673*rs3025373 0.497 0.636 0.000393 2.35 
SLC18A1*FREQ rs17092104*rs4424362 0.490 0.122 0.000076 2.66 
SLC18A1*FREQ rs3779672*rs4424362 0.824 0.122 0.000105 2.05 
SLC18A1*FREQ rs17092104*rs10819611 0.490 0.226 0.000288 2.39 
SLC18A1*FREQ rs3779673*rs4424362 0.497 0.122 0.000335 2.03 
SLC18A1*FREQ rs3779672*rs10819611 0.824 0.226 0.000457 1.89 
SLC18A1*FREQ rs17092107*rs10819611 0.773 0.226 0.000486 2.35 
SLC18A1*FREQ rs17092107*rs4424362 0.773 0.122 0.000604 2.36 
SLC18A1*FREQ rs17092107*rs3829905 0.773 0.156 0.000978 2.15 
SLC18A1*FREQ rs3779673*rs10819611 0.497 0.226 0.000997 1.89 
SLC18A1*PPP1R9B rs903997*rs12453363 0.470 0.235 0.000976 0.48 
SNAP25*CLIC6 rs363043*rs2834590 0.086 0.855 0.000274 2.02 
SNAP25*CLIC6 rs3025873*rs2834590 0.987 0.855 0.000599 2.15 
SNAP25*COMT rs6104567*rs737865 0.330 0.352 0.000042 0.51 
SNAP25*COMT rs6104567*rs1800706 0.330 0.477 0.000114 0.53 
SNAP25*COMT rs6104567*rs8185002 0.330 0.358 0.000139 0.53 
SNAP25*COMT rs8119844*rs737865 0.646 0.352 0.000416 1.77 
SNAP25*COMT rs8119844*rs1800706 0.646 0.477 0.000501 1.75 
SNAP25*COMT rs363016*rs737865 0.111 0.352 0.000642 0.60 
SNAP25*COMT rs363016*rs1800706 0.111 0.477 0.000713 0.60 
SNCA*DRD1IP rs17016274*rs11101694 0.822 0.012 0.000529 3.62 
SNCA*FREQ rs356186*rs870811 0.527 0.842 0.000572 0.56 
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SNCA*FREQ rs356186*rs947513 0.527 0.222 0.000576 0.56 
SNCA*SLC6A3 rs2737020*rs40184 0.424 0.911 0.000918 1.68 
SNCA*TH rs3822095*rs6356 0.255 0.974 0.000052 1.84 
SNCA*TH rs3822095*rs7119275 0.255 0.933 0.000215 0.58 
TH*PICK1 rs3842748*rs3952 0.854 0.505 0.000271 0.56 
TH*PICK1 rs10743149*rs2076369 0.098 0.879 0.000617 0.46 
BIPOLAR DISORDER 
gene-pair SNP pair 
Main 
Effect 
SNP1 
Main 
Effect 
SNP2 
BP1 
Interaction 
p-value 
BP1 
OR 
SLC6A3*COMT rs37022*rs4818 0.827 0.268 0.000051 2.07 
SLC6A3*COMT rs37022*rs4646312 0.827 0.376 0.000065 2.05 
SLC6A3*COMT rs37022*rs3810595 0.827 0.274 0.000169 1.95 
SLC6A3*COMT rs37022*rs6269 0.827 0.274 0.000169 1.95 
SLC6A3*COMT rs37022*rs2239393 0.827 0.278 0.000173 1.95 
SLC6A3*COMT rs37022*rs740601 0.827 0.239 0.000264 1.91 
SLC6A3*COMT rs464061*rs4818 0.510 0.268 0.000929 1.76 
SLC6A3*COMT rs464061*rs4646312 0.510 0.376 0.000936 1.76 
DDC*DRD2 rs745043*rs4274224 0.005 0.583 0.000082 1.90 
DDC*DRD2 rs3807558*rs4274224 0.010 0.583 0.000106 1.88 
DDC*DRD2 rs11575553*rs4620755 0.168 0.733 0.000189 0.22 
DDC*DRD2 rs11575548*rs4620755 0.042 0.733 0.000272 0.28 
DDC*DRD2 rs3735273*rs4274224 0.003 0.583 0.000324 1.76 
DDC*DRD2 rs11575548*rs7125415 0.042 0.325 0.000390 0.21 
DDC*DRD2 rs3779078*rs4274224 0.005 0.583 0.000417 1.78 
DDC*DRD2 rs11575548*rs1124492 0.042 0.793 0.000433 0.29 
DDC*DRD2 rs3779078*rs4630328 0.005 0.652 0.000497 1.78 
DDC*DRD2 rs4602840*rs4620755 0.054 0.733 0.000542 0.31 
DDC*DRD2 rs11575553*rs7125415 0.168 0.325 0.000546 0.19 
DDC*DRD2 rs11575553*rs1124492 0.168 0.793 0.000584 0.25 
DDC*DRD2 rs11575500*rs4936270 0.059 0.867 0.000692 0.24 
DDC*DRD2 rs3807558*rs4630328 0.010 0.652 0.000701 1.74 
DDC*DRD2 rs745043*rs4630328 0.005 0.652 0.000718 1.74 
DDC*DRD2 rs3779078*rs17601612 0.005 0.640 0.000797 1.74 
DDC*DRD2 rs4602840*rs1124492 0.054 0.793 0.000835 0.32 
DDC*DRD2 rs3807558*rs17601612 0.010 0.640 0.000851 1.72 
DDC*DRD2 rs745043*rs17601612 0.005 0.640 0.000856 1.72 
DDC*DRD2 rs4602840*rs7125415 0.054 0.325 0.000870 0.26 
DDC*DRD2 rs11575500*rs4581480 0.059 0.702 0.000945 0.25 
DDC*DRD2 rs3807558*rs17529477 0.010 0.610 0.001000 1.75 
COPG2*DBH rs13241924*rs3025382 0.404 0.331 0.000803 0.53 
DDC*CACNG2 rs3807563*rs2267341 0.358 0.402 0.000239 1.69 
DDC*DBH rs3807558*rs77905 0.010 0.628 0.000812 1.72 
DDC*SLC18A2 rs1451371*rs363399 0.183 0.196 0.000070 0.52 
DDC*SLC18A2 rs1451371*rs363338 0.183 0.747 0.000215 0.58 
DDC*SLC18A2 rs3807562*rs363399 0.298 0.196 0.000825 0.58 
DRD3*DDC rs2046496*rs11575453 0.017 0.799 0.000999 2.16 
 186
Table 20 Continued      
DRD3*DDC rs2046496*rs11575438 0.017 0.799 0.000999 2.16 
EPB41*COMT rs203278*rs174696 0.209 0.460 0.000444 0.56 
EPB41*COMT rs575675*rs174696 0.024 0.460 0.000489 0.36 
EPB41*COPG2 rs126013*rs10954272 0.177 0.574 0.000676 0.60 
EPB41*COPG2 rs126013*rs13241924 0.177 0.404 0.000820 0.65 
NR4A2*Hey1 rs834834*rs6473177 0.836 0.090 0.000465 0.41 
NR4A2*SNAP25 rs12803*rs8636 0.429 0.821 0.000473 0.61 
SLC6A3*NEF3 rs37022*rs196864 0.827 0.944 0.000569 3.54 
SLC6A3*SLC18A1 rs12516758*rs7820517 1.000 0.066 0.000739 0.48 
SNCA*Hey1 rs10002435*rs2461056 0.415 0.791 0.000643 0.34 
SNCA*SLC6A3 rs2737020*rs40184 0.159 0.238 0.000096 1.81 
SNCA*TH rs3822095*rs6356 0.192 0.094 0.000119 1.70 
SNP pairs provided where interaction p < 0.001 in either disorder.  Main effect = result of 
Armitage Trends test for individual SNP.  OR = odds ratio. No interaction tests significant after 
corrections for multiple comparisons
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Table 21 Supplementary Table 6.7: Exploratory analyses for DRD3 and DDC 
  Overall  Gender Specific Analyses Diagnosis specific analyses 
gene SNP 
pval 
(SZ) 
pval 
(BP1) 
Strat     
pval (SZ) 
Strat     
pval 
(BP1) 
Male   
pval 
(SZ) 
 Male 
OR 
(SZ) 
Female 
pval (SZ) 
Female 
OR (SZ)
SZ only   
(pval) 
SZA only 
(pval) 
BP1 + 
psych 
BP1 No 
psych 
DRD3 rs2046496 0.0345 0.0166 0.0423 0.0149 0.3866 1.11 0.0368 1.33 0.0773 0.0904 0.0143 0.5154 
DRD3 rs12636133 0.0239 0.0092 0.0301 0.0083 0.4595 0.91 0.0147 0.71 0.0613 0.0705 0.0137 0.1199 
DRD3 rs10934254 0.0367 0.0092 0.0446 0.0093 0.5532 0.93 0.0182 0.72 0.1048 0.0705 0.0137 0.1528 
DRD3 rs9868039 0.0039 0.0017 0.0032 0.0014 0.1102 1.22 0.0082 1.44 0.0027 0.1175 0.0010 0.4615 
DRD3 rs9817063 0.0123 0.0032 0.0086 0.0035 0.2455 0.87 0.0078 0.69 0.0202 0.0859 0.0042 0.1728 
DRD3 rs3732790 0.0334 0.0117 0.0366 0.0096 0.7359 0.96 0.0054 0.68 0.0375 0.1935 0.0179 0.1304 
DRD3 rs2134655 0.0080 0.0052 0.0065 0.0056 0.3272 1.15 0.0029 1.59 0.0075 0.1100 0.0036 0.8739 
DRD3 rs963468 0.0302 0.0082 0.0336 0.0076 0.6270 0.94 0.0077 0.69 0.0388 0.1645 0.0146 0.1434 
DRD3 rs324035 0.4879 0.8727 0.5898 0.8838 0.5932 1.08 0.8349 1.04 0.7456 0.3745 0.8677 0.1733 
DRD3 rs2630351 0.2630 0.1154 0.3788 0.1557 0.1747 1.41 0.8007 0.93 0.5585 0.1586 0.3912 0.02643
DRD3 rs167771 0.4593 0.6263 0.5956 0.6244 0.5000 1.11 0.9755 1.01 0.5922 0.4784 0.8919 0.1337 
DRD3 rs324032 0.1492 0.0818 0.2351 0.1148 0.1059 1.50 0.9362 0.98 0.3380 0.1156 0.2815 0.02643
DRD3 rs167770 0.2323 0.2301 0.2159 0.2609 0.1336 0.82 0.8689 0.98 0.2698 0.4104 0.2482 0.7912 
DRD3 rs226082 0.2537 0.2489 0.2444 0.2807 0.1200 0.81 0.9952 1.00 0.3374 0.3613 0.2482 0.6827 
DRD3 rs324030 0.2537 0.2489 0.2444 0.2807 0.1200 0.81 0.9952 1.00 0.3374 0.3613 0.2482 0.6827 
DRD3 rs7625282 0.0575 0.0726 0.0527 0.0892 0.0372 0.75 0.5789 0.92 0.0477 0.3092 0.0533 0.6532 
DRD3 rs10934256 0.0355 0.1322 0.0444 0.1470 0.0281 0.72 0.5837 0.91 0.0317 0.2435 0.0948 0.6067 
DRD3 rs7633291 0.0463 0.1467 0.0578 0.1621 0.0331 0.73 0.6525 0.93 0.0470 0.2435 0.0948 0.4985 
DRD3 rs6280 0.5569 0.6806 0.4866 0.6872 0.2817 0.87 0.8619 1.03 0.5934 0.6767 0.5691 0.3388 
DRD3 rs1800828 0.1651 0.5234 0.1601 0.5121 0.1154 0.80 0.7411 0.95 0.1163 0.5581 0.3316 0.271 
DDC rs11575564 0.0602 0.7525 0.0951 0.7327 0.1742 1.51 0.3267 1.41 0.2594 0.0267 0.7739 0.5501 
DDC rs4947510 0.2989 0.2375 0.3197 0.2542 0.2170 0.85 0.9204 0.99 0.4848 0.2925 0.4082 0.6053 
DDC rs11575553 0.9700 0.1576 0.7312 0.1504 0.3335 0.82 0.4630 1.23 0.9412 0.9810 0.0441 0.5413 
DDC rs11575548 0.5770 0.0399 0.8216 0.0342 0.2693 0.80 0.0731 1.58 0.6213 0.6710 0.0031 0.3877 
DDC rs11575542 0.3810 0.5460 0.2749 0.4867 0.6779 1.21 0.2753 1.56 0.3840 0.5847 0.5986 0.4619 
DDC rs4947535 0.0339 0.0325 0.0532 0.0292 0.3043 0.88 0.0792 0.77 0.1027 0.0591 0.0078 0.9468 
DDC rs11575535 0.2255 0.5405 0.1810 0.4892 0.3410 1.46 0.3468 1.42 0.1502 0.6628 0.5066 0.8114 
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DDC rs730092 0.1248 0.2787 0.1528 0.2625 0.1470 0.84 0.6040 0.93 0.2508 0.1564 0.3192 0.5645 
DDC rs11575500 0.4383 0.0637 0.5005 0.0536 0.7402 0.93 0.1475 1.50 0.4517 0.6084 0.0080 0.4719 
DDC rs745043 0.0243 0.0037 0.0448 0.0037 0.1278 0.80 0.1909 0.81 0.0697 0.0594 0.0046 0.5208 
DDC rs4490786 0.8721 0.0592 0.9104 0.0685 0.7111 0.95 0.7893 1.05 0.7379 0.8922 0.0558 0.9236 
DDC rs11575453 0.7460 0.7190 0.6849 0.8167 0.6729 1.09 0.2664 0.76 0.9644 0.4941 0.6079 0.4463 
DDC rs11575441 0.7219 0.6546 0.8978 0.7057 0.7267 1.19 0.7903 0.83 0.4520 0.7216 0.8074 0.9045 
DDC rs1451371 0.2400 0.1927 0.3190 0.1801 0.3243 1.13 0.6972 1.06 0.1379 0.7552 0.1681 0.6151 
DDC rs11575438 0.7460 0.7190 0.6849 0.8167 0.6729 1.09 0.2664 0.76 0.9644 0.4941 0.6079 0.4463 
DDC rs1451372 0.0622 0.3277 0.0671 0.3255 0.1080 0.82 0.3444 0.88 0.1694 0.0783 0.3684 0.5777 
DDC rs4470989 0.0275 0.0284 0.0439 0.0260 0.3300 0.88 0.0526 0.75 0.1063 0.0376 0.0053 0.9016 
DDC rs4602840 0.6406 0.0513 0.9077 0.0443 0.3319 0.83 0.1480 1.44 0.7726 0.6082 0.0063 0.4511 
DDC rs6957607 0.8475 0.7164 0.7338 0.8180 0.5756 1.13 0.2302 0.73 0.8517 0.5336 0.6275 0.3532 
DDC rs3807563 0.8091 0.3693 0.9546 0.3623 0.9336 1.01 0.9931 1.00 0.6131 0.8451 0.2023 0.7971 
DDC rs3807562 0.1768 0.3140 0.2154 0.2991 0.3486 1.12 0.4179 1.12 0.1074 0.6356 0.2616 0.8751 
DDC rs11575387 0.7925 0.8888 0.6855 0.9907 0.6949 1.09 0.2718 0.75 0.8810 0.4778 0.6125 0.6158 
DDC rs3807558 0.0365 0.0079 0.0663 0.0080 0.1506 0.81 0.2505 0.83 0.0997 0.0717 0.0104 0.561 
DDC rs11575375 0.5059 0.2259 0.5016 0.2779 0.8013 1.03 0.4659 1.11 0.9683 0.2297 0.2528 0.9477 
DDC rs4947584 0.4817 0.1799 0.4799 0.2252 0.7234 1.05 0.5055 1.10 0.9503 0.2128 0.2492 0.7485 
DDC rs6592961 0.6377 0.1511 0.8346 0.1737 0.7653 0.96 0.4987 1.13 0.5866 0.8496 0.1205 0.912 
DDC rs10274275 0.4946 0.1270 0.5007 0.1430 0.6051 1.08 0.6658 1.07 0.9719 0.2131 0.1362 0.5077 
DDC rs11575342 0.4253 0.9429 0.3396 0.9030 0.2370 1.25 0.8877 1.03 0.7990 0.0735 0.6266 0.4954 
DDC rs3735274 0.5039 0.1319 0.5177 0.1465 0.5864 1.08 0.7178 1.06 0.9316 0.2483 0.1327 0.5511 
DDC rs3735273 0.1262 0.0024 0.2140 0.0024 0.2016 0.83 0.6569 0.93 0.1876 0.2396 0.0029 0.4721 
DDC rs11575322 0.8701 0.0306 0.8564 0.0303 0.2763 0.80 0.2724 1.34 0.9086 0.8718 0.0093 0.8299 
DDC rs998850 0.3734 0.1608 0.5277 0.1707 0.4798 0.92 0.8770 0.98 0.2342 0.8738 0.1750 0.8719 
DDC rs3779078 0.0357 0.0043 0.0662 0.0051 0.1189 0.80 0.3102 0.85 0.0864 0.0836 0.0057 0.4946 
DDC rs11575288 0.0570 0.4301 0.1062 0.3806 0.0231 3.27 0.9957 1.00 0.0730 0.1501 0.7891 0.1738 
DDC rs11575286 0.8701 0.0365 0.8564 0.0355 0.2763 0.80 0.2724 1.34 0.9086 0.8718 0.0119 0.8299 
DDC rs2044859 0.4794 0.0097 0.7542 0.0081 0.7650 0.96 0.8917 0.98 0.2337 0.8287 0.0051 0.8865 
DDC rs7786398 0.5428 0.1598 0.6897 0.1691 0.3661 0.90 0.6766 1.06 0.2619 0.7674 0.1664 0.977 
DDC rs3829897 0.6724 0.5304 0.8005 0.5649 0.5342 0.93 0.7501 1.05 0.9209 0.5028 0.9031 0.7039 
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Table 22 Supplementary Table 6.7 Allele frequencies of 'alternate controls' for shared risk loci 
Genomic  Association Results Current Study Frequencies 
Frequencies from 
other samples 
Gene SNP Position 
BP1 
Trends 
p-
value 
BP1 
OR 
SZ 
Trends 
p-
value 
SZ 
OR N 
SZ 
Case 
BP1 
Case Control
HapMap 
CEU 
ALT 
Controls
DDC rs4947535 50499175 0.033 0.82 0.036 0.82 A 0.296 0.295 0.340 0.350  
DDC rs745043 50511449 0.004 0.73 0.029 0.78 A 0.206 0.195 0.248 0.207  
DDC rs4470989 50530192 0.028 0.81 0.029 0.81 A 0.297 0.297 0.343  0.350** 
DDC rs3807558 50538516 0.008 0.75 0.043 0.8 A 0.207 0.198 0.246 0.202  
DDC rs3779078 50578412 0.004 0.74 0.042 0.8 A 0.205 0.193 0.244 0.200 0.200** 
DRD1IP rs11101694 134996704 0.008 0.72 0.012 0.73 G 0.129 0.127 0.169 0.150  
DRD3 rs2046496 115317621 0.017 1.24 0.031 1.21 G 0.494 0.502 0.448 0.475 0.480* 
DRD3 rs12636133 115322414 0.009 0.79 0.023 0.81 C 0.424 0.416 0.475  0.436* 
DRD3 rs10934254 115324324 0.009 0.79 0.035 0.83 G 0.428 0.417 0.475  0.438* 
DRD3 rs9868039 115329232 0.002 1.34 0.003 1.30 A 0.451 0.458 0.387  0.450* 
DRD3 rs9817063 115329798 0.003 0.77 0.011 0.79 G 0.456 0.447 0.514 0.475 0.453* 
DRD3 rs3732790 115329973 0.012 0.79 0.033 0.82 A 0.383 0.374 0.431 0.383 0.375* 
DRD3 rs2134655 115340891 0.005 1.33 0.007 1.31 A 0.277 0.280 0.226 0.275 0.238* 
DRD3 rs963468 115345577 0.008 0.78 0.030 0.82 A 0.381 0.370 0.429 0.375 0.372* 
MAOB rs2283729 43562986 0.042 1.34 0.026 1.26 A 0.274 0.286 0.231 0.289  
N = nucleotide of minor allele in these samples.  *Allele frequencies from unscreened neonatal controls, 1020 chromosomes 
(Talkowski et al., 2008).  **CEU_GENO_PANEL (120 Caucasian chromosomes) 
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